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CHAPTER I
Introduction
The scale of life is large – from humans down to the size of cells and molecules over one billion times
smaller at the nanometer scale. Understanding molecules requires us to delve into a strange world from the
perspective of a human observer. At this scale, the Reynolds number is small, that is to say, molecules live
in a viscous world where there is essentially no momentum. Imagine yourself trying to swim in a pool full
of molasses! You are throwing your arms and legs forward and backward up and down, but low Reynolds
number means there will be no momentum to move you forward, only friction slowing you down. The world
at this scale is strange indeed.
It is the monotonous, random heat energy that drives a nanometer sized molecule from one place to
another. This type of motion is known as diffusion, or sometimes referred to as Brownian motion after the
famous botanist Brown who made detailed observations of the random motion of pollen grains in year 1827.
Diffusion is fundamental to life. It is an irreversible process leading to a net increase in the entropy of a
system. Yet, the diffusive spreading out of molecules over time is what is largely responsible for the transfer
of material and information from one place to another at the scale of a cell. Nearly every molecular process
relies on diffusion, from the diffusional exchange of oxygen and carbon dioxide in the human lungs to the
diffusional search of transcription factors for their gene targets. The nature of molecular diffusion, and thus
the activity of molecules is highly dependent on environment. Yet, studies of the properties of molecules
often lacks the context of a complex living system.
The focus of this dissertation is on studying the properties of molecules that emerge in the context of
a living cell. In this chapter, historical perspectives on the problem of understanding life’s complexity and
emergent properties are described. A review of the literature on the autophagy pathway in general and the
protein called LC3 in particular is then given. Introductions to the topics of modern experimental approaches
for studying molecules in living cells using fluorescence microscopy will be given. Finally, an overview of
the specific questions that are investigated is provided.
I.1 Historical perspectives
From antiquity, life was described as “animated matter”. The Latin word for anima means soul, that is, life has
a soul, distinct from the observable chemical and physical forces. Much has changed, over the last 100 years
– dozens of natural laws have been discovered. Although many mysteries about life remain, the properties
of life are now being explored in the terms of natural physical and chemical processes. In 1944 Erwin
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Schro¨dinger set out to define in detail two such properties of life, in his highly influential, and provocatively
titled book What is Life?. Firstly, Schro¨dinger highlighted the importance of what was Boltzmann’s laws of
thermodynamics, that all things tend toward disorder, but that life has the ability to overcome this natural
fact, because it can collect energy from its environment through processes collectively known as metabolism.
Life therefore is said to be a dissipative system. Secondly, Schro¨dinger went on to highlight the problem of
information transfer. How does life transfer its blueprints from generation to generation with such exquisite
fidelity? At the time, Schro¨dinger hypothesized the existence of a molecule, probably some aperiodic crystal,
that was responsible. We now understand a great deal about the underlying mechanisms of information
transmission thanks in no small part to the work of Watson and Crick in the 1950’s. Their discovery, an
aperiodic crystal, is what is now famously known as DNA (deoxy-ribo-nucleic-acid), and is one of the critical
pieces of the puzzle of information transmission. But it is not enough to have mechanisms of acquiring energy
and transferring information.
Life emerged in the form of a cell – a membrane bound compartment that separates inside from outside.
The cell is the smallest recognizable unit of life and is a building block for higher order organisms. The first
cell was observed with the aid of a microscope in the year 1665 by Robert Hooke. Although the molecules that
make up cells are bounded by a protective membrane, they are far from fully shielded from their environment.
The environment is full of damaging agents – UV rays from the sun, pathogens, etc. – for which the cell’s
membrane provides little protection. A struggle for any cell is to resist the natural tendency toward disorder.
Remarkably, healthy cells are robust and capable of maintaining their normal condition in the face of endless
perturbations from their environment (a phenomenon known as cellular homeostasis). On the other hand,
diseased cells show signs of dysfunction in their homeostatic mechanisms. Cancerous cells survive in the
relatively harsh conditions of a tumor where they otherwise should not. Beta cells in pancreatic islet of a
diabetic patient unexpectedly die under conditions of oxidative stress induced by a poor diet. How is it that
a normal cell’s homeostatic mechanisms become dysfunctional? For many of the most important diseases
affecting humans we do not know the answer. However, we do know the problem ultimately lies in the inner
workings of the cell.
I.2 Emergence
The cell is far from equilibrium, and its molecules undergo dynamic self-assembly to form ordered structures
on a scale from nanometers to tens of microns [1]. Some proteins function as isolated monomeric enzymes
continuously processing substrates into products, while many others function as very large, labile multicom-
ponent complexes. Function (and dysfunction), patterns, and behaviors of a cell ultimately emerge from the
collective behaviors of its molecules and assemblies. Emergent complexity occurs at every physical scale of
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the universe. Emergent properties arise when numerous interacting components produce collective patterns
or behaviors that are not attainable by the individual components themselves [2]. Life is rich with examples of
emergent properties at the scales of populations, organisms, organs, tissues, cells, genes, all the way down to
molecules and atoms. Insect colonies organize into wondrously complicated structures. Patterns form on the
furs and shells of animals. The collective force of molecules in specialized muscle cells leads to contraction.
Molecules collectively carry out tasks of unimaginable complexity such as gene replication, and cell division
– all displaying properties of emergent complexity.
I.3 Autophagy
The autophagy pathway is an example of a metabolic process that displays stunning complexity, and that has
exceptional relevance to human health and disease. Autophagy is a major catabolic pathway whereby cy-
toplasmic components including proteins, lipid droplets, glycogen, organelles, and even invading pathogens
are sequestered and degraded via the lysosome. The term autophagy (from the Greek words for “self” and
“eating”) was coined by Christian de Duve in 1963 [3]. Autophagy is a conserved pathway in eukaryotes,
and is vitally important for normal human health, development, and the prevention of disease [4].
A defining feature of the autophagy pathway is the formation of a peculiar double membrane vesicular
intermediate known as an autophagosome, which is responsible for engulfing regions of cytoplasm. The
autophagosome is subsequently trafficked to the lysosome, where the outer membrane of the autophagosome
subsequently fuses with the lysosome thereby degrading its inner membrane and contents [5] (Figure I.1). The
molecular mechanisms of autophagy are becoming more clear thanks to the discovery of a host of autophagy
related genes (Atg) over the last two decades through genetic and proteomic studies [6–9].
I.3.1 Autophagy in human health and disease
Given autophagy’s central role in eukaryotic cells, it is not surprising that the pathway has broad importance
for human health. Early in life, at the stages of the oocyte to embryo transition, and the early neonatal
period, catabolic autophagy plays a critical role in liberating energy and amino acid nutrients [11, 12]. In the
development of red blood cells, autophagy plays important roles in cell remodeling via the selective removal
of mitochondria [13]. In the pancreatic beta cells, autophagy is thought to play a role in protecting against
oxidative injuries resulting from poor diets [14–16]. Similarly, autophagy is important for protecting the
cells of the heart from stresses that ultimately lead to cardiovascular disease [17–23]. Autophagy is also
relevant in cancer. It was suggested that dysregulated autophagy allows for the survival of a cancerous cell
in the nutrient poor environment of the tumor. On the other hand, it was also proposed that autophagy could
help prevent cancer by degrading damaged mitochondria that are generating free radicals [10, 24]. Recently,
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Phagophore
Figure I.1: Basic schematic of autophagosome formation. The autophagosome initiation site is referred to
as the phagophore. As the autophagosome expands, cytosolic materials are captured in a double membrane
bound vesicle called the autophagosome. The autophagosome is subsequently trafficked to the lysosome
where it fuses leading to degradation and recycling of its contents. Adapted from Levine et al. [10].
there has also been intense focus on autophagy due to its connections with immunity, inflammation, and
infection. As an example, it was shown that dysfunctional autophagy plays a major role in the development of
Crohn’s disease [25, 26]. Defects in autophagy have been implicated in many other diseases as well including
Parkinson’s disease, Alzheimer’s disease, Huntington’s disease, and Paget’s disease of bone [24, 27–30].
Given autophagy’s central importance in maintaining cellular homeostasis in eukaryotes, it is not surprising
that autophagy has been implicated in nearly every major human disease. The molecular mechanisms that
underlie autophagy and the factors that lead to its perturbation are currently unknown [31].
I.3.2 Autophagy regulation
Autophagy is constitutively active, and can occur either with or without substrate specificity, termed selective
or macroautophagy respectively. Non-selective autophagy is thought to be a mechanism for bulk turnover
of cytosolic components, and probably evolved as a mechanism to cope with conditions of starvation. On
the other hand, in selective autophagy, a variety of cargo is specifically selected for degradation. Selective
autophagy likely evolved as a mechanism to protect the cell against damaged molecules and organelles, as
well as a mechanism of innate defense against invading pathogens [32].
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Autophagosomes have been said to form de novo by their nucleation, growth, and fusion [33, 34]. The
initial site of autophagosome formation, referred to as the phagophore, is a cup shaped membrane, which
expands to encapsulate cargo. The source of the autophagosome membrane is currently hotly debated. A
variety of different membrane sources have been implicated in the process. One hypothesis is that specialized
regions of the endoplasmic reticulum (ER) called omegasomes might be the site of autophagosome formation.
Zinc finger, FYVE domain containing 1 (DFCP1) is a phagophore marker, and was shown to associate with
omegasomes [35]. Fluorescence microscopy studies identified another possible membrane source as the
outer membrane of mitochondria [36]. Another set of studies showed that autophagosome membranes are
derived from the plasma membrane via a clathrin dependent endocytic pathway [37]. Yet another hypothesis
is that the cycling of the integral membrane protein, ATG9, between the Golgi complex and the site of
autophagosomes could be a mechanism for phagophore expansion [38]. Finally, another study suggests
the ER-Golgi intermediate compartment is a primary source of membrane for autophagosomes [39]. An
intriguing question is whether autophagosomes formed from a particular membrane source are destined to
capture specific cargoes.
The autophagy pathway is tightly regulated, and is under the control of the mechanistic target of ra-
pamycin (mTOR) signaling pathway (Figure I.2). Autophagy is upregulated by perturbations in the levels
of nutrients, hormones, molecular damage, and invasion of pathogens. By breakdown of already assembled
macromolecules, autophagy thereby liberates basic building blocks like amino acids and free fatty acids,
which can be used for producing energy or for building more essential molecules. Downstream of mTORC1,
two main kinase complexes are involved in regulating the formation of autophagosomes. The first, is known
as the unc like autophagy activating kinase (ULK) complex, and the second is known as the phosphatidyli-
nositol 3-kinase, catalytic subunit type 3 (Vps34) complex [40]. In addition to ULK and Vps34 complexes,
two other machineries have been identified as important for autophagosome formation - the ubiquitin like
ATG12 and ATG8 conjugation systems.
ULK complex kinase activity is critical for autophagosome formation and the recruitment of other au-
tophagic factors to the phagophore [41, 42]. The ULK complex is a multicomponent complex consisting
of ULK1, ULK2, ATG13, RB1-inducible coiled-coil 1 (FIP200) , and ATG101. Under basal conditions,
mTORC1 interacts with ULK complex to phosphorylate it thereby inhibiting its activity. When autophagy
is upregulated mTORC1 dissociates from the ULK complex leading to activation of its kinase activity and
targeting to phagophores [43]. The ATG8 family proteins play a scaffolding role in the assembly of the ULK
complex [44, 45].
The Vps34 complex is also critical for autophagosome formation and the recruitment of autophagic fac-
tors to the phagophore. Like the ULK complex, the Vps34 complex is a multicomponent complex com-
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Figure I.2: Regulation of the autophagy pathway. Autophagy is negatively regulated by the mTOR signalling
complex. The activity of autophagy is modulated by the levels of nutrients, the presence of growth factors,
as well as genotoxic stress. The ULK complex and Vps34 complex (Class III PtdIns3K) are downstream
regulators of autophagy. Adapted from Yang and Klionsky [40].
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posed of Vps34, phosphoinositide-3-kinase, regulatory subunit 4 (Vps15) , phosphatidylinositol 3-phosphate
(PI3P), Beclin-1 [46, 47], and ATG14 [40]. Many molecules regulate the assembly of the Vps34 complex
including Bcl-2 [47], cyclin-dependent kinase 1 (Cdk1) [48], AMBRA1 [49], Bif-1 [50], UV radiation resis-
tance associated gene (UVRAG) [51], and Rubicon [52, 53].
In macroautophagy, autophagosomes form randomly throughout the cytoplasm, and are subsequently
trafficked toward the microtubule organizing center where lysosomes are clustered. Phagophores are im-
mobile, while mature autophagosomes utilize bidirectional transport along microtubule tracks to arrive at
their destination [54–57]. Minus end directed movement is mediated by the motor protein dynein [55, 56],
whereas plus end directed movement is mediated by the motor protein kinesin-1, as well as Rab7, and FYVE
and coiled-coil domain containing 1 (FYCO1) [58, 59]. Labile microtubules recruit early autophagic factors,
while acetylated microtubules are associated with mature autophagosomes [58]. The spatial segregation of
lysosomes and autophagosomes has been suggested to be an additional mechanism for regulating the au-
tophagy pathway [38].
Knowledge of the mechanisms of fusion of autophagosomes with lysosomes is limited; however, sev-
eral molecules are thought to be involved in the process. Histone deacetylase 6 (HDAC6) is involved in
fusion processes related to the selective removal of ubiquitinated protein aggregates [60]. In addition, Rab7,
lysosomal-associated membrane protein 1 (LAMP1) , and LAMP2 are all involved in fusion of autophago-
somes with lysosomes [61, 62]. Recently, SNAREs have emerged as important mediators of fusion events
[63–65]. More work needs to be done in this area to determine if there are any autophagy-specific factors
involved.
I.3.3 Selective autophagy
Researcher’s interest in autophagy was kindled by the discovery of selectivity for certain cargoes. In general,
autophagy selectivity is achieved by first conjugating ubiquitin to specific substrates such as protein aggre-
gates. Next, ubiquitin binding cargo receptor proteins associate with the ubiquitinated cargo. Finally, the
cargo is captured in LC3-II labeled autophagosomes for degradation [32].
Autophagy cargo receptor proteins are a crucial component of the process of selective autophagy. Se-
questosome 1 (SQSTM1) is a multifunctional scaffolding protein with functions in regulating signaling, re-
ceptor internalization, and proteasome mediated protein turnover [66]. SQSTM1 was first shown to interact
directly with LC3 to degrade ubiquitinated protein aggregates by autophagy in the context of Huntington’s
disease [67, 68]. SQSTM1’s domain structure consists of PB1, ZZ-type zinc finger (ZZ) , and Ub-associated
(UBA) domains. The protein also contains two NLS signals, an NES signal, an LC3 interacting region (LIR)
motif, and a KEAP1 interacting region (KIR) . The PB1 domain mediates SQSTM1 homo-oligomerization,
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the UBA domain is responsible for binding to ubiquitin chains, while the LC3 interacting region is involved
in direct interactions with LC3 (reviewed in [32]). Additional selective autophagy receptors are known [69],
and more are likely to be discovered.
Selective autophagy is not just limited to degrading protein aggregates. Specific proteins can be degraded
as well, for example, ubiquitinated dishevelled segment polarity protein 2 (Dvl2) involved in the Wnt path-
way is degraded by SQSTM1-mediated selective autophagy [70]. Organelles are also known to be selectively
degraded. Examples include ubiquitinated mitochondria, ER, and peroxisomes [71–75]. Invading pathogens
are also ubiquitinated and degraded by selective autophagy [76]. Interestingly, in yeast, ribosomes are selec-
tively degraded [77], but it remains to be seen if ribosomes are also selectively degraded in higher eukaryotes.
All of these components seem to be specifically degraded using a similar general mechanism. Interestingly,
other specific proteins such as IKKβ in the NF-κβ pathway are degraded using a slight variation of the
theme. Instead of ubiquitination, IKKβ binds to kelch-like ECH-associated protein 1 (KEAP1), which then
undergoes a specific interaction with SQSTM1 [78]. This suggests the selective autophagy mechanism may
have the flexibility to degrade a very broad range of cargoes that may not necessarily be ubiquitinated.
I.3.4 LC3
The protein known as LC3 (also known as ATG8) plays a central role in the process of autophagosome
formation. In yeast there is a single Atg8 gene, whereas in multicellular animals the Atg8 family consists of
three distinct subfamilies. The mammalian LC3 family consists of 8 orthologs belonging to the subfamilies:
microtubule-associated protein 1 light chain 3 (LC3), gamma-aminobutyric acid receptor-associated protein
(GABARAP), and Golgi-associated ATPase enhancer of 16 kDa (GATE-16) [79]. Each LC3 subfamily is
essential for autophagy [80]. LC3 genes are expressed in every human tissue [81], and the level of LC3 is
upregulated in response to a variety of perturbations to the autophagy pathway [82, 83].
Studies have revealed that all of the ATG8 proteins share strong structural, but not sequence similarity
with ubiquitin. Together with the fact that they undergo conjugation reactions resembling ubiquitination,
they have fittingly been categorized as ubiquitin-like proteins [84, 85]. However, unlike ubiquitin, which is
conjugated to other proteins, LC3 is conjugated to the head group of phosphatidylethanolamine (PE) [86].
LC3 is believed to function in autophagosome membrane expansion and elongation, and plays a role in cargo
selection during selective autophagy. There are however also apparently autophagy-independent functions
for LC3 that will be described further below.
Newly synthesized LC3 is processed by a cysteine protease called ATG4B, exposing its glycine residue
at position 120 and priming it for lipid modification [86, 87] (Figure I.3). A large multimeric complex
involving a second ubiquitin-like protein called ATG12 is believed to play important roles in specifying the
8
Figure I.3: The LC3 ubiquitin-like conjugation machinery. Newly synthesized LC3 (ATG8) is cleaved by
ATG4B exposing a C-terminal glycine residue. LC3 is then conjugated to E1-like enzyme ATG7, followed
by conjugation to E2-like enzyme ATG3. Finally, LC3 an isopeptide bond is formed between LC3’s glycine
residue and the amine head group of PE via E3-like enzyme ATG12-ATG5-ATG16. Adapted from Chen and
Klionsky [31].
site of LC3 lipidation, as well as the conjugation reaction itself [88]. ATG12 is conjugated to ATG5 via
intermediate reactions with E1-like and E2-like enzymes ATG7 and ATG10. The ATG12-ATG5 conjugate
non-covalently associates with ATG16 to form a very large 400-800 kDa complex [89]. To date no ATG12-
ATG5 deconjugation reaction has been identified. There is extensive overlap among the component involved
in conjugating ATG12, and those involved in conjugating LC3. The C-terminal glycine residue on LC3
is conjugated to the head group of PE via an isopeptide bond by reactions with E1- and E2-like enzymes
ATG7 and ATG3 [85]. The multimeric ATG12-ATG5-ATG16 is believed to function as an E3-like enzyme
in the process [88]. LC3’s lipidation with PE is reversible by a second cleavage reaction with ATG4B [87].
Cleaved LC3, known as LC3-I, is soluble, whereas lipid modified LC3, known as LC3-II, is tightly associated
with autophagosomal membranes [90, 91]. LC3’s role in autophagosome expansion was demonstrated by
experiments showing the levels of ATG8 determine the size of autophagosome [92]. LC3 is thought to play a
role in mediating membrane tethering and hemifusion [93, 94]. In addition, the evidence shows that different
LC3 subfamilies are each essential, yet act differently in autophagosome biogenesis. The results indicate
that the LC3 subfamily is involved in elongation of the phagophore, whereas the GABARAP and GATE16
subfamilies play a role later in the maturation of autophagosomes [80].
Recent studies have shown that LC3 can be post-translationally modified in at least two additional ways.
First, LC3 was shown to be phosphorylated directly by protein kinase A [95]. Second, LC3 undergoes
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acetylation by the p300 acetyltransferase [96]. Interestingly, these additional post-translational modifications
strongly regulate LC3’s lipidation and activity in autophagy.
Each LC3 subfamily has a unique N-terminus, and it has been suggested that this may confer unique
functionality to the different LC3 family members [97]. The LC3 N-terminus has been shown to play impor-
tant functional roles. It was hypothesized that LC3 provides energy for membrane fusion events by homo-
oligomerization via its N-terminus on opposing membranes [93]. GABARAP was crystallized in two distinct
conformations suggesting LC3’s N-terminus may be flexible [98]. There is some evidence to support the
notion that lipidation of LC3 induces a conformational change in its N-terminus [93, 99]. This suggests a
mechanism whereby LC3 lipidation could regulate LC3’s interaction partners and thus its function. The N-
terminus of LC3 was also shown to be important for recruitment of SQSTM1 into autophagosomes during
selective autophagy [100].
LC3 forms several large complexes with the ubiquitin-like (UBL) conjugation machinery. First, LC3
forms a 2:1 complex with ATG4B. One LC3 is bound to the active site, while the other is bound to the N-
terminus of ATG4B. It is unclear if binding to ATG4B’s N-terminus plays a role in regulating LC3 lipidation.
Alternatively, it may be an artifact of the crystallization environment [101]. More work needs to be done in or-
der to determine if the 2:1 complex observed in the LC3 ATG4B crystal structure is physiologically relevant.
A second large complex was observed during the transfer of LC3 from ATG7 to ATG3. ATG7 dimerizes and
interacts with ATG3. ATG8 is transferred trans from ATG7 to ATG3 bound to the opposite ATG7 [102–104].
Finally, a third large complex is thought to form between LC3 and the E3-like ligase ATG12-ATG5-ATG16.
ATG12-ATG5-ATG16 was found by size exclusion chromatography to have an exceptionally large size at
800 kDa. The ATG12-ATG5-ATG16 complex is thought to contain at least 4 subunits mediated by ATG16
homo-oligomerization [89].
There has, not surprisingly, been a great deal of interest surrounding LC3’s possible homo-oligomerization.
In addition to the proposal that LC3 oligomerization may promote membrane tethering and hemifusion [93],
caution was raised about LC3’s use as an autophagy marker by light microscopy, as it was shown to asso-
ciate with protein aggregates independent of autophagosome membranes. It was speculated that LC3 may
be prone to self aggregating [79, 105, 106]. The LC3 family member GABARAP was shown to oligomer-
ize [107, 108]. However, the self association properties of LC3 have not been thoroughly examined in a
physiological context.
LC3 is also seems to have apparently autophagy-independent functions. LC3 was originally character-
ized as a microtubule-associated protein where it interacts with microtubule-associated protein 1A (MAP1A)
and MAP1B as well as microtubules assembled from purified tubulin [109]. LC3 was subsequently shown
to interact with both polymerized and unpolymerized tubulin by surface plasmon resonance [110]. It also
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undergoes interactions with other cytoskeleton associated proteins such as caldendrin [111]. LC3 forms a
large complex with MAP1B heavy (MAP1B-HC) and light chain (LC1) with an estimated stoichiometry of
MAP1B-HC:LC1:LC3 of 1:2:0.2 [112]. The function of LC3 binding to microtubules is unclear, but several
hypotheses have been proposed. It may play a role in increasing microtubule stability [113], or alternatively
LC3 may link autophagosomes to the microtubule network [59]. LC3 family members are also known to be
involved in membrane trafficking events. GATE16 interacts with the SNARE machinery in the Golgi complex
in order to mediate membrane trafficking. [114]. GABARAP was shown to mediate ER to Golgi transport
[115]. LC3 was proposed to regulate endocytic trafficking events through its interactions with Rab GAPs
[116]. Interestingly, LC3 was also demonstrated to be an RNA binding protein via its triple arginine motif
in the region of residues R68-R70. LC3 binds to fibronectin mRNA, and thus influences the expression of
fibronectin protein [117–119]. There is also evidence for interplay between the autophagy and proteasomal
degradation pathways [70].
Surprisingly, LC3 is found in the nucleus [120, 121]. This is an unexpected finding given that LC3
is primarily thought to function in the cytoplasm where autophagosomes form. This discovery thus raises
the possibility that nuclear LC3 may have currently unknown functions in the autophagy pathway. A small
number of studies have begun to examine LC3’s potential functions in the nucleus. It was shown that LC3
interacts with the nuclear tumor suppressor tumor protein p53 inducible nuclear protein 1 (TP53INP1) and
influences cell death by autophagy [122]. The interaction of LC3 with a TP53INP1 family member called
diabetes and obesity regulated (DOR), also a nuclear protein, functions in the dual regulation of autophagy
and thyroid hormone receptor transcription [123–125]. Recent studies suggest nuclear LC3 may also regulate
signaling via interactions with ERK signaling cascade components [126]. More work needs to be done to
determine what additional roles LC3 may play in the nucleus.
I.3.4.1 LC3’s protein interaction network and the LIR motif
LC3 family members interact with a large network of over 65 different proteins with extensive overlap among
family members [9]. The LC3 interacting region (LIR) motif W/F/Y-X-X-L/I/V has been identified as a
common structural element used by proteins to interact specifically with LC3 [32, 45, 127]. Many LC3
interacting proteins bear this motif, and appear to interact with LC3 via its hydrophobic protein interaction
surface in the region of residues F52, L53, and R70 [69, 128, 129]. Mutations to these key residues on LC3’s
hydrophobic protein interacting surface disrupt binding to tens of proteins, highlighting the importance of this
region for engaging other proteins in productive binding [9, 69, 100, 127, 129, 130]. At this time it is unclear
if LC3 family members associate with proteins in their network in a binary fashion, or if many proteins come
together to form functional complexes. Using FRAP, our group recently showed that the soluble form of
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LC3 diffuses unusually slowly for a cytoplasmic protein of its size under basal conditions [121]. Because the
diffusion coefficient of a soluble, freely diffusing molecule is inversely related to its radius, this slower-than-
expected-diffusion of LC3 could potentially reflect its association with macromolecular complexes comprised
of LC3 and other components of the autophagy pathway. Alternatively, the slow diffusion of soluble LC3
could potentially arise from reversible binding to microtubules in cells or the incorporation of LC3 into
homo-oligomers or aggregates or possibly membranes.
I.4 Investigating biopolymers in vivo with fluorescence microscopy
A common approach to understanding a cell’s molecular machinery involves breaking open the cell and
separating out its components, such that assays for structure and function can be carried out in vitro. This
type of experimental approach is extremely powerful, but it carries some intrinsic limitations.
The function of a protein is highly dependent on context. Firstly, a molecule can have different functions
depending on its subcellular localization. Second, post-translational modifications of molecule can regulate
its involvement in a particular cellular function [90, 131]. Third, once in a dilute solution, labile multicom-
ponent complexes begin to fall apart. Fourth, the cell is a crowded environment, and a dilute solution, by
definition, may not accurately recapitulate this. Lastly, the dynamics of molecular transport processes like
diffusion depend on the nature of the intracellular environment.
Fortunately, new developments in light microscopy are making it possible to overcome these limitations.
Light microscopy is well suited to studying living cells, as the energy of visible light is minimally damaging
to the components of a living cell. In addition, measurements with light microscopy are typically spatially
resolved down to about 250 nm or half the wavelength of light. One fundamental limitation of light mi-
croscopy has been the lack of contrast between constituents with similar densities. However, the advent of
green fluorescent protein (GFP) technologies led to dramatic improvements in contrast, and have fundamen-
tally changed the limits of light microscopy. Today it is routinely possible to genetically fuse GFP to any
protein of interest, and to incorporate this construct into a living cell for observation by light microscopy.
There are currently a variety of different fluorescent proteins each with unique photophysical properties in-
cluding a range of different colors from blue to far red. Likewise, parallel advances in modern microscopy
instrumentation have led to the development of many sophisticated, quantitative experiments [132].
I.4.1 FRET
Fluorescent molecules are dipoles. When two dipoles become sufficiently close together, they can partici-
pate in a dipole-dipole interaction. This interaction results in non-radiative energy transfer from the donor
molecule to an acceptor molecule. This photophysical energy transfer phenomenon was first observed in
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polarization experiments carried out in the 1920s, and was quantitatively explained by Theodor Fo¨rster in
1946 [133]. Paying homage to Fo¨rster’s fundamental contributions to our understanding, the phenomenon
has been named Fo¨rster Resonance Energy Transfer (FRET) .
Due to its very strong 1/r6 distance dependence, changes in FRET were soon exploited as a sort of
molecular ruler [134]. The distance over which FRET occurs between a specific donor and acceptor is
defined with respect to the Fo¨rster distance R0. R0 is a function of the relative dipole-dipole orientation, the
refractive index, and the photophysical properties of the donor and acceptor fluorophores [135]. When the
separation distance between fluorophores is close to R0, small distance changes result in dramatic changes in
the FRET efficiency, but this sensitivity quickly falls off at separation distances < 0.5R0 or > 1.5R0.
Direct protein-protein interactions bring proteins within close physical proximity of one another. If the
two proteins are labeled with fluorescent molecules, this process can be monitored using FRET. Most com-
mon fluorescent labels have R0 values of ∼ 5 nm. This means that FRET can be used as means of detecting
protein-protein interactions when their distance of separation is less than ∼ 10 nm. A variety of fluorescent
proteins can be used as FRET donors and acceptors [136]. One of the most common FRET pairs used is the
cyan and yellow proteins Cerulean and Venus. Cerulean is used as the FRET donor, while Venus is the FRET
acceptor. This FRET pair has an R0 value of 5.4 nm [137].
I.4.2 Diffusion
I.4.2.1 Diffusion and its biological relevance
Diffusion, sometimes referred to as Brownian motion, is a fundamental transport phenomenon that occurs in
nature. The theory of Brownian motion is well grounded thanks to the work of Albert Einstein in the early
1900s. Einstein envisioned a particle suspended in water, with thermal energy propelling individual water
molecules in random directions, sometimes bombarding the particle more in one direction than in the others,
with the net effect of causing the particle to be displaced along a random trajectory. Einstein’s theory shows
that a single particle undergoing stochastic Brownian motion can be described as having a mean squared
displacement x that is directly proportional to time t and a constant coefficient of diffusion D,
< x2 >= 2NDt (I.1)
where N is the spatial dimensions. Einstein proceeded to relate the diffusion constant to physically measur-
able quantities such as the mobility of the particle µ and the temperature T ,
D = µkBT (I.2)
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where kB is the Boltzmann constant. This relationship has been given the name, the Einstein-Smoluchowski
relation, as Marion Smoluchowski independently arrived at the same conclusion in 1906. The relationship
has both practical as well as theoretical significance, as it confirms that the second law of thermodynamics is
a statistical law.
If the mean free path is large relative to the radius of the diffusing particle, as is the case in a dilute
solution, one can combine Stokes’ law with Einstein’s relation to arrive at,
D =
kBT
6piηr
(I.3)
where η is the viscosity and r is the hydrodynamic radius of the diffusing species. This relationship, termed
the Stokes-Einstein relation, allows one to clearly see the connections between the rate of particle diffusivity
and the physical properties of the particle and the solution. For the purposes of studying protein complexes
in vivo this relationship is very useful for directly measuring a particle’s radius assuming knowledge of the
solution properties.
Diffusion also has consequences for the rates of chemical reactions. The connection between the rate
of diffusion and the rate of a chemical reaction was worked out by Smoluchowski in 1917. Smoluchowski
imagined the diffusional encounters of two particles in the real world must be similar to an imaginary system
in which one of the particles is immobilized, and the other is diffusing with a diffusion coefficient equal
to the sum of the diffusion coefficients of the particles in the real system. In the imaginary system, one
of the particles acts as sink for the mobile particle, and the reaction rate is defined as the steady-state flux
of diffusing particles into the immobilized ones. Using this assumption, Smoluchowski determined, in the
diffusion controlled limit, the rate at which two particles, A and B, interact,
φ =CACB4piNAd(DA+DB) (I.4)
This relationship shows that the rate φ depends on the relative separation distance d the reaction partners must
achieve to react, the concentrations of the reaction partners (CA and CB), and their diffusion coefficients (DA
and DB). In the gas phase, where diffusion is relatively fast, the observed rates of reactions are usually due
to a rate-limiting step somewhere along the reaction coordinate and not due to limitations in the frequency of
reactant collisions. However, in solution – where the rates of particle diffusion are far slower – the observed
reaction rate may be limited by the reactant collision frequency rather than some step along the reaction
coordinate. Thus, we arrive at the very important realization that the diffusion rates of molecules that make
up a living cell may, to a large extent, regulate the observable rates of reactions.
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Experimentally, measuring diffusion in living cells using modern technology is now more accessible than
ever before. Fluorescence based methods of measuring diffusion fall into the three main categories: Fluo-
rescence Recovery After Photobleaching (FRAP), Fluorescence Correlation Spectroscopy (FCS), and Single
Particle Tracking (SPT) . Although all of these methods rely on the underlying principles of diffusion, exper-
imentally they are different approaches, and each method carries with it certain strengths and weaknesses.
FRAP was one of the first fluorescence microscopy experiments for quantitatively measuring molecular
dynamics [138–140]. FRAP is carried out by irreversibly photobleaching a small population of molecules in
a particular region of the sample and then monitoring the exchange of unbleached and bleached molecules
over time. FRAP curves yield information about both the recovery kinetics and the fraction of molecules
free to diffuse. Originally, FRAP measurements were performed using a focused, static laser beam to
bleach molecules. A theoretical basis for the analysis of FRAP measurements of lateral diffusion by spot-
photobleaching approaches for a static laser was established shortly after the development of FRAP [140].
The earliest applications of FRAP were predominantly confined to measurements of cell-surface proteins or
lipids that could be fluorescently labeled by exogenous probes [139, 140]. The discovery of GFP and molec-
ular techniques to tag proteins with GFP, or similar fluorescent proteins, has vastly expanded the number of
proteins that can be studied by FRAP. Furthermore, technical advances in microscopes in the late 1980s to
early 1990s have made this approach widely available to many researchers. One disadvantage of FRAP is
that it is rarely sensitive enough to accurately quantify recoveries that are dominated by complicated scenar-
ios such as the diffusion of different sized complexes [141]. FRAP has a major advantage over alternative
methods however, in that it is capable of accurately measure the fraction of immobile molecules [132].
FCS approaches are another set of powerful tools for investigating molecular dynamics in vivo. In the
modern FCS approach, particle fluctuations in a small, diffraction limited, observation volume are passively
monitored with high temporal resolution. The average number of particles in the volume and the diffusivity
of the particles are quantified by analysis of the fluctuation autocorrelation function [142]. FCS is exquisitely
sensitive, allowing measurements on samples with concentrations in the pico- to nanomolar range [142,
143]. FCS works best when measuring the dynamics of faster moving molecules, as measurements of slower
moving molecules may be confounded by photobleaching artifacts.
SPT measures diffusion by directly observing the trajectories of individual particles [144]. After data
acquisition, the individual particle trajectories must be reconstructed from the set of coordinates of particles
at each time point. This is a correspondence problem that can be particularly challenging, and thus a variety
of approaches have been developed to solve it [145]. Next, the trajectories are typically analyzed in terms of
their mean squared displacement [146]. The advantage of SPT is that it enables one to measure heterogeneity
in a population of molecules. In addition, often the lifetime of a molecule as well as its lateral diffusion at the
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membrane can be quantified [147].
Given the assumptions that the particle is a sphere undergoing Brownian motion in a dilute solution, mea-
suring diffusion might not seem to be a valid approach to determining the size of a protein or its binding
reactions; however, recently this approach has been highlighted as a valuable way to at least get a first ap-
proximation. For example, Sprague et al. [148] used the Stokes-Einstein relation to quantify the binding of a
transcription factor to DNA in living cells; Kang et al. [149] quantified the binding of a protein to membranes
in living cells; and Drake et al. [121] used the approach to test if LC3 was a monomer in living cells. At
this time, it remains unclear if the assumptions made explicit in the Stokes-Einstein relation are valid for
measurements in living cells. To make matters worse, the technical approaches used to quantify diffusion in
living cells are in their relative infancy, and there is a lack of a general consensus about the protocols to not
only acquire, but also to analyze the data. Most of the assumptions either implicit or explicit in quantifying
diffusion in living cells have already been acknowledged, but they still require more experimental evidence
to determine the degree to which they may interfere with the interpretation of results.
I.5 Overview
Over the past two decades the importance of autophagy in human health and disease has come to the forefront.
It is clear that discovery of new forms of treatment for human disease affecting such a complicating process
as autophagy will require a greater understanding of the inner workings of the cell. The molecules involved
in autophagy display emergent complexity, and to fully understand some of their properties will require their
study in the living cell. The ubiquitin-like protein LC3 is a central component of the autophagy pathway.
LC3 has an extensive network of interacting proteins, but little is known about their physiological regulation.
To begin, we sought to develop tools to make our FRAP approaches more broadly available to the biolog-
ical community. Toward this end we developed a freely accessible software program called FRAP-Toolbox to
perform quantitative FRAP analyses using the most up-to-date models for recoveries dominated by reactions,
or diffusion. We also demonstrate how this software can be used to analyze actual FRAP. Next, in order to ex-
amine how the LC3 protein interaction network is regulated, we first characterized the size and stoichiometry
of autophagosome independent LC3 in the cytoplasm of living cells and in cytoplasmic extracts and investi-
gated how these properties are regulated by specific residues on LC3’s hydrophobic protein binding surface
as well its G120 residue required for lipid modification. In this study we found that individual soluble LC3
molecules associate with a ∼ 500 kDa complex and that residues on LC3’s hydrophobic protein interaction
surface are important for regulating its association with these complexes. We then sought to develop tools
to study LC3 complex formation in live cells by analyzing the interactions of LC3 with a catalytically inert
mutant form of ATG4B using FRET and FRAP. Here we found that our data are consistent with a model in
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which Atg4B(C74A) and LC3 not only directly interact, but also associate with a slowly diffusing complex
in both the cytoplasm and nucleus of living cells. This complex could either have a relatively high molecular
weight or be elongated in shape. In addition, our data suggest that the organization of LC3 within complexes
in the nucleus may be different from that in the cytoplasm. Next, we developed an assay that can be more
broadly used to study LC3 protein interactions using confocal microscopy. The method relies on quantifying
LC3’s nucleocytoplasmic ratio both with and without co-overexpression of potential LC3 interacting pro-
teins. This method can be easily extended to a high throughput format. Lastly, in order to gain novel insights
into the nature of nuclear LC3, I present several works in progress, and propose future directions. Through
these studies, we have uncovered a wholly novel LC3 associated complex, and we have developed several
tools that will aid in future investigations of LC3 and other proteins in the autophagy pathway more generally.
The results in this dissertation also demonstrate the usefulness of fluorescence based microscopy methods for
investigating protein dynamics in living cells.
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CHAPTER II
FRAP-Toolbox: Software for the analysis of Fluorescence Recovery After Photobleaching
Fluorescence recovery after photobleaching (FRAP) reports on the mobility of fluorescently labeled molecules.
FRAP is a powerful approach used to study the dynamic properties of proteins in their native environment
- living cells. Questions of interest include quantifying reversible binding events, transport between cellu-
lar compartments, and intracompartmental diffusion. Although advances in microscope technologies have
made this approach increasingly straightforward to carry out, quantitative data analysis using newly devel-
oped FRAP models currently requires training in computer programming and data analysis. It thus presents a
significant barrier to its widespread use by the scientific community. In order to make analyzing FRAP data
using newly developed FRAP models more accessible, we developed a modular software program called
FRAP-Toolbox. This chapter begins by introducing the problem of measuring molecular mobility in living
cells by FRAP. Next, the design of our open source software program to analyze FRAP data is described. In
depth examples of how to use FRAP-Toolbox to analyze several test data sets is given. Finally, the useful-
ness of FRAP-Toolbox is demonstrated by analyzing the dynamics of the autophagy protein ATG5 in living
cells. A webpage dedicated to all aspects of the development of FRAP-Toolbox can be accessed online at
http://www.fraptoolbox.com.
II.1 Introduction
Mobility is a property of fundamental importance, which can control the availability of a molecule for re-
actions, and has even been proposed to contribute to the establishment of patterns in organism development
[150]. One of the most useful tools for characterizing a molecule’s mobility is fluorescence recovery after
photobleaching (FRAP). FRAP is a widely accessible technique, which can be performed on virtually any
modern fluorescence microscope, and is applicable to studies in both solution as well as living cells [132].
New FRAP methodology and quantitative FRAP models are greatly facilitating the use of this technology to
make important advances in basic studies of biology [151, 152]. FRAP data is often analyzed qualitatively
by making comparisons among FRAP curves collected under identical conditions [153, 154]; however, more
sophisticated quantitative analysis strategies are available, but researchers often struggle with these methods
due to a lack of simple to use software for image-processing and data analysis. Therefore, in order to facili-
tate obtaining quantitative information from FRAP experiments, we have developed an open source software
This manuscript was prepared for publication in PLoS Comp Biol.
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program called FRAP-Toolbox, which provides automated batch image-processing and data analysis.
The FRAP method is carried out by irreversibly photobleaching a small population of fluorescent molecules
within a defined region, and monitoring their recovery back to the steady-state (Figure II.1). FRAP reports
on the fraction of molecules that are free to recover over the time scale of the experiment termed the mobile
fraction (M f ), and the rate at which those molecules recover (related to the recovery halftime τ1/2). Typi-
cally, M f is a readout of stable associations with immobile structures, while τ1/2 is a parameter related to
the characteristic dynamics of the molecules such as directed flow, diffusion, and reversible reactions. τ1/2
is also affected by experiment specific parameters such as the size and geometry of the bleach region em-
ployed. Although τ1/2 and M f can be used in comparative studies to make qualitative arguments for faster
or slower dynamics, better quantitative FRAP approaches and models have been developed to gain even
deeper insights into the nature of the underlying molecular dynamics. For example, models have been devel-
oped to specifically distinguish between recoveries dominated by the kinetics of a reaction, diffusion, flow,
and even by a mixture of reactions and diffusion (discussed in more detail in the supplementary material)
[140, 148, 149, 151, 155–160].
Despite the relative ease of acquiring robust FRAP data, an ongoing obstacle for subsequent quantitative
analyses of FRAP experiments lies in the image processing and data analysis steps. In order to overcome
this obstacle and help make these quantitative methods more broadly available to the biological community,
several software tools have been developed. These software tools are all mostly freely available and have been
developed to aid in normalizing FRAP data and non-linear least squares analysis using analytical one and
two component reaction dominant FRAP models (Table II.1). However, the tools that have been developed
generally lack one or more of the features in high demand such as: 1) easy-to-use integrated image processing;
2) analytical models for obtaining an instrument independent diffusion coefficient (D); and 3) a streamlined
approach to batch processing many datasets.
In order to meet all of these needs, we have developed a freely accessible software program called FRAP
Toolbox to perform quantitative FRAP analyses using the most up-to-date models for recoveries dominated
by reactions or diffusion. We demonstrate how this software can be used to analyze actual FRAP data using
Venus-ATG5 as a test case. FRAP-Toolbox can be accessed at https://www.fraptoolbox.com.
II.2 Design and implementation
II.2.1 Overview of the software
For an overview of the FRAP-Toolbox design refer to the schematic in Figure II.2. FRAP-Toolbox begins
with a main GUI. The main GUI accepts several basic user inputs including a FRAP model selection. The
user then has a choice: the user can a) preview their FRAP dataset, or b) proceed to the FRAP data analysis;
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Figure II.1: Schematic of a typical FRAP experiment. (A) A region of a cell expressing a fluorescently labeled
molecule is selectively photobleached. The recovery of fluorescence as unbleached molecules exchange with
bleached molecules is followed over time. (B) The FRAP curve is the mean fluorescence in the bleach
region versus time. The FRAP curve provides quantitative information about the mobility of the underlying
molecules (qualitatively related to t1/2), as well as the fraction of those molecules which are free to recover
(the mobile fraction M f ). Note that different underlying physical processes result in differently shaped FRAP
curves with identical t1/2 values. Here is an example of recoveries dominated by diffusion (black line), and a
first order reaction (gray line).
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Figure II.2: An overview of the FRAP-Toolbox design.
however, before the user can perform the FRAP data analysis, FRAP-Toolbox will automatically load their
image data from the raw microscope files using Bioformats [161] (an opensource java library for reading a
variety of proprietary and non-proprietary life science image formats). During these steps, information is
extracted from the metadata of the raw file including timestamps and pixel size; in addition, image analysis is
performed to obtain FRAP curves and initial conditions (if applicable). Next, the user is presented with a data
analysis and visualization window where they interact with the program and run the fitting routine. If these
results are satisfactory, the user has the option to save the data generated by FRAP-Toolbox. In the sections
below we explain in more detail each of the steps in the FRAP-Toolbox design.
II.2.2 Main GUI
The main GUI serves as a means of collecting seven basic pieces of information from the user.
1. Where are the raw FRAP datasets located?
2. Which FRAP model should be used for the analysis? Current choices are: Diffusion, Reaction 1, and
Reaction 2 models.
3. What type of bleaching ROI was used in the experiment? Current choices are a circle and user defined.
4. Which frame number corresponds to the post-bleach image?
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5. What is the background fluorescence intensity?
6. Should the data be normalized by the whole cell intensity?
7. How many pre-bleach images need to be used for normalizing the FRAP curve?
II.2.3 Preview image data
The first selected FRAP dataset in the list is loaded and displayed along with user defined circular ROIs. The
user can scroll through the images in the FRAP dataset and verify that their basic inputs are correct.
II.2.4 Load image data
During this stage of the algorithm, each raw FRAP dataset from the microscope is read using Bioformats,
and the relevant data extracted. Using the basic inputs from the user, bleaching ROIs, and cell ROIs are
initialized. Next, image analysis is performed to obtain FRAP curves. Finally, the FRAP data are normalized
to the pre-bleach steady-state intensity. Here the diffusion model deviates from the Reaction 1 and Reaction
2 models in that it requires the use of a circular bleach region; in addition, image analysis is performed to
obtain radial post-bleach profiles that are used later to find the initial conditions for the diffusion equation.
II.2.5 Data Analysis
After the FRAP datasets are loaded, the user is directed to a data analysis and visualization GUI provid-
ing the user with an opportunity to supply inputs for the initial parameter guesses, lower and upper bounds
on parameters, and the range of data to fit (for example, the user can exclude FRAP curve timepoints after
reaching post-bleach steady-state). FRAP-Toolbox uses the trust-region reflective algorithm – a constrained
non-linear least squares approach – to fit the data. The fitting routine finds the parameters x that solve the
problems (where applicable),
min
x
∑
0
(I(x; t = 0)− i(x; t = 0))2 (II.1)
min
x
∑
0
(I(t)− i(t))2
t+∑t0 I(t)
(II.2)
Here, I(x; t = 0) is the normalized post-bleach profile, and i(x; t = 0) is the analytical approximation. I(t)
is the normalized FRAP data, and i(t) is the analytical FRAP model.
The FRAP-Toolbox currently supports three different models. The first model is called Diffusion. The
Diffusion model is a series representation of a closed-form analytical FRAP equation describing free diffusion
of unbleached molecules into a circular bleach ROI, which is applicable to data obtained on a laser scanning
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confocal microscope [158]. This equation corrects for the diffusion that occurs during the photobleaching
event.
The second and third models are called Reaction 1 and Reaction 2 respectively. The Reaction 1 model
describes FRAP recoveries that are dominated by pseudo-first order reaction kinetics, while the Reaction 2
model describes FRAP recoveries that are dominated by the sum of two independent first order reactions
kinetics. Many physical-chemical situations are thought to be appropriately modeled using equations of this
type. Some examples include the turnover kinetics of actin binding proteins [162] and the nucleocytoplasmic
exchange of molecules [163].
II.2.6 Data visualization
For the purposes of examining the results of the fitting routine, theoretical FRAP curves using the optimized
parameters are plotted along with the experimental data. In addition, the residuals are plotted so that the user
can check for systematic deviations between the fit and the data. The optimized parameters are automatically
uploaded into the table in the data analysis GUI.
II.2.7 Save data
Finally, once the user is satisfied with the results of their fitting routine the optimized parameters and pro-
cessed data can be exported as a tab delimited text file for later use in downstream statistical analyses and the
generation of publication quality figures.
II.3 Results
II.3.1 Published examples of the FRAP-Toolbox algorithms
The algorithms that underlie FRAP-Toolbox have been validated by measurements of the diffusion of EGFP
in cells and solutions of known viscosity. D was shown to be independent of experimental conditions [158].
They also have been used to gain novel insights into biological problems. Previously, we quantitatively ana-
lyzed the diffusion rate of microtubule associated protein 1 light chain 3 beta (MAP1LC3B/LC3) in vivo and
uncovered quantitative information about its effective hydrodynamic radius [164], as well as its interactions
with ATG4B(C74A) in living cells [165].
II.3.2 Quantifying the effective size of Venus-ATG5 in living cells
In order to further demonstrate the usefulness of FRAP-Toolbox for this class of problems, in what follows,
we examine the intracellular mobility of a GFP tagged form of the autophagy protein ATG5 (Venus-ATG5).
We built our Venus-ATG5 construct by performing a BglII and EcoRI double restriction digest on the original
GFP-ATG5 vector [166]. ATG5 (∼ 30 kDa monomer) is a key component of the autophagy pathway where
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Figure II.3: The effective diffusion of Venus-ATG5 is slower than expected for a freely diffusing monomer.
(A) A quantitative FRAP assay was carried out on HeLa cells expressing either Venus as a control for a 27 kDa
monomer or Venus-ATG5. We selectively photobleached a small 1 µm bleach region placed in a region of the
cytoplasm independent of puncta. (B) The initial conditions for the diffusion equation are obtained from the
radial post-bleach profile. (C) The FRAP recovery was well fit by the FRAP-Toolbox Diffusion model. (D)
Diffusion coefficients and (E) corrected mobile fractions from measurements on multiple cells. (N=15)
it is thought to contribute to the assembly of autophagosomes via formation of a membrane scaffold together
with ATG12, ATG16, and ATG8 [167]. It is known that ATG5 forms a covalent complex with ATG12; this
conjugate – together with non-convalent association with ATG16 – plays a role as an E3-like factor in the
conjugation of ATG8 to phosphatidylethanolamine [168]. The ATG12-5-16 complex has been proposed to
be in the range of ∼ 400 kDa–800 kDa based on in vitro chromatography experiments [89]. However, an
analysis of the properties of ATG5 complexes within the context of living cells has not been carried out.
In the case of ATG5, we are motivated to understand if ATG5, independent of autophagosomes, normally
behaves as if it is associated with an ∼ 400 kDa–800 kDa complex in living cells. In order to address this
question we carried out a quantitative FRAP assay using a Zeiss LSM 510 confocal microscope. Our mea-
surements were directed at the diffuse cytosolic pool of the protein independent of any visible fluorescent
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puncta, using a 1 µm radius circular bleach region (Figure II.3A). We expect this cytoplasmic form of ATG5
is largely independent of that associated with autophagic membranes, but may be constitutively associated
with ATG12 and ATG16 to form freely diffusing ATG12-5-16 complexes. Figure II.3B shows an example of
the postbleach radial fluorescence profile from our measurements that is fit to obtain the initial conditions for
the diffusion FRAP model. The FRAP recovery curve for this diffuse cytoplasmic pool of Venus-ATG5 was
well fit by the single component diffusion model in FRAP-Toolbox (Figure II.3C). The measurements were
repeated for a number of different cells, and the diffusion coefficients and mobile fractions from the fits to
the data are shown as scattered dot plots in (Figure II.3D and E).
Next, we estimated the effective size of the diffusing Venus-ATG5 species in order to test if Venus-ATG5’s
diffusion is consistent with its association with ATG12 and ATG16 in a ∼ 400 kDa–800 kDa complex. To
accomplish this, we quantified the diffusion coefficient of Venus as a control for a monomer with a known
molecular weight of 27 kDa. Using the Stokes-Einstein relation (D is proportional to MW−1/3), and the
measured diffusion coefficient of Venus-ATG5, we estimate the size of the diffusing Venus-ATG5 is approx-
imately 1100±500 kDa assuming a spherical geometry. This is consistent with the hypothesis that ATG5
constitutively associates with ATG12 and ATG16 to form a large multiprotein complex rather than existing
as a freely diffusing monomer in the cytosol of living cells.
II.3.3 Quantifying the nucleocytoplasmic exchange rate of ATG5 in living cells
Interestingly, in a putatively autophagy independent role, ATG5 was proposed to translocate into the nucleus
where it promotes apoptosis [169]. In our own experiments, we noticed Venus-ATG5 was, in fact, localized in
the nucleus as well as in the cytoplasm where it is thought to function in autophagy (Figure II.4A). However,
relatively little is known about the dynamics of ATG5 nucleocytoplasmic transport.
In order to further investigate this, we carried out a quantitative FRAP assay where we selectively photo-
bleached Venus-ATG5 in the nuclear compartment and monitored its recovery over time in order to quantify
the rate of nucleocytoplasmic transport (Figure II.4A and C). We carried out this set of FRAP experiments
using a Nikon Eclipse Ti laser scanning confocal microscope. Our FRAP curves for Venus-ATG5 nucleocy-
toplasmic transport, and a Venus control are shown in Figure II.4B. While the nucleocytoplasmic recovery
for Venus was well fit by a one component exponential function, the Venus-ATG5 recovery required the sum
of two independent exponential components. We attribute the faster component of the ATG5 recovery to
intracompartmental diffusion, as this rate (1.8±0.2×10−2 s−1) is consistent with our measured diffusion
coefficient, whereas the slower component of the ATG5 recovery is due to nucleocytoplasmic exchange. The
rate we obtained from our measurements of Venus nucleocytoplasmic exchange was 9.7±0.4×10−3 s−1.
This is very close to what was previously measured for passive diffusion of GFP through nuclear pores in
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Figure II.4: The nucleocytoplasmic exchange rate of Venus-ATG5 is slower than expected for a monomer
undergoing passive diffusion. (A) A quantitative FRAP assay was carried out on HeLa cells expressing either
Venus as a control for a (2 nm monomer or Venus-ATG5. We selectively photobleached the entire nuclear
region, and monitored the recoveries of fluorescence. Shown are representative examples of the experiment
just prior to the bleach (pre), just after the bleach (t = 0s), and after a significant amount of time had elapsed
(t = 300s)). (B) The recoveries from 2 different cells were averaged together and plotted according to the
following transformation: ln
(
I(∞)−I(t)
I(∞)−I(0)
)
. The 95 % confidence intervals for the fit to Venus are shown as
solid gray lines, while those for Venus-ATG5 are shown as solid black lines.
COS7 cells [170]. On the other hand, the rate we obtained from our measurements of Venus-ATG5 nucleocy-
toplasmic exchange was 2.7±0.5×10−4 s−1. That is about 30 fold slower than Venus. This result is not at
all surprising given our measured D for ATG5 is quite slow suggesting Venus-ATG5 is bound to a very large
complex. Our results are consistent with a model whereby the binding of Venus-ATG5 to a large∼ 1000 kDa
complex may be hindering its ability to undergo passive nucleocytoplasmic exchange.
II.3.4 Summary
Many biological hypotheses are experimentally untestable without the use of in vivo techniques such as FRAP
due to the complexity of purifying and reconstituting the molecular components. The power of FRAP is in
quantifying the nature and rate of molecular mobility in living cells. Here, we provide two examples of
important biological processes for which a detailed understanding of the underlying molecular mobility is
crucial. Most modern confocal microscopes have out-of-the-box capability to perform FRAP experiments
in simple and complex geometries. In addition, there have been many advances in the theoretical analysis
of FRAP experiments with the addition of methods and models to quantify, for example Brownian motion.
However, a remaining hurdle for the widespread adoption and use of FRAP among the scientific community
is that quantitative FRAP analysis requires handling of large datasets, and programming of complicated data
fitting routines using consensus approaches. Our solution to these problems is the development of an open
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source software program called FRAP-Toolbox.
II.4 Availability and future directions
We have created a website dedicated to all aspects of the development of FRAP-Toolbox and consensus
FRAP methods at http://www.fraptoolbox.com. The source codes for FRAP-Toolbox can be downloaded at
https://github.com/kraftlj/frap-toolbox.
II.5 Supplementary Material
II.5.1 Installation
The user has two options to run FRAP-Toolbox:
1. Using the source files and a full installation of MATLAB
2. As a standalone application by first installing the royalty-free MATLAB Compiler Runtime.
The standalone application and information about where to find the source files can found on our down-
load page at http://www.fraptoolbox.com/Download.
II.5.1.1 System requirements
FRAP-Toolbox has been tested on a PC running 32 bit Windows XP and 64 bit Windows 7, as well as a
MAC running OS X 10.9. The installation requirements for MATLAB 2013 can be found at http://www.
mathworks.com/support/sysreq/current release/.
II.5.1.2 FRAP-Toolbox using source code
In MATLAB, navigate to the FRAP−Toolbox directory containing the source files. Open and run MainGUI.
m.
II.5.1.3 FRAP-Toolbox as a standalone application
Instructions for a PC
1. Move the folder FRAP−Toolbox to a suitable location, e.g. C:\FRAP−Toolbox, on your hard drive.
2. Install the MATLAB Compiler Runtime by double clicking on the MCR R2013a win32 installer.exe
file, and following the on screen instructions.
3. Open classpath . txt for editing. By default this file is located in C:\Program Files\MATLAB\MATLAB
Compiler Runtime\v81\toolbox\local\classpath.txt. You need to first give yourself administrative
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privileges for editing classpath.txt by right clicking the file, click properties, click Security, click Edit,
and giving Full control to Users. Press OK to save the changes giving you rights to edit classpath . txt .
On a new line, at the end of the file, append the text file with, C:\FRAP−Toolbox\loci tools.jar. Save
the changes before closing.
4. You can now run FRAP-Toolbox by double clicking the FrapToolbox.exe file. Note: you can place
the FRAP−Toolbox directory in any desired location on your hard drive, but be sure to add the correct
path to loci tools . jar in classpath . txt .
Instructions for a MAC
1. Move the folder FRAP−Toolbox to the location, / Applications /FRAP−Toolbox, on your hard drive. /
Applications /FRAP−Toolbox can be accessed by selecting Applications in finder and then navigating
to the FRAP-Toolbox folder.
2. Install the MATLAB Compiler Runtime by double clicking on the MCR R2013b maci64 installer.zip
file, and following the on screen instructions.
3. Open classpath . txt for editing. This file can be found in / Applications /MATLAB R2013b/toolbox
/local/classpath.txt. You may need to right-click the MATLAB R2013b icon in your Applications
folder and select “Show Package Contents” in order to navigate there. You may need to give yourself
administrative privileges. On a new line, at the end of the file, append the text file with, / Applications
/FRAP−Toolbox/loci tools.jar. Save the changes before closing.
4. You can now run FrapToolbox Mac.app located in / Applications /FRAP−Toolbox. Note: you can
place the FRAP−Toolbox directory in any desired location on your hard drive, but be sure to add the
correct path to loci tools . jar in classpath . txt .
II.5.2 Supported image formats
FRAP-Toolbox directly opens raw image formats by integrating with Bio-Formats a standalone Java library
for reading and writing life science image file formats [161]. For a full list of the supported image formats
by Bio-Formats see http://www.openmicroscopy.org/site/support/bio-formats4/supported-formats.html. We
have verified FRAP-Toolbox correctly reads . lsm and .nd2 raw image formats from Zeiss and Nikon micro-
scopes.
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II.5.3 Using FRAP-Toolbox
FRAP-Toolbox begins with a main window (Figure II.5) that requires the user to provide several basic inputs.
The first input is the location where raw FRAP data is stored. The files in the selected directory appear in a
right hand panel, which allows the user to select one or more files. In the example (Figure II.5) we selected 10
FRAP datasets, which were acquired with a Zeiss LSM 510, and have the raw file extension . lsm. For these
datasets we photobleached a circular region in the nucleus of COS7 cells expressing the Venus fluorescent
protein. Next, the user must enter a set of basic inputs including the model to use for the data analysis,
the geometry of the bleaching ROI, the image frame number of the bleaching event, a constant background
intensity (experimentally determined with unlabeled controls), an option to correct the fluorescence intensity
using the mean intensity of the whole cell, as well as the number of pre-bleach images that should be used
for normalization purposes. Finally, the user will either choose to preview their settings by loading and
visualizing the first FRAP data set, or the user will press the next button to proceed to data fitting and data
saving.
Pressing the image preview button on the main window will load the first FRAP data set selected in the
list of files (Figure II.6). The previewing window includes a scroll bar at the bottom to allow previewing of
each image in the image stack, and will also plot a user defined bleaching ROI. If instead the user proceeds
to data fitting and data saving by pressing the next button, FRAP-Toolbox will load all of the selected FRAP
data sets using the Bio-Formats library for reading and writing life sciences image file formats [161]. A
new data analysis and visualization window will pop-up after the data is finished loading (Figure II.7). In
this example, we chose to use the FRAP-Toolbox diffusion model, and loaded all 10 FRAP data sets as was
shown in Figure II.5. The data analysis and visualization window (FigureII.7) consists of three parts. The
first part allows the user to provide several basic inputs to the fitting process, namely, initial guesses on fitting
parameters, boundaries on fitting parameters, and an option to exclude data points (for example, the fitting
can be constrained to early time points).
Next, the user will press the Run button to fit the FRAP data. As the software finishes the fitting routine,
several windows will automatically pop-up to provide the user with the ability to visually inspect the results
of the fitting routine (Figure II.8). For the case of the diffusion model, the initial conditions are plotted, as
well as the diffusion model fits to the FRAP curves. The optimized parameters from the fitting routine are
automatically uploaded in tabular form (Figure II.7). These optimized parameters, the raw FRAP data, as
well as the processed FRAP data, and fits to the FRAP data may now be conveniently saved to text files
by pressing the save button in the data analysis and visualization window (Figure II.7). Thus, with a few
steps, the FRAP-Toolbox provides users with easy access to the latest advancements in quantitative FRAP
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Figure II.5: FRAP Toolbox begins with a main window requesting several basic inputs from the user. First,
the user must navigate to the location of saved FRAP datasets on their computer or network (these are raw
microscope files, in this case named 1.lsm, 2.lsm, 3.lsm, ...). The user can select one or more of these files
at a given time depending on whether they wish to process them all at once or one at a time (Note: batch
processing requires all datasets to have the same structure.) Next, the user must select a suitable model for
data fitting, the geometry of the bleaching ROI, the frame number for the first post-bleach image, background
fluorescence intensity, as well as options for data normalization. Finally, the user can either preview their
settings and dataset using the preview button, or proceed to the data analysis screens.
Figure II.6: Previewing a FRAP dataset allows the user to verify the correctness of basic inputs.
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Figure II.7: The data analysis and visualization window allows the user to customize their fitting routine, as
well as view and save the results. In the left panel the user has the option of inputting specific initial guesses,
and lower and upper bounds for the fitting parameters. In addition, the user has the ability to specifically
control how many data points should be fit (often the user will not want to include data points after the
fluorescence has plateaued.) The user can specify if all of the FRAP data sets should be fit individually or
if the FRAP data sets should be averaged together before fitting. In the right panel the optimal parameters
returned by the fitting routine are displayed in table form. In addition, the user can choose to exclude certain
datasets by toggling them on and off in the far right panel. After the user is satisfied with the results of the
fitting routine there is a button which will save the data as a tab delimited text file.
data analysis. For more information about potential uses for FRAP, acquiring FRAP data, and quantitative
analysis we refer the user to recent literature on the topic [164, 165, 171].
II.5.4 Considerations for designing FRAP experiments
II.5.4.1 Diffusion
The user must:
1. Use a circular bleach ROI, record the (x,y) center of the ROI, and its radius (units are in pixels).
2. Record the frame number of the post-bleach image.
3. Independently measure the mean background intensity from unlabeled samples. Often background
fluorescence can be approximated as zero.
4. Acquire images that capture the entire cell within the frame if normalizing the FRAP curve by the mean
intensity of the whole cell.
5. Acquire at least one pre-bleach image so that the FRAP curves can be normalized.
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Figure II.8: Diffusion model pop-up windows allow easy inspection of the curve fitting results. (A) In the left
panel the radial post-bleach profiles and fits from each individual data set are displayed along with fits and
residuals. In the right panel the average post-bleach profile for all datasets and fit is displayed. (B) In the left
panel the normalized FRAP curves from each individual data set are displayed along with fits and residuals.
In the right panel is the average FRAP curve for all datasets and optimized model with residuals.
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Note: Decay due to imaging, and loss of fluorescence in a compartment due to the bleaching event are
both inherently corrected if the images are normalized by the mean intensity of the cell. If the FRAP curves
are not normalized by the mean intensity of the whole cell, the rate of unintentional photobleaching must be
taken into account. FRAP-Toolbox can model this slow decay as a single exponential if the user carries out
the recovery for a period of time after again reaching steady-state. Alternatively, the user can measure the
decay due to imaging using independent control samples, and input a decay constant as a fixed parameter in
FRAP-Toolbox.
II.5.4.2 Reaction 1 and Reaction 2 models
The user must:
1. Use a circular bleach ROI or a user defined polygon, If the bleach geometry is circular, record the (x,y)
center of the ROI, and its radius (units are in pixels).
2. Record the frame number of the post-bleach image.
3. Independently measure the mean background intensity from unlabeled samples. Often background
fluorescence can be approximated as zero.
4. Acquire images that capture the entire cell within the frame if normalizing the FRAP curve by the mean
intensity of the whole cell.
5. Acquire at least one pre-bleach image so that the FRAP curves can be normalized.
II.5.5 FRAP Models and their Applications
II.5.5.1 Diffusion
The Diffusion model is useful for simulating FRAP recoveries dominated by single component Brownian
motion. The Diffusion model is a closed form analytical equation for extracting an instrument independent
diffusion coefficient [158]. The model has several assumptions: 1) a homogeneous distribution of molecules;
2) a complete bleach through the sample in the z-direction such that diffusion occurs in two dimensions; 3)
infinite boundary conditions; and 4) a single diffusing component.
Denote the mean fluorescence intensity within the bleach region as, I(t). I(t) is normalized to the pre-
bleach steady-state intensity. The diffusion coefficient D and mobile fraction M f are found by fitting the data
to the FRAP model,
I(t) = I0
(
m=20
∑
m=0
−Kmr2e
m![r2e +m(8Dt+ r2n)]
)
M f +(1−M f )I(0) (II.3)
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where I0 is 1 for a normalized FRAP curve, and rn is the nominal radius of the bleaching ROI. This is a
modified form of the Axelrod equation [140] where the laser is assumed to be a Gaussian, and the parameters
re and K take into account the initial conditions for the solution of the diffusion equation. We determine re
and K by fitting the normalized radial post-bleach profile, I(x; t = 0), to an analytical approximation,
I(x; t = 0) = I0 exp
(
−K exp
[
−2x
2
r2e
])
(II.4)
where I0 is 1 for a normalized post-bleach profile, and x is the radial distance from the center of the
bleaching ROI [155]. D is a coefficient that is related to the physical properties of the diffusing species, and
the surrounding medium. Consider spherical molecules undergoing Brownian motion where the relationship
is as follows:
D =
kBT
6piηR
(II.5)
Here, kB is Boltzmanns constant, T is the absolute temperature, η is the viscosity of the medium, and R
is the radius of the diffusing sphere.
The M f quantifies the percentage of molecules that are free to diffuse.
Corrections
To correct for unintentional photobleaching during the imaging and loss of fluorescence in the com-
partment due to the bleaching event, we divide by the integrated intensity of the whole cell. Alternatively,
unintentional photobleaching can be corrected by approximating it as a single exponential decay process at
time points after the fluorescence has once again reached steady-state,
I(t) = e−kdecayt (II.6)
kdecay is the unintentional photobleaching rate constant.
The loss of fluorescence in the compartment due to the bleach leads to misleading mobile fractions less
than 1 unless this is corrected. To do this we measure the intensity inside an ROI adjacent to the bleach region
and correct by,
M fcorrect = 1− (Iad jacent(t)− I(t)) (II.7)
Curve Fitting Parameters
Initial conditions: K and re
Diffusion model: D and M f
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II.5.5.2 Reaction 1
The Reaction 1 model simulates FRAP recoveries that can be modeled using a single component exponential
function with the following form:
I(t) = a−be−ct (II.8)
There are a variety of physical problems where this model is appropriate. As an example, consider molecules
that are either free to diffuse f1, or bound in an immobile complex c1,
f1←→ c1 (II.9)
Assuming f1 equilibrates rapidly in the bleach region, f1 = Feq, and the differential equation governing
the change in the concentration of complex over time is,
dc1
dt
= k∗onFeq− ko f f c1 (II.10)
k∗on and ko f f are the pseudo-on-rate and off-rate for complex formation respectively. In this case, the
FRAP curve is modeled using,
I(t) = I(∞)− [I(∞)− I(0)]Ceqe−ko f f t (II.11)
where Ceq =
k∗on
ko f f
Feq from the equilibrium expressions. Therefore, for this example, in equation II.8,
a = I(∞), b = [I(∞)− I(0)], and c = ko f f .
Curve Fitting Parameters
a, b, and c
II.5.5.3 Reaction2
The Reaction 2 model simulates FRAP recoveries that can be modeled using a two component exponential
function with the following form:
I(t) = a−be−ct −de− f t (II.12)
Again, this model is appropriate for a variety of physical problems. As an example, consider molecules
that are either free to diffuse f1, or bound in an immobile complex c1, or a second immobile complex c2,
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f1←→ c1
f1←→ c2
(II.13)
In the same fashion as in the example presented for the Reaction 1 model, assuming f1 equilibrates rapidly
in the bleach region, f1 = Feq, and the differential equations governing the change in the concentration of
complex over time is,
dc1
dt
= k∗1onFeq− k1o f f c1
dc2
dt
= k∗2onFeq− k2o f f c2
(II.14)
where k∗1on and k
∗
2on, k1o f f and k2o f f , and c1 and c2 are the pseudo-on rates the off rates, and the concentrations
for the first and second complexes. In this case, the FRAP curve is modeled using,
I(t) = I(∞)− [I(∞)− I(0)]C1eqe−k1o f f
−[I(∞)− I(0)]C2eqe−k2o f f
(II.15)
where 1C1eq = 1+
k1o f f
k∗1on
(1+ k
∗
2on
k2o f f
), and 1C2eq = 1+
k2o f f
k∗2on
(1+ k
∗
1on
k1o f f
) from the equilibrium expressions. Therefore,
for this example, in equation II.12, a = I(∞), b = [I(∞)− I(0)]C1eq, c = k1o f f , d = [I(∞)− I(0)]C2eq, and
f = k2o f f .
Curve fitting parameters
a, b, c, d, and f
II.5.6 Test Data
You will find fully documented examples of how to work with each of the FRAP-Toolbox models along with
links to download the test datasets in what follows.
II.5.6.1 Diffusion
Using a Zeiss LSM 510 confocal microscope we photobleached a small 1 µm circular region in the cytoplasm
of HeLa cells expressing the fluorescent protein Venus or Venus-ATG5. We found the recoveries of these
FRAP datasets are fit well by the FRAP-Toolbox diffusion model.
1. Download the test datasets at http://fraptoolbox.com/DownloadFiles/Diffusion.zip.
2. Open FRAP-Toolbox.
3. Select the “Diffusion” model from the dropdown list of models, select “Circle” for the ROI, the post-
bleach image is “21”, the mean background intensity is “0”, Do not normalize by the whole cell, and
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Table II.2: Curve fitting parameters for the Diffusion test data
Initial Guess Lower Bound Upper Bound Fixed/Adj
K 1 0 Inf Adjustable
re 3 0 Inf Adjustable
D 10 0 Inf Adjustable
M f 1 0 2 Adjustable
kdecay 1e-3 0 Inf Adjustable
First Data Point Last Data Point
Profile Fit 1 5626
FRAP Fit 1 600
Decay Fit 500 600
use “10” pre-bleach images for the normalization.
4. Select all of the test datasets with names “Venus Cytoplasm *.lsm”. in the right hand panel.
5. Click the next button. FRAP-Toolbox will display a prompt requesting more information about the
bleaching ROI. Enter “256 23” for the center of the bleach ROI, and “9” for the radius of the bleach ROI
before pressing ok. Next, FRAP-Toolbox will ask you if you would like to calculate a corrected mobile
fraction. Choose “yes”. After the program loads the test datasets, the data analysis and visualization
window will appear.
6. Define the curve fitting parameters as shown in Table II.2. Select “No”, do not fit the averaged data.
Make sure all of the data sets in right hand panel are selected, and press Run.
7. As FRAP-Toolbox finishes the parameter optimization routine, two windows will automatically pop-up
to visualize the results. The first window is the initial conditions of the FRAP experiment. This is the
radially averaged intensity versus distance from the center of the bleaching ROI calculated from the
first image after the bleaching event. The second window is the FRAP curves. This is the integrated
intensity inside the bleaching ROI versus time. In both windows you will find the individual datasets
plotted on the left with optimized fits, and the average of all of the datasets plotted on the right with
the fit calculated by averaging the optimized parameters from the individual fits. Below each of these
plots you will find the residuals, which is the difference between the FRAP data and the optimized fit.
8. The optimized parameters from the fits are automatically uploaded into the table in the data analysis
and visualization window. See Table II.3 for a summary of these results.
9. In order to save these optimized parameters to a tab delimited . txt file, click the save button and
enter a descriptive tag-name for the files such as Venus Cytoplasm. FRAP-Toolbox will append *
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Diffusion Fit Parameters . txt , * Diffusion FRAP datasets . txt , and * Diffusion Postbleach profiles
. txt on the end of your tag-name. This will help you keep track of the model these save files came
from. You will notice that the optimized parameters, the optimized FRAP curves, and the optimized
post-bleach profiles all have their own . txt files.
That’s all! With a few easy clicks, one can extract quantitative diffusion coefficients, and mobile fractions
from raw image files using FRAP-Toolbox. We also included the Venus-ATG5 datasets, which should be
analyzed using the same procedure that was outlined above for Venus.
Table II.3: Optimized Curve fitting parameters for the Diffusion test data
FileNames k re D MF MF Corrected SS
Venus Cytoplasm 1.lsm 1.49227 3.52497 10.71 0.778875 0.944335 1.50E-06
Venus Cytoplasm 10.lsm 1.50518 3.92221 31.2611 0.798046 1.00502 6.80E-07
Venus Cytoplasm 11.lsm 1.24909 4.24756 69.1622 0.82531 0.990743 1.56E-06
Venus Cytoplasm 12.lsm 1.625 3.56148 28.1604 0.907764 0.951867 3.61E-07
Venus Cytoplasm 13.lsm 1.42082 3.62627 37.9302 0.842007 0.963113 1.97E-06
Venus Cytoplasm 14.lsm 1.43272 3.9784 38.5733 0.835316 0.998234 1.27E-06
Venus Cytoplasm 15.lsm 1.37271 3.86398 32.2078 0.794803 0.944473 1.70E-06
Venus Cytoplasm 2.lsm 1.41287 3.89225 34.0451 0.78997 1.00995 8.89E-07
Venus Cytoplasm 3.lsm 1.23637 4.32865 34.7806 0.795314 1.00073 1.73E-06
Venus Cytoplasm 4.lsm 1.13864 4.49717 49.0692 0.868395 1.04124 4.70E-07
Venus Cytoplasm 5.lsm 1.34346 3.90619 35.1196 0.808686 1.0077 2.00E-06
Venus Cytoplasm 6.lsm 1.25745 4.1467 24.0467 0.962918 1.02806 1.99E-06
Venus Cytoplasm 7.lsm 1.21802 4.05839 37.3884 0.857001 1.05485 1.80E-06
Venus Cytoplasm 8.lsm 1.19425 4.21281 47.7528 0.86983 0.963787 9.31E-07
Venus Cytoplasm 9.lsm 1.40613 3.99158 24.7671 0.87384 0.992741 6.77E-07
Avg. 1.35366 3.98391 35.665 0.840538 0.993123 1.40E-07
Venus-Atg5 Cytoplasm 1.lsm 2.13326 3.03023 12.3554 0.760985 0.960108 2.87E-06
Venus-Atg5 Cytoplasm 10.lsm 2.1835 2.99236 8.77951 0.901954 1.01935 3.03E-06
Venus-Atg5 Cytoplasm 11.lsm 1.9164 3.25953 13.375 0.866339 1.04926 3.25E-06
Venus-Atg5 Cytoplasm 12.lsm 2.08378 2.95893 10.5893 0.848098 1.00169 3.66E-06
Venus-Atg5 Cytoplasm 13.lsm 2.08839 3.0656 10.1128 0.790749 0.984935 2.99E-06
Venus-Atg5 Cytoplasm 14.lsm 2.59773 2.83641 5.36561 0.759974 0.994943 8.72E-07
Venus-Atg5 Cytoplasm 15.lsm 1.91945 3.14534 17.8351 0.80017 0.978091 3.13E-06
Venus-Atg5 Cytoplasm 2.lsm 2.29892 3.0424 8.89663 0.805056 0.982664 2.08E-06
Venus-Atg5 Cytoplasm 3.lsm 2.02854 3.13199 13.7669 0.824206 1.00859 3.04E-06
Venus-Atg5 Cytoplasm 4.lsm 2.20468 2.89709 13.3891 0.808597 1.01588 3.59E-06
Venus-Atg5 Cytoplasm 5.lsm 2.30317 2.82927 7.96808 0.769746 0.936311 2.46E-06
Venus-Atg5 Cytoplasm 6.lsm 2.29612 2.92836 7.18344 0.844084 0.9718 1.25E-06
Venus-Atg5 Cytoplasm 7.lsm 2.09037 3.10371 10.4623 0.854266 1.04887 2.11E-06
Venus-Atg5 Cytoplasm 8.lsm 2.20337 2.90907 9.52221 0.821008 0.990787 2.71E-06
Venus-Atg5 Cytoplasm 9.lsm 2.01298 3.13327 6.02719 0.858868 1.0058 1.96E-06
Avg. 2.15738 3.01757 10.3752 0.82094 0.996604 2.50E-07
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Table II.4: Curve fitting parameters for the Reaction 1 test data
Initial Guess Lower Bound Upper Bound Fixed/Adj
a 1 0 Inf Adjustable
b 1 0 Inf Adjustable
c 1 0 Inf Adjustable
kdecay 1e-3 0 Inf Adjustable
First Data Point Last Data Point
Profile Fit 1 130
Decay Fit 135 185
II.5.6.2 Reaction 1
Using a Nikon Eclipse Ti confocal microscope we photobleached Venus in the nuclear region of HeLa cells
using a user defined bleaching ROI. We found the recoveries of these FRAP datasets are fit well by the
FRAP-Toolbox Reaction 1 model.
1. Download the test datasets at http://fraptoolbox.com/DownloadFiles/Reaction1.zip.
2. Open FRAP-Toolbox.
3. Select the “Reaction 1” model from the dropdown list of models, select “User Defined” for the ROI,
the post-bleach image is “6”, the mean background intensity is “0”, Do normalize by the whole cell,
and use “5” pre-bleach images for the normalization.
4. Select all of the test datasets with names “Venus *.nd2” in the right hand panel.
5. Click the next button. FRAP-Toolbox will display a prompt requesting the user to draw the bleaching
ROI. The user must draw an ROI in the nuclear regions as shown in Figure II.9A. Next, FRAP-Toolbox
will ask the user to draw the whole cell ROI. The user must draw an ROI around the whole cell as
shown in Figure II.9A. After the program loads the test datasets, the data analysis and visualization
window will appear.
6. Define the curve fitting parameters as shown in Table II.4. Select “No”, do not fit the averaged data.
Make sure all of the data sets in right hand panel are selected, and press Run.
7. As FRAP-Toolbox finishes the parameter optimization routine, a single window will automatically
pop-up to visualize the results. Inside this window is the plotted FRAP curves. This is the integrated
intensity inside the bleaching ROI versus time. In both windows you will find the individual datasets
plotted on the left with optimized fits, and the average of all of the datasets plotted on the right with
40
Venus_1001 Venus_1002
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A
B
Figure II.9: User Defined ROIs for Reaction 1 and Reaction 2 test data. (A) Reaction 1 test data consists of
Venus 1001.nd2 and Venus 1002.nd2. (B) Reaction 2 test data consists of Venus−Atg5 1002.nd2 and Venus
−Atg5 1003.nd2. The bleach ROIs are shown as dashed black lines, and the whole cell ROIs are shown as
dashed white lines.
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the fit calculated by averaging the optimized parameters from the individual fits. Below each of these
plots you will find the residuals, which is the difference between the FRAP data and the optimized fit.
8. The optimized parameters from the fits are automatically uploaded into the table in the data analysis
and visualization window. See Table II.5 for a summary of these results (note that due to the user
input in the process of drawing ROIs these parameters may not be exactly the same, but should be very
close).
9. In order to save these optimized parameters to a tab delimited . txt file, click the save button and
enter a descriptive tag-name for the files such as Venus NCTransport. FRAP-Toolbox will append *
Reaction Fit Parameters . txt , and * Reaction FRAP datasets . txt on the end of your tag-name. This
will help you keep track of the model these save files came from. You will notice that the optimized
parameters, and the optimized FRAP curves all have their own . txt files.
That’s all! With a few easy clicks, one can extract quantitative kinetic data from raw image files using the
Reaction 1 model in FRAP-Toolbox.
Table II.5: Optimized Curve fitting parameters for the Reaction 1 test data
FileNames a b c SS
Venus 1001.nd2 0.873656 0.762292 0.00844 8.33E-08
Venus 1002.nd2 0.855588 0.753077 0.015899 6.70E-08
Avg. 0.864622 0.757685 0.01217 2.10E-07
II.5.6.3 Reaction 2
Using a Nikon Eclipse Ti confocal microscope we photobleached Venus-ATG5 in the nuclear region of HeLa
cells using a user defined bleaching ROI. We found the recoveries of these FRAP datasets are fit well by the
FRAP-Toolbox Reaction 2 model.
1. Download the test datasets at http://fraptoolbox.com/DownloadFiles/Reaction2.zip.
2. Open FRAP-Toolbox.
3. Select the “Reaction 2” model from the dropdown list of models, select “User Defined” for the ROI,
the post-bleach image is “6”, the mean background intensity is “0”, Do normalize by the whole cell,
and use “5” pre-bleach images for the normalization.
4. Select all of the test datasets with names “Venus−Atg5 *.nd2” in the right hand panel.
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Table II.6: Curve fitting parameters for the Reaction 2 test data
Initial Guess Lower Bound Upper Bound Fixed/Adj
a 1 0 Inf Adjustable
b 0.5 0 Inf Adjustable
c 0.05 0 Inf Adjustable
d 0.5 0 Inf Adjustable
f 5e-4 0 Inf Adjustable
kdecay 1e-3 0 Inf Adjustable
First Data Point Last Data Point
Profile Fit 1 185
Decay Fit 135 185
5. Click the next button. FRAP-Toolbox will display a prompt requesting the user to draw the bleaching
ROI. The user must draw an ROI in the nuclear regions as shown in Figure II.9B. Next, FRAP-Toolbox
will ask the user to draw the whole cell ROI. The user must draw an ROI around the whole cell as
shown in Figure II.9B. After the program loads the test datasets, the data analysis and visualization
window will appear.
6. Define the curve fitting parameters as shown in Table II.6. Select “Yes”, fit the averaged data. Make
sure all of the data sets in right hand panel are selected, and press Run.
7. As FRAP-Toolbox finishes the parameter optimization routine, a single window will automatically
pop-up to visualize the results. Inside this window is the plotted FRAP curves. This is the integrated
intensity inside the bleaching ROI versus time. In both windows you will find the individual datasets
plotted on the left with optimized fits, and the average of all of the datasets plotted on the right with
the fit calculated by averaging the optimized parameters from the individual fits. Below each of these
plots you will find the residuals, which is the difference between the FRAP data and the optimized fit.
8. The optimized parameters from the fits are automatically uploaded into the table in the data analysis
and visualization window. See Table II.7 for a summary of these results (note that due to the user
input in the process of drawing ROIs these parameters may not be exactly the same, but should be very
close).
9. In order to save these optimized parameters to a tab delimited . txt file, click the save button and enter
a descriptive tag-name for the files such as Venus−Atg5 NCTransport. FRAP-Toolbox will append *
Reaction Fit Parameters . txt , and * Reaction FRAP datasets . txt on the end of your tag-name. This
will help you keep track of the model these save files came from. You will notice that the optimized
parameters, and the optimized FRAP curves all have their own . txt files.
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That’s all! With a few easy clicks, one can extract quantitative kinetic data from raw image files using the
Reaction 2 model in FRAP-Toolbox.
Table II.7: Optimized Curve fitting parameters for the Reaction 2 test data
FileNames a b c d f SS
Venus-Atg5 1002.nd2
Venus-Atg5 1003.nd2
Avg. 1.4704 0.228479 0.0207795 1.12884 0.000442516 1.78E-07
II.5.7 Troubleshooting
FRAP-Toolbox has several built-in warning dialogs that will display when it detects potential errors. For ex-
ample, when batch processing, all of the datasets must have been acquired using identical settings; otherwise,
FRAP-Toolbox will halt and display the appropriate error dialogue. If a user comes across bugs they are en-
couraged to report these by following the instructions on our Bug Reporting page at http://www.fraptoolbox.
com/BugReporting.
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CHAPTER III
Size, stoichiometry, and organization of soluble LC3-associated complexes
Although LC3 is known to associate with tens of proteins, relatively little is known about soluble LC3 aside
from its interactions with the LC3 lipid conjugation machinery. In previous studies we found autophagosome-
independent GFP-LC3B diffuses unusually slowly for a protein of its size, suggesting it may constitutively
associate with a high molecular weight complex, form homo-oligomers or aggregates, or reversibly bind
microtubules or membranes. In this chapter we begin with an introduction to the problem. We then go on
to examine the source of LC3’s slow diffusion by characterizing the size, stoichiometry, and organization of
autophagosome-independent LC3B in living cells and in cytoplasmic extracts using fluorescence recovery
after photobleaching (FRAP) and fluorescence polarization fluctuation analysis (FPFA). The details of our
FRAP assay were described in Chapter II. These findings provide new insights into the nature of soluble
LC3B and illustrate the power of FRAP and FPFA to investigate the emergent properties of protein complexes
in the autophagy pathway.
III.1 Introduction
Autophagy is a major pathway for the capture and degradation of cytosolic materials via the lysosome. A
distinctive feature of the pathway is the formation of a double membrane bound vesicle called the autophago-
some [31]. Autophagosome membrane expansion, fusion and substrate selection are carried out, in part, by
a family of ATG8 proteins [32, 67, 80, 92–94, 127, 172, 173]. Despite these proposed major roles for ATG8
proteins in autophagy, there are still many open questions in regard to how ATG8 proteins carry out these
tasks [174].
ATG8 proteins share high structural (but not sequence) homology with ubiquitin, and thus have been
termed ubiquitin-like proteins [79]. Interestingly, unlike ubiquitin, which is conjugated to other proteins,
ATG8 proteins are conjugated to the head group of the lipid phosphatidylethanolamine [84]. In mammals,
the best-studied ATG8 family member, MAP1LC3B (LC3), exists in both soluble (LC3-I), as well as lipid
modified form (LC3-II) [90]. Under conditions of stress or starvation, LC3 lipid modification becomes upreg-
ulated, in turn targeting the protein to autophagosome membranes [91]. LC3 is released from autophagosome
membranes by the cysteine protease activity of ATG4B [87].
LC3 and other members of the ATG8 protein family have numerous interacting proteins, suggestive of
This chapter is adapted from the published manuscript: Kraft et al. [164]
45
their possible participation in multi-protein complexes [9, 44, 59, 69, 116, 122–124, 129]. In addition, many
LC3 interacting proteins contain a consensus LC3 interacting motif (W/F/Y-X-X-L/I/V) for efficient binding
to a hydrophobic surface on LC3 in the region of residues F52/L53 and R70 [32, 45, 127]. Mutations to these
key residues on LC3’s hydrophobic protein interacting surface disrupt binding to tens of proteins, highlighting
the importance of this region for engaging other proteins in productive binding [9, 69, 100, 127, 129, 130].
Importantly, it is unknown if soluble LC3 interacts with its protein partners in a binary fashion or if instead
it constitutively associates with multi-protein or other multicomponent complexes to accomplish its varied
functions in autophagy.
Using confocal FRAP, our group recently showed that the soluble form of LC3 diffuses unusually slowly
for a cytoplasmic protein of its size under basal conditions [121, 165]. Because the diffusion coefficient of
a soluble, freely diffusing molecule is inversely related to its radius, this slower-than-expected-diffusion of
LC3 could potentially reflect its association with macromolecular complexes comprised of LC3 and other
components of the autophagy pathway. Alternatively, the slow diffusion of soluble LC3 could potentially
arise from reversible binding to microtubules in cells[109] or the incorporation of LC3 into homo-oligomers
or aggregates or possibly membranes [93, 105, 106].
To address these possibilities, in the current study, we investigate the size, stoichiometry, and organization
of LC3-containing protein complexes using two complementary fluorescence based approaches, confocal
Fluorescence Recovery After Photobleaching (FRAP) and Fluorescence Polarization Fluctuation Analysis
(FPFA). The first of these methods, FRAP, is a powerful and versatile tool for measuring the ensemble dy-
namics of molecules. The instrumentation for FRAP is now widely accessible in many laboratories, and
by analyzing FRAP data with recently described models it is now possible to accurately measure diffusion
coefficients, as well as quantify reversible interactions [149, 158, 175]. FRAP also has the unique ability to
quantify the extent of irreversible interactions and very slow turnover on the timescale of the measurements as
reflected in the mobile fraction. The second approach, FPFA, is a newly developed experimental method com-
bining Fluorescence Correlation Spectroscopy (FCS) and Time Resolved Fluorescence Anisotropy (TRFA)
[176]. Like FRAP, FCS reports on the diffusional mobility of molecules. However, FCS has exceptional
sensitivity enabling measurements of the concentrations of fluorescent proteins in the pM to nM range and
is capable of resolving the diffusion coefficients of multiple diffusing species, and their molecular brightness
[142]. By combining FCS and TRFA into a single measurement, FPFA enables the simultaneous measure-
ment of translational and rotational mobility, concentration, brightness, and homo-FRET [176]. Thus, FPFA
is a tool that can be used to simultaneously investigate a protein’s mobility, stoichiometry, and organization.
Our FRAP and FPFA measurements reveal that under basal conditions, soluble Venus-LC3 diffuses as
if it associates with a complex with an effective molecular weight of approximately 500 kDa in size, and
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each complex contains on average a single LC3. Similar complexes were observed in living cells and in
cytoplasmic extracts depleted of intact microtubules. In addition, we show that the size and stoichiometry of
complexes containing LC3 are altered by mutational disruption of LC3’s hydrophobic binding surface, but not
mutational disruption of LC3’s lipid modification. The effective size of the LC3 associated complexes only
modestly changes after perturbations to the autophagy pathway with rapamycin or chloroquine treatments.
These findings provide new insights into the nature of soluble LC3 and illustrate the power of confocal FRAP
and FPFA to provide novel insights into the emergent properties of protein complexes in the autophagy
pathway.
III.2 Results
III.2.1 Effect of mutations of the hydrophobic binding interface and lipid modification site on the
subcellular distribution of LC3.
In previous studies, we found GFP-LC3 and Venus-LC3 diffuse more slowly in the cytoplasm of cells than
expected for a monomer using confocal FRAP, suggesting LC3 may associate with a high molecular weight
complex [121, 165]. Given many LC3 interacting proteins interact with a hydrophobic interaction surface on
LC3 using a W/F/Y-X-X-L/I/V motif,[32] we asked whether disruption of specific residues in this region on
LC3 will disrupt its association with the putative high molecular weight complexes. To address this question,
we focused on two sets of mutations, R70A and F52A/L53A. These mutations were shown to disrupt binding
to at least 18 and 9 binding partners respectively [9]. Several of the disrupted binding partners are involved
in activities ranging from LC3’s lipid modification to autophagy substrate specificity [9, 59, 69, 129]. For
comparison, we also examined a G120A mutant of LC3, which is unable to undergo lipid modification [106].
We first examined the effects of the R70A, F52A/L53A, and G120A mutations on the subcellular distri-
bution of LC3 in HeLa cells. As previously described, Venus-LC3 was found in a diffuse cytoplasmic form
as well as in discrete 0.5 µm–2 µm puncta in the cytoplasm corresponding to LC3 labeled autophagosomes
as well as autophagosome independent substrates and aggregates [105]. Some diffuse Venus-LC3 was also
observed in the nucleus, consistent with our previous findings quantifying the amount of GFP tagged LC3 in
the nucleus (Fig. III.1A) [121].
Like wild type Venus-LC3, a substantial fraction of diffuse Venus-LC3(F52A/L53A), Venus-LC3(R70A),
and Venus-LC3(G120A) was present in both the cytoplasm and nucleoplasm of live HeLa cells (Fig. III.1B-
D). However, on average about two fold fewer puncta were present in cells expressing Venus-LC3(R70A)
than in cells expressing Venus-LC3 (p < 0.008; Bonferonni corrected t-test), and even fewer puncta were
positive for Venus-LC3(F52A/L53A) or Venus-LC3(G120A) (p< 0.008; t-tests) (Fig. III.1E). These findings
are consistent with the idea that LC3’s hydrophobic binding surface regulates protein-protein interactions,
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Figure III.1: Venus-LC3(F52A/L53A) and Venus-LC3(R70A) show a reduced association with cytoplas-
mic puncta compared to wild type Venus-LC3. (A) Venus-LC3, (B) Venus-LC3(F52A/L53A), (C) Venus-
LC3(R70A), and (D) Venus-LC3(G120A) were expressed individually in HeLa cells and imaged live under
basal conditions (complete media, 37 ◦C) using confocal microscopy. Scale bar is 10 µm. (E) The numbers of
∼ 0.5 µm–2 µm punctate spots per cell cytoplasm were counted for each of the indicated constructs. Bars rep-
resent the median. One-way ANOVA test p < 1×10−4 . Pairwise comparisons between all of the constructs
were made using Bonferonni corrected t-tests as described in the text.
including SQSTM1/p62 binding, which facilitate targeting LC3 to autophagy-independent puncta [130]. In
addition, they suggest that the F52A/L53A and G120A mutants are more strongly defective in their ability to
bind to cytoplasmic puncta than is the R70A mutant of LC3.
III.2.2 LC3 retains the ability to associate with autophagosomal membranes upon disruption of its
hydrophobic binding interface.
Since the Venus-LC3(F52A/L53A), Venus-LC3(R70A), and Venus-LC3(G120A) mutants have defects in the
numbers of puncta present under steady-state conditions, we wanted to determine if these mutants retain their
ability to associate with autophagosomal membranes. To test this, we monitored their accumulation on au-
tophagosomal membranes after inhibition of lysosomal acidification with chloroquine. After treatment with
chloroquine, both Venus-LC3(F52A/L53A) and Venus-LC3(R70A) accumulated on autophagosomal mem-
branes, similar to wild type Venus-LC3 (Fig. III.2A-F). This result is consistent with what was previously
reported for a GFP-LC3(F52A) mutant after treatment with both starvation and Bafilomycin A1 [100]. In con-
trast, no changes to the localization of Venus-LC3(G120A) were observed after treatment with chloroquine
(Fig. III.2G,H). This is consistent with the inability of the G120A mutant to be targeted to autophagosomes
by lipid modification of this residue [106].
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Figure III.2: Venus-LC3(F52A/L53A) and Venus-LC3(R70A), like wild type Venus-LC3, accumulate on
lysosomal membranes after treatment with chloroquine. Cells expressing (A,B) Venus-LC3, (C,D) Venus-
LC3(R70A), (E,F) Venus-LC3(F52A/L53A), or (G,H) Venus-LC3(G120A) were imaged under basal condi-
tions (A,C,E,G) or after a 2 hour incubation with 100 µM chloroquine (B,D,F,H). Scale bar is 10 µm. The
steady-state localization of LC3, R70A, and F52A/L53A on autophagosomal membranes is upregulated af-
ter blocking lysosome function with chloroquine. In contrast, G120A was not targeted to autophagosomal
membranes under these conditions. (I) Individual spots as seen in (B,D,F,H) were selectively photobleached
using a 1 µm radius Bleach ROI revealing a slow turnover rate for membrane associated LC3, R70A, and
F52A/L53A puncta in contrast with the faster turnover rate of substrate associated G120A puncta. The
differences in the recovery of membrane associated LC3 versus substrate associated LC3 are reflected in
the mobile fractions quantified in (J). Symbols for the R70A recovery are underneath the symbols for the
F52A/L53A recovery. (K,L) SDS-PAGE and western blot for LC3-I versus LC3-II under basal conditions
and after chloroquine treatment. (K) Antibodies against LC3 show there are no major defects in the formation
of GFP-LC3-II for LC3, R70A, or F52A/L53A, in contrast with the negative control G120A. (L) Similar to
(K), except the electrophoresis was carried out for a longer period of time in order to obtain better resolution
of the higher molecular weight GFP-LC3-I versus GFP-LC3-II bands and blotting was performed using an
anti-GFP antibody. Antibodies against tubulin were used as loading controls.
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Table III.1: Predicted molecular weights and mobile fractions for Venus, Venus-LC3, and Venus-LC3 mutants
based on the FRAP diffusion measurements in live HEK 293 cells using under basal conditions.
Monomer ξ FRAP Predicted FRAP Mobile
Construct MW (kDa) MW (kDa) Fraction (%)
Venus 27 N/A 100±1 (34)
Venus-LC3 45 500±200 (30) 99±1 (30)
Venus-LC3 (F52A/L53A) 45 1200±400 (30) 100±1 (30)
Venus-LC3(R70A) 45 130±50 (30) 102±2 (30)
ξ calculated assuming diffusing species has a spherical shape; mean ± 95 % CI (N = #cells)
It was recently shown, using selective photobleaching of GFP-LC3 associated puncta, that LC3 in-
corporated into autophagosomal membranes turns over much more slowly than GFP-LC3 associated with
autophagy substrates [153]. We used this method to further characterize the nature of the LC3-positive
puncta present after incubation with chloroquine (Fig. III.2I). The FRAP analysis revealed that while Venus-
LC3, Venus-LC3(R70A) and Venus-LC3(F52A/L53A) puncta had very large immobile fractions, Venus-
LC3(G120A) had a relatively high mobile fraction indicative of more rapid turnover (Fig. III.2J). This is
consistent with the notion that R70A and F52A/L53A mutants of LC3 retain their ability to become lipid
modified and subsequently incorporated into the membranes of autophagosomes, whereas the LC3(G120A)
mutant does not. In order to further verify that there are no defects in the LC3-I to LC3-II processing of
the R70A and F52A/L53A mutants we performed SDS-PAGE and western blotted for LC3 (Fig. III.2K)
and GFP (Fig. III.2L) both under basal conditions and after treatment with chloroquine. This experiment
showed that there are no defects in the LC3-I to LC3-II processing of Venus-LC3, Venus-LC3(F52A/L53A),
or Venus-LC3(R70A) in stark contrast with the GFP-LC3(G120A) negative control [106].
III.2.3 Disruption of LC3’s hydrophobic binding interface changes the effective diffusion of LC3-
associated complexes in living cells.
Next, we tested the effect of the R70A and F52A/F53A mutations on the diffusional mobility of soluble
cytoplasmic LC3 in living cells using a quantitative confocal FRAP assay [158, 175]. As shown in (Fig.
III.3A), this experiment was aimed towards quantifying the diffusion of the diffuse pool of LC3, and excludes
any LC3 associated with puncta. As an internal control, we performed FRAP experiments of Venus, a soluble,
freely diffusing protein. The Venus FRAP curve was well fit by a single component model for Brownian
motion with a diffusion coefficient of 41±4 µm2/s and a mobile fraction of 100 % in HEK 293 cells (Fig.
III.2B,C, Table III.1). Next, we carried out FRAP experiments on Venus-LC3 in the cytoplasm. Consistent
with our previous findings[121, 165], we found Venus-LC3 had an approximately two and half fold slower
D compared to that of Venus, much slower than the predicted diffusion coefficient for monomeric Venus-
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LC3 (p ≤ 0.008; t-test) (dashed line in Fig. III.3C). This corresponds to an effective molecular weight of
∼ 500 kDa (Table III.1). We found similar results in HeLa cells (p≤ 0.008; t-test) (Fig. III.3D, Table III.2).
After establishing baselines for diffusion comparisons, next, we measured the diffusion of soluble Venus-
LC3(F52A/L53A) and Venus-LC3(R70A) by confocal FRAP. We found that their mobile fractions were also
both approximately 100 % (Tables III.1,III.2), similar to that of soluble Venus-LC3 itself (ns; p > 0.008;
t-tests). However, their diffusion coefficients differed from that of one another as well as from that of Venus
LC3. Interestingly, in HEK 293 cells, D for Venus-LC3(F52A/L53A) (11.6±0.7 µm2/s) was slower than that
of wild type Venus-LC3 (15±2 µm2/s) (p≤ 0.008; t-test), while D for Venus-LC3(R70A) (24±2 µm2/s) was
faster than Venus-LC3, but still not to the level expected for a Venus-LC3 monomer (p≤ 0.008; t-test) (Fig.
III.3). Similar results were obtained in HeLa cells (Fig. III.3D). Assuming the slow diffusion of the proteins
reflects their association with spherical complexes, their predicted molecular weights would be ∼ 1.2 MDa
for Venus-LC3(F52A/L53A) and ∼ 130 kDa for Venus-LC3(R70A) (Tables III.1,III.2).
III.2.4 The slow diffusion of LC3 is not due its lipid modification or association with autophagosome
membranes
Although our FRAP experiments were directed towards the soluble pool of LC3, it is formally possible that
LC3’s slow diffusion is a result of a small fraction of lipid modified LC3 incorporated into sub-diffraction
vesicles or autophagosomes. This seemed unlikely, because, theoretically, ∼ 250 nm radius vesicles would
be expected to diffuse ∼ 100 fold slower than Venus (D1/D2 = 2nm/250nm), whereas, experimentally,
Venus-LC3 diffused only∼ 2.5 fold slower. However, our FRAP measurements do not have the resolution to
adequately test this possibility without additional experimental information [141]. Therefore, to address this
question we performed FRAP measurements on Venus-LC3(G120A), since this mutation of LC3 prevents
its lipid modification and subsequent incorporation into autophagosomal membranes [86]. As shown in Fig.
III.3D, Venus-LC3(G120A) diffuses similarly to wild type Venus-LC3 (ns; p > 0.005; t-test). These data
support the notion that the slow diffusion of LC3 is not the result of its association with autophagosomes or
interactions with other molecules that depend on lipid modification of the protein. Rather, the slow diffusion
could reflect the association of LC3 with other molecules.
III.2.5 The effective size of putative LC3 associated complexes are modestly affected by autophagy
modulators
In order to gain further insights into how these complexes are modulated by perturbations to the autophagy
pathway, we extended our analysis of the diffusion of LC3 under basal conditions to two additional condi-
tions known to modulate the autophagy pathway. The first condition was to inhibit autophagy by incubating
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Figure III.3: Mutations to LC3’s hydrophobic protein interaction surface at residues R70 or F52/L53 change
the diffusional mobility of Venus-LC3 in the cytoplasm of living cells. (A) Cells expressing Venus, Venus-
LC3, Venus-LC3(R70A, Venus-LC3(F52A/L53A), or Venus-LC3(G120A) were photobleached using a 1 µm
radius Bleach ROI placed in the cytoplasm such that puncta were avoided. Dashed lines designate the typical
Imaging ROI and Bleach ROI used in these experiments. (B) Comparison of the mean FRAP data from
approximately 30 HeLa cells expressing either Venus or Venus-LC3 (symbols) were well fit by a Brownian
diffusion model (solid lines). The data are normalized between 0 and 1 using (F(t)−F(0))/(F(∞)−F(0))
to more clearly demonstrate the differences in their recovery rates. (C, D, E, F) Box plots of the diffusion
coefficients obtained from FRAP experiments on either HEK 293 cells or HeLa cells. While experiments
summarized in (C) and (D) were carried out under basal conditions those in (E) were obtained from HeLa cells
pre-treated for 2 hours with 100 µm chloroquine, and those in (F) were obtained from HeLa cells pre-treated
for 2 hours with 200 nM rapamycin. The ratio of D for the monomeric Venus control to LC3, F52A/L53A,
R70A, or G120A is a quantitative indicator of their effective sizes. Whiskers represent the minimum and
maximum. N can be found in Table III.1. The dashed horizontal lines in (C, D, E) are the predicted diffusion
coefficients for a 45 kDa Venus-LC3 monomer assuming both Venus and Venus-LC3 are spherical. For (C,
D, E) One-way ANOVA test p ≤ 1×10−4. Pairwise comparisons between all of the constructs were made
using Bonferonni corrected t-tests as described in the text.
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the cells with 100 µM chloroquine for 2 hours, and the second condition was to stimulate autophagy by in-
cubating the cells with 200 nM rapamycin for 2 hours before performing FRAP measurements. We found
that rapamycin and chloroquine treatments produced similar changes in the diffusion of the constructs shown
in Fig. III.3. At first glance, the trends between the constructs appear to be maintained. However, after
normalization to the diffusion of Venus, using the Stokes Einstein relationship as before, we found that the
effective molecular weights for the LC3 associated complexes were modestly upregulated approximately two
fold compared to basal conditions (p≤ 0.005; t-tests; see Table III.2 for a summary). These data suggest that
the effective sizes of the soluble LC3 associated complexes are only modestly affected by perturbations to
the autophagy pathway with rapamycin and chloroquine in vivo.
III.2.6 Disruption of LC3’s hydrophobic binding interface but not of its lipidation site changes the
effective diffusion of LC3-associated complexes in cytoplasmic extracts.
In order to test if the complexes observed in cells are intrinsically stable, or if they require cellular compo-
nents, such as microtubules, we next examined the properties of the LC3 constructs in cytoplasmic extracts.
In principle, it is possible to measure the diffusion of LC3 in cytoplasmic extracts using confocal FRAP;
however, we wished to obtain additional information about the putative complexes, such as whether multiple
types of complexes were present and how many LC3 molecules were present in each complex. Therefore,
we turned to another technique that is sensitive to protein mobility and stoichiometry, FPFA[176], to analyze
the LC3 associated complexes cytoplasmic extracts. To carry out FPFA measurements on the fluorescently
labeled proteins in our cytoplasmic extracts, we utilized a recently described custom-built FPFA instrument
with two-photon excitation to define the focal volume [176]. HEK cells expressing Venus or Venus-LC3 were
extracted using passive lysis buffer and clarified by a brief high speed spin before the FPFA measurements
were performed.
In order to determine the diffusivity and molecular brightness of the species, FPFA macro-time measure-
ments of orthogonally polarized fluorescence emission were cross-correlated. The cross-correlation curves
for both Venus and Venus-LC3 were well fit by a single-component model for Brownian motion suggesting
the absence of multiple diffusing species with large differences in their sizes (See Fig. III.4A for an exam-
ple of one versus two component models). The diffusion coefficients from the fits to Venus and Venus-LC3
were 67±2 and 25±2 µm2/s, respectively (Fig. III.4B). Thus, the diffusion coefficient for Venus-LC3 in
cell extracts was much slower than Venus alone (approximately 2.5 fold) as seen previously using FRAP in
live cells, and much slower than predicted for a freely diffusing Venus-LC3 monomer (p ≤ 0.003; t-tests).
Making the simplifying assumption that the complexes containing Venus-LC3 are spherical, we calculated
their predicted size is about 500 kDa (Table III.3).
54
Ve
nu
s
LC
3
F5
2A
/L5
3A
 (fa
st)
F5
2A
/L5
3A
 (s
low
)
R7
0A
G1
20
A
0
20
40
60
80
Di
ff
us
io
n 
co
ef
fic
ie
nt
 ( µ
m
2 /s
)
A
100 101 102 103 104 105 106
-0.005
0.000
0.005
Time (µs)
Re
si
du
al
s
100 101 102 103 104 105 106
0.000
0.002
0.004
0.006
0.008
0.010
Venus-LC3
(F52A/L53A)
One Component
Tw o Component
C
ro
ss
-c
or
re
la
tio
n
B
HEK293 Basal HEK293 Chloroquine
C
NZ - nocodazole
TXL - Paclitaxel
Lysis Buffer + 5 μg/ml NZ + 20 μM TXL
S200 P200 P200 P200S200 S200
α tub
D
LC
3
F5
2A
/L5
3A
R7
0A
G1
20
A
0
20
40
60
80
Figure III.4: Mutations to LC3’s hydrophobic pro-
tein interaction surface at residues R70 or F52/L53
change the diffusional mobility of Venus-LC3 in cy-
toplasmic extracts. FPFA measurements were col-
lected from cytoplasmic extracts of HEK 293 cells
individually expressing Venus, Venus-LC3, Venus-
LC3(F52A/L53A), Venus-LC3(R70A), or Venus-
LC3(G120A); the macro time fluorescence fluctua-
tions were cross-correlated and fit with diffusion mod-
els, see (A) for an example of one and two component
fits to the Venus-LC3(F52A/L53A) data. In this case,
the two component model was a better fit than the one
component model. (B,C) Diffusion coefficients ob-
tained from the fits to the data collected under basal
conditions or after the cells were incubated for 2 hours
in 100 µM chloroquine respectively. Compare the ra-
tio of the Venus control to each of the constructs as an
indicator of their effective sizes. The dashed lines are
the predicted diffusion coefficients for a 45 kDa Venus-
LC3 monomer assuming both Venus and Venus-LC3
are spherical. Bars represent the median. Samples
are replicate measurements from 4-5 extract prepara-
tions. One-way ANOVA test p ≤ 1×10−4. Pairwise
comparisons between all of the constructs were made
using Bonferonni corrected t-tests as described in the
text. (D) Assay to quantify the amount of polymer-
ized microtubules in the extract preparations. Unpoly-
merized tubulin remains in the supernatant (S200) af-
ter centrifugation at 2×105 RCF over a sucrose cush-
ion, while polymerized microtubules pellet (P200). As
controls, extracts were treated with nocodazole (NZ)
to depolymerize microtubules or taxol (TXL) to stabi-
lize microtubules. Note the buffer that was used for
the extract preparations is not suitable for stabilizing
polymerized microtubules.
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After establishing baselines for diffusion comparisons, next, we performed FPFA measurements of the
Venus-LC3(R70A) and Venus-LC3(F52A/L53A) mutants in cytoplasmic extracts. Interestingly, the cross-
correlation curve for Venus-LC3(F52A/L53A) was not well described by a single component model (Fig.
III.4A). It was, however, fit well by a two component diffusion model where approximately three quarters of
the molecules have a diffusion coefficient of 28±4 µm2/s while the remainder have a diffusion coefficient
of 5±2 µm2/s (Fig. III.4A,B). The diffusion coefficient for the faster diffusing Venus-LC3(F52A/L53A)
species was similar to that of Venus-LC3 (p > 0.003; t-test), while the diffusion coefficient for the slower
diffusing species was much slower than Venus-LC3 (p ≤ 0.003; t-test). The cross-correlation curve for
Venus-LC3(R70A) on the other hand was well fit by a single component diffusion model with a diffusion
coefficient of 35±3 µm2/s, which was statistically faster than Venus-LC3 (p ≤ 0.003; t-test) (Fig. III.4B).
Assuming the complexes have a spherical geometry, the predicted sizes of the Venus-LC3(F52A/L53A) as-
sociated complexes are about 300 kDa and 50 MDa (note however that we observed relatively high variability
in the measurements of the F52A/L53A construct), and the predicted size of Venus-LC3(R70A) associated
complexes is about 190 kDa (Table III.3). These values are in agreement with those measured by confocal
FRAP in live cells, assuming the D measured for Venus-LC3(F52A/L53A) by FRAP reflects the contributions
of two diffusing species detected by FPFA.
In order to directly test if LC3’s incorporation into protein complexes is regulated by its lipid mod-
ification we performed FPFA measurements on Venus-LC3(G120A). The diffusion coefficient for Venus-
LC3(G120A), 23.4±0.9 µm2/s, was identical to wild type Venus-LC3 (ns; p > 0.003; t-test), further sup-
porting our conclusion based on the FRAP results that the slow diffusion of Venus-LC3 is not due to its lipid
modification (Fig. III.4B). In addition, these data further suggest that LC3’s lipid modification is not a major
factor in regulating the effective size of the LC3 associated complexes.
Our in vivo results revealed the effective sizes of complexes are modestly upregulated by perturbations
to the autophagy pathway. We next explored the possibility that the effective sizes of these soluble LC3
associated complexes under chloroquine conditions are maintained in vitro. We prepared cytoplasmic ex-
tracts from cells incubated in 100 µM chloroquine for 2 hours before cell lysis. We found that in cells treated
with chloroquine, there was little effect on the sizes of the wild type Venus-LC3, Venus-LC3(R70A), and
Venus-LC3(G120A) associated complexes compared to basal conditions (ns; p > 0.003; t-test) (Fig. III.4C).
The diffusion of the Venus-LC3(F52A/L53A) complex under chloroquine conditions was primarily fit with a
single component model. These results differed slightly from what we observed in living cells, and suggest
that some of the components of the soluble LC3 associated complexes present after treatment with chloro-
quine were not maintained in vitro. These results further support the conclusion that the complexes we are
detecting are independent of lipid modified LC3 incorporated in autophagosomal membranes, as this would
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have shown up as a component with a diffusion coefficient approximately two orders of magnitude slower
than Venus.
III.2.7 Interactions of LC3 with polymerized microtubules are not responsible for the slow diffusion
of soluble LC3.
It is formally possible that LC3’s slow diffusion could be due to interactions with microtubules given that LC3
was originally identified as a microtubule associated protein [109]. To address this possibility we specifically
tested for the presence of polymerized microtubules in the cytoplasmic extracts by sedimentation at a rela-
tively high centrifugal force [177]. We were unable to detect significant levels of polymerized microtubules
under the conditions of our experiments (Fig. III.4D). This suggests that the slow diffusion of Venus-LC3
detected by FPFA is not the result of reversible binding to polymerized microtubules. We further tested this
possibility in vivo, by performing FRAP experiments on cells depleted of polymerized microtubules by treat-
ment with nocodazole for 15 minutes on ice followed by 1 hour at 37 ◦C. We observed that the effective sizes
of the complexes were maintained in live cells treated with nocodazole (Table III.2), further supporting the
notion that reversible interaction with polymerized microtubules is not responsible for LC3’s slow diffusion.
III.2.8 There is no evidence of homo-FRET between Venus-LC3, Venus-LC3(F52A/L53A), Venus-
LC3(R70A), or Venus-LC3 (G120A).
Our diffusion measurements indicate soluble LC3 is constitutively associated with a high molecular weight
complex; however, it is possible the complexes we detect by diffusion may correspond to small aggregates of
LC3. We previously tested for oligomerization of puncta independent LC3 in vivo using Cerulean-LC3 and
Venus-LC3 as FRET donors and acceptors. FRET microscopy failed to detect significant levels of energy
transfer, suggesting soluble LC3 is unlikely to homo-oligomerize or aggregate [165]. However, unfavorable
dipole-dipole orientation may have prevented energy transfer, even between fluorophores in close proximity
[178, 179]. Thus, LC3’s oligomerization state remains unclear.
In order to test if there are multiple LC3 molecules within FRET proximity in our cytoplasmic extracts,
next, we examined our FPFA measurements for evidence of homo-FRET. Homo-FRET analysis provides
information about the proximity of Venus fluorophores, and thus may be able to detect homo-oligomerization
of Venus-LC3 or the Venus-LC3 mutants. For the purpose of performing an analysis of homo-FRET, our
FPFA micro-time measurements of orthogonally polarized fluorescence emission were used to calculate time-
resolved fluorescence anisotropy decay curves. The decay of fluorescence anisotropy can be due to several
factors including rotational diffusion and the presence or absence of FRET [178]. In the absence of FRET, we
expect the fluorescence anisotropy curve will exhibit a single exponential decay as was previously measured
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for Venus, and in the presence of FRET we expect the fluorescence anisotropy curves will exhibit a multi
component exponential decay as was previously measured for a series of positive controls consisting of
Venus molecules separated by short linkers [176].
We found the fluorescence anisotropy decay curves for both Venus and Venus-LC3 were well fit using a
single exponential decay model, indicating little, if any, homo-FRET was occurring in these samples (Fig.
III.5A). This result is consistent with a previous study in which we found no significant FRET occurs between
soluble Cerulean-LC3 and Venus-LC3 in the cytoplasm of living cells [165]. The single exponential decay
rates of the fluorescence anisotropies for Venus and Venus-LC3 are related to the rotational diffusion of the
Venus fluorophore attached to LC3 by a flexible linker (Table III.3) [180]. However, because of the flexible
nature of the linker it is not possible to use these values to calculate the size of the Venus-LC3-associated
complexes based on their rotational correlation times alone.
Next, we examined our FPFA measurements of Venus-LC3(F52A/L53A), Venus-LC3(R70A), and Venus-
LC3(G120A) for evidence of homo-FRET in order to determine if these mutations resulted in a change in
the proximity of multiple LC3 molecules. In both cases, the anisotropy decay curves were fit by a single
exponential, with similar rotational correlation times to that of wild type Venus-LC3 (Fig. III.5A, Table
III.3). This suggests the Venus proteins attached to the LC3 mutants are also, to some extent, free to rotate
independently of LC3, and that no detectable homo-FRET occurs in either case.
III.2.9 There is on average only one soluble Venus-tagged LC3 protein per complex, and disruption of
LC3’s hydrophobic binding interface changes the stoichiometry of LC3-associated complexes.
A negative FRET result cannot conclusively rule out the presence of multiple Venus-LC3’s per complex, as
the Venus fluorophores may be positioned such that their proximity or their average relative dipole orienta-
tions does not satisfy the FRET requirements [178]. Fortunately, FPFA measurements provide an additional
opportunity to gain insights into the stoichiometry of a protein by quantifying its molecular brightness. Fluo-
rescence brightness is extracted from the statistics of fluorescence intensity fluctuations using a method that
has been termed brightness analysis [142]. The principle behind the interpretation of our data lies in the idea
that a Venus labeled molecule with a stoichiometry of two will have twice the brightness compared to Venus
alone, and it follows that higher order oligomerization states will have quantized brightness values of Venus
as was previously measured using a series of positive controls [176].
After establishing the Venus baseline for brightness comparisons, next, we investigated the brightness of
Venus-LC3 using our FPFA measurements. We found Venus-LC3 has a normalized brightness of 1.16±0.09,
which is approximately 16 % brighter than Venus (p≤ 0.008; t-test) (Fig. III.5B). These data strongly suggest
the majority of Venus-LC3 does not extensively oligomerize or aggregate in solution. Instead, they suggest
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Figure III.5: The majority of complexes contain one soluble Venus-LC3, and mutations to LC3s hydropho-
bic surface at residues F52/L53 but not R70 alter the stoichiometry of LC3 in complexes. Time Resolved
Fluorescence Anisotropy analysis was performed using the microtime FPFA measurements collected from
cytoplasmic extracts of HEK 293 cells individually expressing Venus, Venus-LC3, Venus-LC3(F52A/L53A),
Venus-LC3(R70A), or Venus-LC3(G120A) under (A) basal conditions, or (C) after incubation in 100 µM
chloroquine for 2 hours. The decays are single exponential (linear on a semilog plot) indicating no detectable
homo-FRET in all cases. Brightness analysis was performed using the macrotime from the FPFA measure-
ments under (B) basal conditions or (D) after incubation in 100 µM chloroquine for 2 hours. Anisotropy
correlation times from replicate measurements can be found in Table III.3. Brightness data is normalized to
the average brightness of Venus. Bars represent the median. One-way ANOVA test p ≤ 1×10−4 for the
brightness measurements from either condition. Pairwise comparisons between all of the constructs under
either condition were made using Bonferonni corrected t-tests as described in the text.
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Venus-LC3 primarily has a stoichiometry of close to one in cytoplasmic complexes.
Finally, in order to gain additional information about the stoichiometry of the mutant LC3 proteins, we
performed brightness analysis using our FPFA measurements of Venus-LC3(F52A/L53A), Venus-LC3(R70A),
and Venus-LC3(G120A). Assuming the brightness values of the two Venus-LC3(F52A/L53A) species with
distinct diffusion times are the same, the normalized brightness of the Venus-LC3(F52A/L53A) complexes
is about 1.8±0.1. This brightness value was approximately twice that of Venus, suggesting either one or
both of the Venus-LC3(F52A/L53A) complexes has a stoichiometry of two (p≤ 0.008; t-test) (Fig. III.5B).
On the other hand, the brightness values obtained from the Venus-LC3(R70A), and the Venus-LC3(G120A)
FPFA data, were both similar to Venus-LC3. Venus-LC3(R70A) had a normalized brightness of 1.1±0.1, or
about 10 % brighter than Venus (p > 0.008; t-test), and Venus-LC3(G120A) had a normalized brightness of
1.0±0.1 which was indistinguishable from that of Venus (ns; p > 0.008; t-test) (Fig. III.5B). Thus, like wild
type Venus-LC3, these data suggest only one Venus-LC3(R70A) and only one Venus-LC3(G120A) molecule
is associated with a given complex.
Given the effective sizes of complexes appear to change upon treatment with chloroquine, we reasoned
there may also be changes in LC3’s stoichiometry or organization under these conditions. We tested for
these changes by examining the time resolved anisotropy and the molecular brightness from our FPFA mea-
surements of the LC3 constructs, after treatment with chloroquine, in cytoplasmic extracts. However, we
found the anisotropy decays for the constructs were similar to basal conditions (Fig. III.5C), and the molec-
ular brightness values were also similar to basal conditions (Fig. III.5D). On the other hand, the Venus-
LC3(F52A/L53A) construct’s brightness became more similar to Venus at 1.0±0.2. These data suggest
soluble LC3 does not have a propensity to aggregate or homo-oligomerize either under basal conditions or
after treatment with chloroquine.
III.3 Discussion
In this study, we analyzed the size and stoichiometry of puncta independent LC3 in the cytoplasm of living
cells and in cytoplasmic extracts and examined how these properties are regulated by specific residues on
LC3’s hydrophobic protein binding surface as well its G120 residue required for lipid modification. On the
basis of our findings, we suggest the following working model for the basal organization of LC3 (Fig. III.6).
A single soluble Venus-LC3 protein associates with a cytoplasmic complex with a molecular weight about
an order of magnitude greater than expected for a spherical monomer. Similarly slow diffusion for puncta
independent LC3 was detected in HeLa, COS7, and HEK293 cells ([121, 165] and current study), suggesting
this is a general feature of LC3 in the cytoplasm.
We also find that disruption of specific residues on LC3’s hydrophobic protein binding surface alters
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Figure III.6: Working model of the size, stoichiometry and organization of cytoplasmic LC3 associated com-
plexes. On average one soluble Venus-LC3 is constitutively bound to an approximately 500 kDa complex
of unknown composition. Mutating LC3 residue R70 to an alanine disrupts LC3s association with the large
complex. Mutating LC3 residues F52/L53 to alanines results in altered stoichiometry and binding to a sec-
ond, ∼ 50 MDa, complex. Mutating LC3 residue G120 to an alanine does not change its effective size or
stoichiometry.
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both the hydrodynamic radius and stoichiometry of LC3-associated complexes (Fig. III.6). We studied two
mutants known to disrupt the interaction of multiple proteins with LC3. The first is an F52A/L53A double
mutation to LC3 that has been reported to disrupt the interaction of LC3 with several important protein
binding partners including SQSTM1 and NBR1, cargo adaptor proteins involved in targeting substrates for
autophagic degradation [9, 69, 100, 129, 130]. The second, an R70A mutation to LC3, is also known to
disrupt interactions with important binding partners such as SQSTM1 and NBR1, but also additional proteins
including FYCO1, a RAB7 effector mediating microtubule plus-end directed vesicular transport [9, 59, 69,
129].
Both Venus-LC3(F52A/L53A) and Venus-LC3(R70A) were poorly targeted to puncta in the cytoplasm
under steady state conditions, but showed no dramatic defects in their accumulation on autophagosomal mem-
branes, consistent with the idea that these residues are important for the interactions of LC3 with cargo adap-
tors, but not autophagosomal membranes [69, 100, 129]. Remarkably, however, the R70A and F52A/L53A
mutations had dramatically different effects on LC3’s rate of diffusion. Venus-LC3(F52A/L53A) diffused
more slowly than Venus-LC3, indicating the complexes it associates with become larger, rather than smaller.
The predicted size of the larger Venus-LC3(F52A/L53A) associated complex is exceptionally large, with
a predicted molecular weight on the order of 50 MDa. This corresponds to an effective Stoke’s radius of
∼ 25 nm; although, we note there is large variability in this estimate. For comparison, the measured hy-
drodynamic radius of the 70 S ribosome is between ∼ 12 nm–15 nm [181, 182]. Furthermore, the Venus-
LC3(F52A/L53A) mutant appears to associate with at least two discrete complexes, in which one or both con-
tain multiple copies of LC3(F52A/L53A). The Venus-LC3(F52A/L53A) data provides an excellent example
of how FPFA can overcome the limitations of FRET by simultaneously providing information about molecu-
lar brightness. In particular, we found no evidence of homo-FRET, but the brightness indicated a stoichiome-
try of approximately two suggesting the two Venus-LC3(F52A/L53A) proteins are part of the same complex,
but further than 10 nm apart. Although it is appealing to imagine the larger Venus-LC3(F52A/L53A) com-
plex revealed by FPFA might serve as a sink for many LC3 proteins, this is not supported by the molecular
brightness data.
In contrast to F52A/L53A, the R70A mutant largely disrupted LC3’s slow diffusion. In addition, the
measured stoichiometry of LC3 in complexes containing the R70A mutant is one, similar to Venus and
wild type Venus-LC3. Thus, the R70A mutation decreases the size of LC3 associated complexes, while
the F52A/L53A increases the size LC3 associated complexes as well as the number of LC3 molecules in
the complexes (Fig. III.6). This was unexpected, since both mutants were reported to be less efficient at
binding to numerous important LC3 interacting proteins compared to wild type [9]. If the residues on LC3’s
hydrophobic protein interaction surface were all required for its association with a high molecular weight
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complex, we would have predicted that both mutants would have smaller hydrodynamic radii compared
to wild type LC3. The data taken together raise the possibility that F52A/L53A mutations to LC3 may
change the properties of the protein such that it is sequestered in an entirely new complex, whereas the R70A
mutation to LC3 nearly completely disrupts its ability to associate with the complex altogether. Furthermore,
the complexes appeared to change upon treatment of cells with rapamycin or chloroquine, suggesting they
could be modulated by perturbations to the autophagy pathway.
The identity of the components of these soluble LC3 associated cytoplasmic complexes and their func-
tion(s) in the regulation of autophagy or autophagy-independent processes remain to be determined. Given
that both the F52A/L53A and R70A mutations interfere with the binding of LC3 to SQSTM1 and NBR1,
it seems unlikely that binding to cytoplasmic cargo adaptors, and thus sub-diffraction aggregates could ac-
count for the composition of the complexes. Instead, we speculate that these complexes may consist of other
LC3 interacting proteins or LC3 interacting protein complexes that may be disrupted due to the R70A mu-
tation. At first glance, the LC3 lipid conjugation machinery is an obvious candidate given ATG7 is known
to homo-oligomerize and form a complex with ATG3 to carry out E1- and E2-like LC3 processing reac-
tions [102]. The ATG12, ATG5, and ATG16L1 proteins form complex as large as ∼ 800 kDa[89], which is
thought to function as an E3-like ubiquitin ligase for LC3 lipid modification[168] and direct LC3 to the site
of autophagosome formation [88]. However, our observation that the diffusion of the LC3(G120A) mutant
is similar to the wild type protein, despite the fact that it fails to interact with the LC3 ubiquitin-like conju-
gation machinery[106], suggests the possibility that puncta independent LC3 constitutively associates with
the ATG12/ATG5/ATG16L1 complex is unlikely. There are however, several other proteins whose binding
to LC3 is completely disrupted by mutation of LC3’s residue R70 that would make for prime candidates
[9]. Future work will be required to determine whether the ∼ 500 kDa LC3 associated complexes consist
of these other known autophagy related proteins, or perhaps include others of the recently identified LC3
interacting proteins [9]. One approach that can be used in the future to test for the presence of specific multi-
protein complexes in cells is through the combined use of FRET and FRAP, as we illustrated previously for
the case of complexes containing LC3 and ATG4B(C74A) [165]. The study of the interaction of LC3 and
ATG4B(C74A) validated these approaches as a useful means for characterizing the properties of protein com-
plexes under physiological conditions. Intriguingly, LC3 has also been reported to associate with the 3 UTR
of fibronectin mRNA[117], and this interaction depends on a triple arginine motif (residues 68-70) which
overlaps with the R70A mutant analyzed in our current study. Thus, LC3-associated complexes detected in
our experiments could also potentially represent mRNA-containing complexes.
Our findings also allow us to rule out several alternative models that could account for the slow diffusion
of Venus-LC3. First, we found that the measured diffusion of Venus-LC3(G120A) was indistinguishable
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from wild type LC3. This implies that neither lipidation of LC3 nor its ability to bind to autophagosomal
membranes contribute to its slow diffusion. Second, we compared the diffusion of Venus-LC3 in live cells un-
der control conditions and following microtubule disruption, as well in cytoplasmic extracts under conditions
that are unfavorable for the maintenance of polymerized microtubules in order to determine if its diffusion is
slowed as the result of reversible binding to microtubules. We observed no difference in LC3’s diffusion in
cells following microtubule disruption, and very close agreement between our in vivo measurements and our
in vitro measurements for the diffusion of LC3. This suggests that microtubule binding is not responsible for
the slow diffusion of LC3, at least under basal conditions. Finally, our homo-FRET and brightness results
strongly suggest that the slowly diffusing complexes of LC3 do not represent either homo-oligomers[93] or
aggregates[105] of LC3. These findings imply that if LC3 homo-oligomerization is involved in contributing
energy to membrane fusion events in autophagy[93], this event must be limited to autophagosomal mem-
branes.
In this study we utilized two complementary fluorescence-based approaches, FRAP and FPFA to char-
acterize the properties of soluble LC3 associated complexes. The FPFA and FRAP results were in excellent
agreement, lending confidence in the conclusions of our studies. However, like any method, each approach
has some limitations. First, both FRAP and FPFA rely on measurements of exogenous, fluorescently tagged
versions of the protein of interest. This could have several possible consequences on the interpretation of our
findings. Our experiments were carried out under conditions where Venus-LC3 is overexpressed, and thus
other LC3 binding partners could potentially become limiting for complex formation. Under these conditions
one might expect to find excess monomeric Venus-LC3, but our data suggest this is unlikely given the com-
bination of our FRAP and FCS measurements failed to show any evidence for such a scenario. On the other
hand, one advantage of over-expressing Venus-LC3 is that it is in excess over the endogenous protein, and
thus it is likely that the complexes we detect contain primarily the tagged form of the protein. This increases
the likelihood that our measurements accurately report the effective size, stoichiometry, and organization of
LC3 associated complexes.
Second, both FRAP and FPFA interpretation requires the fitting of models which carry with them certain
a priori assumptions. Often, several competing models can fit a particular dataset equally well, e.g. a small
percentage of LC3 associating with membranes or a fraction of LC3 reversibly binding to a microtubule
network. Therefore, additional experiments are required to distinguish between competing models, such as
the use of mutants, drug treatments, or comparisons of in vivo versus in vitro results as we have done here.
Even with such information in hand, there are still circumstances which different models cannot be resolved
by an analysis of diffusion alone. For example, although our FRAP and FPFA data were well fit by single
component diffusion models, we cannot conclusively rule out the possibility that there are multiple distinct
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complexes of similar size present. Similar assumptions are inherent in our modeling of the FPFA brightness
measurements; in the case of a mixture of complexes, as we detected for F52A/L53A, we cannot rule out the
possibility that the two fold increased brightness may have originated from one of the complexes in particular
and not both.
Third, although FPFA can potentially provide information about rotational diffusion, and thus yield in-
sights into the size and shape of the diffusing species, our current data cannot be quantitatively analyzed in
this way. This is because in our experiments, the Venus label is not rigidly attached to LC3 allowing it to un-
dergo rotational motion independently of LC3 or the LC3 associated complexes. In addition, the lifetime of
the Venus fluorophore (on the order of a few nanoseconds) is not long enough to allow accurate quantitation of
rotational diffusion for slowly rotating complexes [180]. Thus, our rotational diffusion measurements should
not be expected to match our translational diffusion measurements. A rigidly attached fluorophore with a
much longer lifetime would be a better choice for measuring the rotational mobility of large complexes.
Lastly, the details of our experimental design should be considered carefully as they also constrain our
conclusions in several ways. Our FRAP measurements were specifically designed to avoid LC3 in puncta,
and instead focus on the diffuse pool of LC3 independent of bright puncta. Under certain conditions, upreg-
ulation of the autophagy pathway for example, the cytoplasm may become full with large numbers of puncta
making it difficult or impossible to avoid puncta with a 1 µm radius bleach region. Although this was not
a problem under the conditions examined in our study, in the future, methods of analysis may need to be
devised in order to extend the range of conditions which can be analyzed by FRAP, for example, the applica-
tion of reaction and diffusion models[149] to accurately quantify autophagy protein turnover rates on puncta.
Similarly, our method of cellular extract preparation should be taken into consideration when interpreting our
FPFA findings; we prepared them in such a way that LC3-II incorporated into autophagosomal membranes
was either solubilized by detergent and/or excluded from the extract by centrifugation. In the future, FPFA
measurements could be performed on LC3-II in autophagosomes using an alternative extraction procedure or
using an in vivo configuration in order to test if lipid modified LC3 homo-oligomerizes on autophagosomal
membranes and to follow up on previous stoichiometry determinations for ATG proteins on autophagosomes
[183].
In summary, our data suggest that in the cytoplasm, individual soluble LC3 molecules associate with a
∼ 500 kDa complex and that residues on LC3’s hydrophobic protein interaction surface are important for
regulating its association with these complexes. In the future, we anticipate FRAP and FPFA will become
valuable methods for uncovering the emergent properties of protein complexes in the autophagy pathway.
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III.4 Materials and Methods
III.4.1 cDNA constructs
GFP-LC3 was the kind gift of T. Yoshimori [173]. Cerulean and Venus tagged versions of LC3 were as pre-
viously described [165]. Venus-LC3(R70A), Venus-LC3(F52A/L53A), and Venus-LC3(G120A) mutations
were constructed using the Stratagene’s QuikChange site- directed mutagenesis kit (Agilent Technologies,
Inc.; 200523). For LC3(R70A) the forward and reverse primers were 5’catcaagataattagaagggccctgcagct-
caatgctaac3’ and 5’gttagcattgagctgcagggcccttctaattatcttgatg3’ respectively. For LC3(F52A/L53A) the for-
ward and reverse primers were 5’gtcctggacaagaccaaggcccttgtacctgatcacgt3’ and 5’acgtgatcaggtacaagggccttg-
gtcttgtccaggac3’ respectively. For
LC3(G120A) the forward and reverse primers were 5’caggagacgttcgcgacagcactggct3’ and 5’agccagtgctgtcgc-
gaacgtctcctg3’ respectively.
III.4.2 Cell culture and transfections
HeLa cells and HEK 293T cells (American Type Culture Collection; CCL-2 and CRL-1573) were main-
tained in Dulbecco’s Modified Eagle Medium (DMEM) containing 10 % fetal bovine serum (Life Technolo-
gies; 10437028), 1 % PenStrep, and phenol red or High Glucose DMEM containing L-Glutamine, sodium
pyruvate, 10 % fetal bovine serum, 1 % PenStrep, and phenol red respectively at 37 ◦C, 5 % CO2.
For our live cell imaging experiments, on the day prior to transfection, HeLa cells were plated in MatTek
35 mm No. 1.5 glass bottom culture dishes (Ashland; P35G-1.5-10-C). On the following day the cells (50 to
80 % confluent monolayer) were transfected with described mammalian expression constructs using FuGENE
6 transfection reagent according to the manufacturer’s recommended protocol (Promega Corp.; E2691). HEK
293T cells were plated and transfected similarly, except the MatTek chambers were first coated with poly-
D-lysine (Sigma-Aldrich; P7886). On the day of the experiment (24 hours after transfection) cell culture
medium was rinsed and replaced with phenol red-free DMEM supplemented with 10 % fetal calf serum, 1 %
PenStrep, and 25 mM HEPES. The cells were allowed to come to equilibrium at 37 ◦C for ∼ 5 min before
transferring to the temperature-controlled microscope stage and objective set to 37 ◦C.
For our FPFA measurements in cytoplasmic extracts, on the day prior to measurements, plasmid DNA
(typically 1µg/2.5×105 cells) were transfected using electroporation (Digital Bio/BTX MicroPorator). On
the following day, the cells were harvested and lysed using passive lysis buffer (Promega; E1941) containing
1 % Protease & Phosphatase Inhibitor Cocktail (Thermo Fisher Scientific Inc.; 78440). The homogenates
were centrifuged at 2×104 RCF for 15 minutes, and the supernatants were diluted ∼ 20 fold with purified
water for FPFA to yield a photon count rate between ∼ 25 kcps and 100 kcps (> 30 x the dark count rate)
to avoid TCSPC pile-up artifacts.54 The clarified homogenates were then loaded into 35 mm glass bottom
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dishes for measurements at 25 ◦C.
III.4.3 Analysis of LC3-I to LC3-II processing
The LC3-I to LC3-II processing assay was performed by lysing cells plated in 6 well culture dishes using
CellLytic M reagent (Sigma-Aldrich Co. LLC; C2978) as per the manufacturer’s instructions; spinning down
at 1.3×104 RCF for 20 minutes; followed by SDS-PAGE of the supernatant. We blotted using antibodies
against beta-tubulin (Developmental Studies Hybridoma Bank; E7), GFP (JL-8) (Clontech; 632380), and
LC3 (Novus Biologicals; NB100-2220).
III.4.4 Drug Treatments
In order to block lysosomal degradation of LC3 or upregulate the autophagy pathway we incubated the cells
with either 100 µM chloroquine (Sigma-Aldrich Co. LLC; C6628) or 200 nM rapamycin (Sigma-Aldrich;
R8781) for 2 hours at 37 ◦C before performing live cell imaging or preparing cell extracts. In order to disrupt
microtubules in live cells, we incubated the cells on ice with 5 µg/ml nocodazole (Sigma-Aldrich Co. LLC;
M1404) for 15 minutes before transferring to 37 ◦C for an additional hour. The cells were imaged in the
continued presence of nocodazole.
III.4.5 Microtubule pelleting assay
We examined the extent of polymerized microtubules in our cytoplasmic extracts using a microtubule pellet-
ing assay [177]. The cytoplasmic extracts were loaded onto a 40 % sucrose cushion and spun at 2×105 RCF
for 20 minutes at 25 ◦C. Fractions from the pellet and supernatant were analysed by SDS-PAGE. Although
the conditions of the passive lysis buffer are not suitable for maintenance of polymerized microtubules in
vitro, we attempted to further depolymerize microtubules or repolymerize tubulin by incubating our extracts
with nocodazole (5 µg/ml) for 15 minutes on ice or with paclitaxel (20 µM) at 37 ◦C for 15 minutes before the
pelleting assay.
III.4.6 Laser scanning confocal microscopy and quantification of LC3-associated puncta
Cells were imaged live using a Zeiss LSM 510 confocal microscope (Carl Zeiss MicroImaging Inc., Thorn-
wood, NY) equipped with an Argon/2 30 mW laser (458, 488, 514 nm) using an oil immersion 40x 1.3
N.A. Zeiss Plan-Neofluar objective. The total numbers of bright, Venus-LC3 labeled spots (∼ 0.5 µm–2 µm)
obtained in single confocal sections (1 Airy unit) were manually counted in the cytoplasm of each cell and
reported as the mean number of cytoplasmic spots per cell.
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III.4.7 FRAP methods
Confocal FRAP measurements were performed using a Zeiss LSM 510 confocal microscope (Carl Zeiss
MicroImaging Inc.) equipped with an Argon/2 30 mW laser (458, 488, 514 nm) using an oil immersion 40x
1.3 N.A. Zeiss Plan-Neofluar objective. Confocal FRAP data were obtained using 512 X 45 pixel images
at 4X digital zoom using a 1 Airy unit pinhole at a rate of 42 frames per second. Venus was irreversibly
photobleached by iteratively scanning a 514 nm laser (30 mW nominal power) 10 times in a circular ROI
with a nominal radius rn of 0.99 µm, centered in the imaging window. Imaging of the prebleach steady
state fluorescence and the postbleach recovery was carried out using a much lower nominal laser power of
0.06 mW. In order to separate excitation and emission light sources we employed several standard filter sets
for the Zeiss LSM 510 (HFT 458/514, and LP 530). A total of 600 images were acquired for each recovery
(∼ 15 seconds), and the bleaching event required 129 ms before acquisition of the postbleach image under
our conditions.
To analyze the confocal FRAP data we utilized a recently developed analytical equation for simple Brow-
nian motion to extract an instrument independent diffusion coefficient [158]. The first step in the approach is
to plot the mean fluorescence intensity within the bleach region as a function of time to yield a FRAP curve,
I(t). We next normalize I(t) by dividing by the pre-bleach steady-state fluorescence and correct for any un-
intentional photobleaching encountered during normal imaging. To do this we fit the last 50 data points, at a
time sufficiently long enough after the bleach to reach diffusional steady-state, of I(t) to a first order decay
process,
I(t) = exp(−kdecayt) (III.1)
where t is time, and kdecay is the unintentional photobleaching rate constant. I(t) is corrected by dividing by
the exponential decay [157]. Next, the diffusion coefficient D and mobile fraction M f were found by fitting
the data to a one component FRAP model for Brownian motion with infinite boundary conditions,
I(t) = I0
(
m=200
∑
m=0
−Kmr2e
m![r2e +m(8Dt+ r2n)]
)
M f +(1−M f )I(0) (III.2)
where I0 is 1 for a normalized FRAP curve, and rn is the nominal radius of the bleaching ROI [158]. This is a
modified form of the Axelrod equation[140] where the laser is assumed to be a Gaussian, and the parameters
re and K take into account the initial conditions for the solution of the diffusion equation. The FRAP model
assumes a homogenous distribution of molecules were bleached along the Z-axis resulting in diffusional
exchange along the X and Y axes. We determined re and K by fitting the normalized radial post-bleach
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profile, I(x; t = 0), to an analytical approximation,
I(x; t = 0) = I0 exp
(
−K exp
[
−2x
2
r2e
])
(III.3)
where I0 is 1 for a normalized post-bleach profile, and x is the radial distance from the center of the bleaching
ROI [155].
For comparison, we also analyzed a subset of the data using a newly described simplified FRAP equation
for Brownian motion [175]. In this approach, I(x; t = 0) was further approximated as,
I(x; t = 0) = 1−K exp
(
−2x
2
r2e
)
(III.4)
resulting in the simplified FRAP model,
I(t) = I0
(
1−K
[
1+
r2n
r2e
+
8Dt
r2e
]−1)
M f +(1−M f )I(0) (III.5)
A comparative analysis of these two analytical FRAP models (Equations III.2 and III.5) revealed no signif-
icant differences in D or M f with the level of noise present in our data. This means using Equation III.5
is the preferred method of extracting diffusion coefficients and mobile fractions, as it greatly reduces the
complexity in programming a non-linear fitting routine. Furthermore, if there is a priori knowledge that the
fluorescence recovery is dominated by Brownian motion rather than reaction kinetics, and the system was
allowed to relax back to a steady-state one could use linear interpolation to find the half time of the recovery
(τ1/2) and resultant D without any fitting required using
D =
r2e + r
2
n
8τ1/2
(III.6)
where indicated, D values were used to calculate the Stokes radius using the Stokes-Einstein equation:
D =
kBT
6piηr
(III.7)
where kB is Boltzmann’s constant, T is temperature, r is the Stokes radius, and η is viscosity. The apparent
molecular weight MW was then calculated as follows (assuming a spherical geometry):
MW = MWGFP
(
DGFP
D
)3
(III.8)
where MWGFP is the molecular weight of GFP (27 kDa) and DGFP is the measured diffusion coefficient of
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the GFP control.
In principle, a freely diffusing control such as Venus should be 100 % mobile on the time scale of our
experiments as indicated by M f . However, under the conditions of our experiments a significant fraction of
molecules in the cytoplasm were irreversibly destroyed during the experiment resulting in M f values less
than 1. In order to correct for the significant loss of fluorescence in the compartment due to the bleaching
event, we calculated the true mobile fraction (M fcorrect ) by,
M fcorrect = 1− (Iad jacent(t)− I(t)) (III.9)
where Iad jacent(t) is the intensity inside an ROI placed adjacent to the bleaching ROI.
III.4.8 FPFA methods
An 80 MHz, 200 fs mode locked Ti:sapphire laser (Coherent Chameleon Ultra-2) operated at 950 nm provided
pulsed two-photon excitation. The excitation beam, passed through a power attenuator, a spatial filter system
(KT310, Thorlabs), a near-IR linear polarizer (100,000:1 extinction ratio, Thorlabs), and finally a multiphoton
short-pass dichroic beamsplitter (FF670-SDi01-25x36, Semrock) was used to reflect the excitation beam to
a Zeiss 63x 1.2 N.A. water objective (back aperture slightly overfilled). This setup focused the beam to a
diffraction-limited spot (∼ 0.4 µm in diameter). The excitation power was kept low (typically ∼ 10.2 mW at
the focal point) to avoid bleaching during acquisition (150-200 s).
Fluorescence collected from the observation volume in the sample was guided through a BG39 filter (to
block residual near-IR photons), a high throughput band-pass filter (FF01-540/50-25, Semrock), and finally
a polarizing beam splitter (Thorlabs) augmented with two orthogonally oriented linear polarizers (Thorlabs)
to increase the extinction ratio. At the beam splitter, parallel and perpendicular emitted photons were sepa-
rated and focused onto two HPM-100-40 hybrid detectors (Becker & Hickle). The dark count rate for these
detectors was typically 200-750 cps at 25 ◦C. Photons detected by each detector were processed by a SPC-
132 TCSPC card (Becker & Hickle). For synchronization between excitation pulses and detected photons, a
small fraction of the excitation beam was extracted and focused onto a high-speed photodetector (DET10A,
Thorlabs) powered by a battery to avoid crosstalk. Note that all optics used in the excitation pathway were
selected to minimize group delay dispersion.
For each homogenate, three to five replicate measurements were performed and these were averaged for
each point. All measurements were performed at room temperature.
SPCM software (Becker & Hickle) running in FIFO mode was used to calculate time-resolved fluores-
cence and cross-correlation functions. Time-resolved anisotropy was calculated based on fluorescence decay
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of parallel and perpendicular channels using the following equation[180, 184]:
r(t) =
I‖(t)−gI⊥(t)
I‖(t)+2gI⊥(t)
(III.10)
where I‖(t) and I⊥(t) are the fluorescence intensity of parallel and perpendicular channels (dark noise sub-
tracted) respectively, and g is an instrument correction factor which for our microscope had a value of 0.96
as determined by tail fitting calibration measurements of fluorescein.
For FPFA, independently measured emission events detected in the parallel and perpendicular light paths
were cross-correlated, G(τ). The time dependence of these curves were initially fit using a single component
three-dimensional (3D) diffusion equation to estimate the value of < N >, the average number of fluorescent
molecules in the excitation volume, and τD, the correlation time (the average time that a molecule spends in
the detection volume) for each sample:
G(τ) =
γ
< N >
1
1+(τ/τD)
1√
1+(ω/z)(τ/τD)
(III.11)
where ω and z, are the radial and axial beam waists respectively calculated from calibration experiments, and
the constant γ has a value of 0.35 for a three-dimensional Gaussian PSF [142]. The molecular brightness b is
the average number of photon emitted per second per molecule (cpsm)
b =
< k >
< N >
(III.12)
where < k > is the average photon count rate recorded during data acquisition.
To model a mixture of two species having the same brightness but independent diffusion times:
G(τ) =
γ
(< N1 >+< N2 >)
2(
< N1 >
1
1+(τ/τD1)
1√
1+(ω/z)(τ/τD1)
+< N2 >
1
1+(τ/τD2)
1√
1+(ω/z)(τ/τD2)
) (III.13)
In this case,
b1 = b2 =
< k >
< N1 >+< N2 >
(III.14)
With two-photon excitation the relationship between correlation time τD and D is given by61:
τD =
ω2
8D
(III.15)
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III.4.9 FPFA Calibrations
The instrument correction factor g for calculating time-resolved anisotropy (Equation III.10) was measured
using tail-fitting[180] of fluorescein samples and found to be 0.96. The value of ω/z for our microscope
(used in Equations III.11 and III.13) was 0.1 at an excitation power of 10.2 mW (at 950 nm) using calibra-
tion standards of fluorescein in water at pH 9.5 [176]. Assuming fluorescein has a diffusion coefficient of
300 µm2/s, using the measured correlation time of 75±9 µs, the value of ω was 424±30 nm. The validity
of this calibration procedure was confirmed by measuring the diffusion coefficient of Venus monomers under
identical conditions. Using ω/z = 0.1, the measured correlation time for Venus monomers with 10.2 mW
excitation power was 343±17 µs (n = 3). This corresponds to a diffusion coefficient for Venus monomers
in solution of 65.5±8.6 µm2/s (n = 3), in good agreement with the diffusion coefficient measured for GFP
[185].
III.5 Curve fitting and statistics
IGOR Pro software (Version 6.22) was used for fitting of time-resolved anisotropy, cross-correlation curves,
and for global fitting of calibration standards. FRAP data was fit using custom routines written in MATLAB
based on the trust-region-reflective algorithm (The MathWorks; R2010B). The errors reported throughout
the text are 95 % confidence intervals unless otherwise stated. To test the hypothesis that two group means
are not different, under circumstances where there were multiple groups being compared, we used the Bon-
feronni method to control the overall type-I error rate such that for all pairs of comparisons the familywise
significance level was 0.05. For example, if 4 groups are being compared the total number of comparisons is
6, thus the p value cutoff is 0.05/6 = 0.008.
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CHAPTER IV
Imaging protein complex formation in the autophagy pathway: analysis of the interaction of LC3 and
Atg4B(C74A) in live cells using Fo¨rster Resonance Energy Transfer and Fluorescence Recovery After
Photobleaching
In Chapter III we discovered that the slow diffusion of autophagosome independent LC3 is due to its asso-
ciation with a ∼ 500 kDa complex. This raises the question: what are the other components in the complex
with LC3? In the current study, we aimed to develop FRET and FRAP based methods to investigate protein
complexes in the autophagy pathway. This chapter begins with a brief introduction. As a model system for
studying protein complex formation we investigated the interactions of LC3 with Atg4B(C74A), a catalyti-
cally inactive mutant of the cysteine protease involved in lipidation and de-lipidation of LC3. These FRET
and FRAP studies suggest Atg4B(C74A) and LC3 form a larger than expected complex in the cytoplasm of
live cells, consistent with the size and shape of a recent crystal structure for the interaction. We conclude
that the FRET and FRAP methods can be useful tools for studying the properties of protein complexes in the
autophagy pathway.
IV.1 Introduction
The influx of information about protein-protein interactions from bioinformatics and proteomics analyses
has shifted the bottleneck to discovery towards a more thorough characterization of these interactions within
the context of living cells [132, 186–188]. Fortunately, recent advances in live cell imaging are making it
possible to quantitatively characterize the spatial and temporal regulation of green fluorescent protein (GFP)
tagged proteins in the complex environment of the living cell. For example, protein-protein interactions
are readily monitored through the use of FRET microscopy [178, 189–193], and the dynamics of individual
proteins and protein complexes can be quantitatively characterized using techniques sensitive to mobility such
as confocal fluorescence recovery after photobleaching (FRAP) and fluorescence correlation spectroscopy
(FCS) [121, 140, 148, 149, 155, 157, 194–199].
One example of an intracellular pathway whose function depends on the coordinated effort of a network
of interacting proteins is macroautophagy (referred to here as autophagy) [9]. The process of autophagy
is activated in response to stress signals such as low nutrient availability, and up-regulation of the pathway
leads to the capture of cytosolic materials in a double membrane structure termed the autophagosome that is
This chapter is adapted from the published manuscript: Kraft and Kenworthy [165]
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subsequently trafficked to the lysosome for degradation and recycling [5, 10, 24]. LC3 (ATG8 in yeast) plays
a central role in the autophagy pathway[9, 10, 24] facilitating the formation of autophagosomes [84, 85, 200].
Under basal conditions LC3 is known to exist in a soluble form termed LC3-I, and upon upregulation of the
autophagy pathway LC3 is converted to a lipidated form termed LC3-II that associates with autophagosomal
membranes [90].
Recently, a large-scale proteomics screen of the human autophagy pathway revealed LC3 and orthologs
interact with a network of 67 proteins [9]. In independent studies, our group discovered soluble EGFP-LC3
diffuses much more slowly than predicted for a freely diffusing monomer in both the cytoplasm and nucleus of
live cells [121]. This raises the possibility that LC3 may constitutively associate with a high molecular weight
complex containing multiple proteins, perhaps comprised of one or more LC3-interacting proteins identified
in the large scale proteomics screen [9]. Importantly, constitutive association of LC3 with a multi-protein
complex could be a potential mechanism for regulating the autophagy pathway. However, it is unclear how
many of these proteins come together in live cells to perform the diverse functions associated with autophagy
related proteins, or how these complexes are regulated.
In the current study, we sought to develop tools to further investigate protein complex formation in the
autophagy pathway. As a test case, we examined the properties of the complex formed between LC3 and
Atg4B(C74A), a catalytically inactive mutant of the cysteine protease known to play important roles in both
the lipidation and de-lipidation of LC3 [201]. Previous studies reported over-expression of wild type Atg4B
reduces LC3 lipidation as well as LC3 membrane localization [173]. Fujita et al. demonstrated this effect
was likely the result of Atg4B non-productively binding to LC3. In their study, they showed expression of
a protease inactive mutant, Atg4B(C74A), has similar effects, and proposed the use of this construct as a
tool for studying autophagy [173]. Given the strong biochemical evidence that shows Atg4B(C74A) directly
interacts with LC3 to form a stable complex, we used this pair of proteins as a model for developing FRET
and diffusion based methods to characterize protein complexes in living cells. The basis for using FRET to
analyze protein-protein interactions lies in the distance dependence of near field non-radiative energy transfer
between two suitable fluorophores known as the donor and acceptor,
E =
1
1+(r/R0)
6 (IV.1)
where the energy transfer efficiency E varies with the inverse sixth power of the separation distance r be-
tween them[135, 202, 203], and the Fo¨rster distance R0 is the distance between a given pair of donor and
acceptor fluorophores at which E = 50%. R0 is ∼ 5 nm for commonly used donors and acceptors used in
microscopy-based FRET experiments, such as the GFP variants Cerulean and Venus [204]. Considering the
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lengthscale of a typical protein-protein interaction, FRET can be used to determine if two fluorescently la-
beled proteins are either directly interacting or are close together in a complex. Live cell FRET measurements
can be carried out in a number of ways by fluorescence microscopy, for example by measurements of sensi-
tized acceptor emission, analysis of fluorescence lifetime, or quantification of donor dequenching following
acceptor photobleaching [135, 191, 202, 203].
While FRET is clearly a powerful tool for mapping protein-protein interactions in the cell, diffusion-based
measurements can provide complementary information about the nature of protein complexes. A commonly
used technique to measure the diffusion of fluorescently labeled molecules in single living cells is FRAP.
In recent years, FRAP has become a popular technique to study the dynamics of GFP-tagged proteins in
intracellular compartments using confocal microscopes [132, 194, 195, 197]. In these experiments, cells
expressing a fluorescently tagged protein of interest are visualized by fluorescence microscopy. In order to
probe the underlying motions of the proteins, an intense pulse of laser light is directed to a defined region of
interest in the cell, inducing permanent photobleaching of the fluorophores within that region. Subsequently,
unbleached molecules from the surrounding regions exchange with the bleached molecules (termed recovery).
The rate at which exchange occurs reveals useful information about the state of the underlying molecules of
interest, including the translational diffusion coefficient D and the fraction of mobile molecules, commonly
referred to as the mobile fraction or M f . For the case of simple diffusion of soluble proteins, D is related to
the size and shape of the diffusing species, the viscosity η of the medium and the absolute temperature T .
The precise relationship is given by the Stokes-Einstein relation,
D =
kBT
6piηR
(IV.2)
for spherical molecules with radius R, where kB is Boltzmanns constant. Thus, the diffusion coefficients for
two soluble proteins within the same multi-protein complex should be identical, and correspond to the size
and shape of the complex itself.
To obtain this information from FRAP data, it is necessary to quantitatively analyze the recovery curves
to obtain an accurate measurement of D. In a classic paper, Axelrod et al. described an analytical solution
for FRAP involving a circularly symmetric stationary focused laser beam that can be used to extract D [140].
However, several of the assumptions underlying derivation of this equation do not hold when applied to
FRAP data obtained using confocal microscopes, such as the assumption that the bleaching event occurs
rapidly relative to the characteristic recovery time. Recently, our lab described an approach that generalizes
the Axelrod equation to a form that can be applied to data obtained using a laser scanning confocal microscope
[140, 158]. Here, we use FRET microscopy and confocal FRAP as complementary methods to characterize
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the properties of LC3 and Atg4B(C74A) complexes in single living cells.
IV.2 Results
IV.2.1 The subcellular localization of LC3 is altered upon co-expression of Atg4B(C74A).
The interaction of Atg4B(C74A) with LC3 has been reported to cause a shift in the subcellular localization
of LC3, leading to its sequestration in the cytoplasm [121, 173]. To confirm this shift in localization occurs
under the conditions of our experiments, we compared the subcellular distribution of Venus and Cerulean-
tagged forms of LC3 and Atg4B(C74A) expressed individually versus under conditions where they were
co-expressed using confocal microscopy (Figure IV.1). COS-7 cells were used as a model system for these
studies, and as a control, we confirmed Venus itself is evenly distributed between the nucleus and cytoplasm
(Figure IV.1A).
When expressed on its own, Venus-LC3 was found localized in both the cytoplasm and nucleoplasm, but
was notably enriched in the nucleoplasm (Figure IV.1B). Venus-Atg4B(C74A) expressed individually was
also localized in both the cytoplasm and nucleus; however, unlike Venus-LC3, Venus-Atg4B(C74A) was en-
riched in the cytoplasm over the nucleus (Figure IV.1C). We next compared the distribution of Venus-LC3 and
Cerulean-Atg4B(C74A) when the two proteins were co-expressed in the same cells. Under these conditions,
Cerulean-ATG4B(C74A) was further concentrated in the cytoplasm, and almost completely absent from the
nucleus (Figure IV.1E). Similarly, a significant shift in the distribution of Venus-LC3 out of the nucleus was
observed in cells co-expressing Cerulean-ATG4B(C74A) (Figure IV.1D).
These findings show Venus and Cerulean tagged versions of these proteins behave as expected, consistent
with a previous study where we showed by quantitative image analysis that the levels of EGFP-LC3 are signif-
icantly higher in the nucleus relative to the cytoplasm, and that co-expression of Strawberry-ATG4B(C74A)
with EGFP-LC3 results in a redistribution of EGFP-LC3 out of the nucleus [121, 173].
IV.2.2 ATG4B(C74A) and LC3 are within FRET proximity in living cells.
Catalytically inactive Atg4B mutants were previously shown to constitutively bind to LC3 [101, 173]. In
addition, a recent crystal structure shows two molecules of LC3 bind to catalytic and regulatory domains on
a single molecule of Atg4BC74S [101]. These findings suggest LC3 and ATG4B(C74A) should be within
FRET proximity in living cells. To test this prediction, we performed acceptor photobleaching FRET mi-
croscopy measurements, using Cerulean and Venus as the FRET donor and acceptor, respectively.
To establish conditions for the FRET assay, we measured a series of FRET standards consisting of
Cerulean and Venus separated by 5, 17, or 32 amino acids as positive controls [205]. The measured en-
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Figure IV.1: Subcellular localization of Venus and Cerulean-tagged versions of Atg4B(C74A) and LC3 when
expressed individually or in combination. COS-7 cells were transiently transfected with the indicated con-
structs and imaged live. (A) Venus is evenly distributed between the cytoplasm and nucleus. (B) Venus-LC3
is enriched in the nucleus relative to the cytoplasm. (C) Venus-Atg4B(C74A) is enriched in the cytoplasm
relative to the nucleus. (D) In cells co-expressing Venus-LC3 and Cerulean-Atg4B(C74A), LC3 is pulled
out of the nucleus. The relative distribution of LC3 between the nucleus and cytoplasm varies between cells
depending on levels of Atg4B(C74A) present (not shown). (E) In cells co-expressing Venus-Atg4B(C74A)
and Cerulean-LC3, Atg4B(C74A) is further enriched in the cytoplasm, compared to its distribution in cells
expressing Venus-Atg4B(C74A) alone. Bar, 10 µm.
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Figure IV.2: Controls for FRET microscopy. (A)
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Figure IV.3: FRET is detected between LC3 and
Atg4B(C74A) in both the cytoplasm and nucleus of
living cells. FRET efficiency between Cerulean- LC3
and Venus-Atg4B(C74A), or Cerulean-Atg4B(C74A)
and Venus-LC3 as measured using acceptor photo-
bleaching FRET. Data are shown for measurements in
both the cytoplasm and the nucleus. FRET efficiencies
between the negative control Cerulean and Venus are
shown for comparison. Error bars represent 95 % CI
with N ≥ 16 COS-7 cells from at least two indepen-
dent experiments.
ergy transfer efficiencies (E) under our conditions (Figure IV.2) were slightly less than the values previously
reported, possibly due to a small population (< 5%) of acceptor remaining after bleaching [205]. How-
ever, the relative trend between samples was identical. As negative controls, we measured FRET in cells
co-expressing Cerulean and Venus-LC3, Cerulean and Venus-ATG4B(C74A), Cerulean-LC3 and Venus, and
Cerulean-ATG4B(C74A) and Venus. For these constructs, the mean E ranged from ∼ 0 %–2.6 % (Figure
IV.2).
We measured significant FRET in the cytoplasm and nucleus of cells co-expressing either Cerulean-
LC3 and Venus-ATG4B(C74A) or Cerulean-ATG4B(C74A) and Venus-LC3 (Figure IV.3). Additionally,
the measured FRET efficiencies were ∼ 2–3 times larger when the FRET acceptor, Venus, was attached to
LC3 compared to when Venus was attached to ATG4B(C74A) in the cytoplasm and nucleus (Figure IV.3).
These results show ATG4B(C74A) and LC3 are within FRET proximity in the cytoplasm of living cells, in
agreement with previous biochemical evidence showing the two proteins constitutively interact in solution
(32). In addition, our results suggest LC3 and ATG4B(C74A) also interact in the nuclear compartment.
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Both ATG4B(C74A) and LC3 diffuse more slowly than freely diffusing monomers as measured by confo-
cal FRAP. In a previous study, we found EGFP-LC3 diffuses more slowly than expected for a freely diffusing
monomer, suggesting it may be part of a multi-protein complex [121]. This raises the possibility that other
proteins known to interact with LC3 may also be part of this complex, and diffuse similarly to LC3. Since
ATG4B(C74A) is predicted to interact with endogenous LC3, we hypothesized ATG4B(C74A) may also
diffuse as if it is part of a much larger complex, rather than a freely diffusing monomer.
To test this, we performed measurements of Venus-ATG4B(C74A) using confocal FRAP to obtain a
translational diffusion coefficient which is related to its size assuming a particular geometry, such as a sphere
or rod. Although a monomer and a dimer are difficult to discern from one another using this approach,
molecules that exhibit large differences in molecular weight or shape from one another can be distinguished.
As internal controls, we performed parallel FRAP studies for Venus and Venus-LC3, where Venus serves as
an inert reporter of free diffusion [148]. Soluble proteins like Venus diffuse rapidly, making it technically
challenging to analyze their diffusional mobility because they recover completely within seconds following a
photobleaching event. Because a laser scanning confocal microscope takes ∼ 1 s to acquire a full frame (512
x 512) image, it is not possible to resolve the early time points of the recovery curve while collecting images
of this size. Therefore, to analyze the diffusional mobility of these proteins, we bleached a small circular
region of interest located either in the nucleoplasm or the cytoplasm, and imaged only the area immediately
surrounding the bleach ROI during the recovery (Figure IV.4A-B) [155]. Under these conditions, we were
able to acquire images every 0.0451 s.
We bleached a 0.99 µm circular bleach ROI positioned in either the cytoplasm or nucleus by scanning
10 iterations of a higher intensity laser light, requiring approximately 0.15 s (Figure IV.4A-B). Because the
bleaching event is not instantaneous and soluble proteins diffuse rapidly, some diffusion of the protein from
the bleached region to the surrounding area occurs in the time it takes to acquire the post-bleach image. This is
evidenced by the presence of bleached molecules outside of the user-defined bleach ROI (Figure IV.4B). It is
important to take this into account, because the intensity profile of the bleach spot defines the initial conditions
to solve Ficks second law in the derivation of the FRAP equation (Eq. IV.6) [155, 158]. This is accomplished
by fitting the post-bleach profile to obtain parameters K and re (Figure IV.4C) (Eq. IV.5) [155]. With the
parameters K and re in hand, the corrected FRAP data is fit with equation IV.6 to obtain parameters D and
M f (Figure IV.4D) [158]. The value of the diffusion coefficient D obtained for this example is 17.1 µm2/s,
and the mobile fraction M f is 0.82. However, because a significant fraction of fluorophores is lost as the
result of the photobleaching event, this does not reflect the true fraction of mobile molecules. To obtain a
more accurate estimate of M f (0.99±0.01, 95 % CI N = 30), we compared the fluorescence intensity inside
an ROI positioned adjacent to the bleach regions after the fluorescence had completely recovered [206].
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Figure IV.4: Confocal FRAP assay. (A) Example of the imaging ROI used for confocal FRAP experiments,
and the position and size of bleach ROI’s used to perform FRAP in the nucleus and cytoplasm. The image
is representative of COS-7 cells expressing Venus-Atg4B(C74A). Bar, 10 µm. (B) Normalized images of
selected time points from a representative FRAP experiment on Atg4B(C74A) in the nucleus. The white
circle shows the nominal bleach ROI. Bar, 10 µm. For visualization purposes a 1 pixel median filter was
applied to the images. (C) Representative example of a fit (black line, Eq. IV.5) to the mean post-bleach
profile of Venus-Atg4B(C74A) in the nucleus (gray line, N = 30 cells) obtained from images such as in B at
t = 0. The bleach depth (K = 1.09) and effective radius (re = 3.9) parameters from the post-bleach profile fit
provide an empirical estimate of the initial conditions for the diffusion equation. The normalized post-bleach
fluorescence intensity was obtained as described in the Materials and Methods. (D) Representative example
of the mean confocal FRAP data from Venus-Atg4B(C74A) in the nucleus (gray line, N = 30) fit with a
theoretical FRAP curve assuming a single diffusing species (Eq. IV.6).
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Table IV.1: Mobile fractions (M f ) for Venus-LC3 and Venus-Atg4B(C74A)
Protein Cytoplasm Nucleus
Venus 0.99±0.02 (30) 0.99±0.01 (30)
Venus-LC3 0.98±0.01 (30) 0.99±0.01 (30)
Venus-Atg4B(C74A) 0.99±0.01 (30) 0.99±0.01 (30)
Venus-LC3 (+ Cerulean-Atg4B(C74A)) 0.99±0.01 (30) 0.99±0.01 (30)
Venus-Atg4B(C74A) (+ Cerulean-LC3) 1.00±0.02 (20) N/A
Values are the mean ± 95 % CI (N = #cells)
Table IV.2: Comparison of the experimentally determined apparent molecular weights to the expected molec-
ular weights for Venus-Atg4B(C74A) and Venus-LC3.
*Apparent MW (kDa)
Protein Expected MW (kDa) Cytoplasm Nucleus
Venus-Atg4B(C74A) 72 250±80 (30) 600±200 (30)
Venus-LC3 45 500±100 (30) 1800±600 (30)
Venus-LC3 (+ Cerulean-Atg4B(C74A)) 117 400±200 (30) 2500±800 (30)
Venus-Atg4B(C74A) (+ Cerulean-LC3) 117 400±100 (30) N/A
Values are the mean ± 95 % CI (N = #cells). *Calculated assuming a spherical geometry
By comparison of the mean FRAP curves we found Venus-LC3 and Venus-ATG4B(C74A) both diffuse
more slowly than Venus in the cytoplasm (Figure IV.5A) as well as in the nucleus (Figure IV.5B). We mea-
sured mobile fractions close to 100 % for all of these proteins on the timescale of our experiments (Table
IV.1). To obtain D values, the FRAP curves for Venus, Venus-LC3, and Venus- ATG4B(C74A) were fit
with a one component diffusion model (Eq. IV.6). This model fit the recovery curves effectively in both the
cytoplasm (Fig. IV.5C-E) and nucleus (data not shown). The mean D from fits to Venus-LC3 and Venus-
ATG4B(C74A) FRAP curves were 2.6±0.3 and 2.1±0.2 times smaller respectively than the mean D for
Venus in both the cytoplasm and nucleus (95 % CI, N = 30) (Figure IV.5F).
Using the Stokes-Einstein relation (D∝MW−1/3, with Venus as a standard for MW )[148] we determined
Venus-LC3 diffuses with an apparent molecular weight of 500±100 kDa, and Venus-ATG4B(C74A) diffuses
slightly faster with an apparent molecular weight of 250±80 kDa in the cytoplasm assuming a spherical
geometry (95 % CI, N = 30). In the nucleus we see a similar trend; Venus-LC3 diffuses with an apparent
molecular weight of 1800±600 kDa, and Venus-ATG4B(C74A) diffuses with an apparent molecular weight
of 600±200 kDa (95 % CI, N = 30). Importantly, these molecular weights are much larger than the expected
molecular weights for monomeric Venus-LC3 (45 kDa) and Venus-ATG4B(C74A) (72 kDa) (Table IV.2).
The above estimates of the size of the putative complex containing ATG4B(C74A) and LC3 assume a
spherical geometry. Given the crystal structure of the LC3-Atg4B complex appears roughly rod shaped[101],
if we estimate a fluorescently labeled complex is ∼ 22 nm long, and ∼ 5 nm wide the expected diffusion
coefficient is ∼ 17 µm2/s [207], consistent with our diffusion measurements in the cytoplasm. However, in
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Figure IV.5: The diffusional mobilities of Venus-LC3 and Venus-Atg4B(C74A) in both the cytoplasm and
nucleus are significantly slower than that of Venus as assessed by confocal FRAP. (A) Comparison of mean
FRAP curves for Venus, Venus-LC3, and Venus-Atg4B(C74A) in the cytoplasm. (N = 30 cells from 3
independent experiments). (B) Comparison of mean FRAP curves for Venus, Venus-LC3, and Venus-
Atg4B(C74A) in the nucleus. (N = 30 cells from 3 independent experiments). (C-E) Representative examples
of fits using a one component diffusion model to the experimentally determined recovery curves for Venus
(C), Venus-LC3 (D), or Venus-Atg4B(C74A) (E) in the cytoplasm (Error bars represent 95 % CI N = 30 cells
from 3 independent experiments). (F) Diffusion coefficients for Venus, Venus-LC3, and Venus-Atg4B(C74A)
in the cytoplasm and nucleus. Error bars represent 95 % CI N = 30 cells from 3 independent experiments.
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Figure IV.6: The diffusional mobility of Venus-Atg4B(C74A) is significantly slower upon co-expression
with Cerulean-LC3, whereas no significant change was observed for the mobility of Venus-LC3 upon
co-expression with Cerulean-Atg4B(C74A). (A) Mean diffusion coefficients for Venus-Atg4B(C74A) and
Venus-Atg4B(C74A) co-expressed with Cerulean-LC3 in the cytoplasm (N > 20 COS-7 cells). (B) Mean
diffusion coefficients for Venus-LC3 and Venus-LC3 co-expressed with Cerulean Atg4B(C74A) in the cyto-
plasm and nucleus. Error bars represent 95 % CI with N = 30 COS-7 cells.
the nucleus the measured diffusion coefficient of LC3 is significantly smaller suggesting the formation of a
higher molecular weight complex or a much more anisotropic complex in this compartment.
IV.2.3 ATG4B(C74A) and LC3 co-expression slows ATG4B(C74A) diffusion as measured by confocal
FRAP.
If ATG4B(C74A) and LC3 are bound to the same complex, we expect the diffusion coefficients for these
proteins should be identical, and correspond to the size and shape of the complex. However, we determined
D for Venus-ATG4B(C74A) is 21±1 µm2/s while D for Venus-LC3 is slightly slower at 17±1 µm2/s in
the cytoplasm (95 % CI N = 30) (Figure IV.5F). A simple explanation for this finding is that there may be
different fractions of bound and unbound forms of LC3 and ATG4B(C74A). For example, 100 % of Venus-
ATG4B(C74A) may not be bound to LC3 if endogenous LC3 levels are limiting. Thus, the recoveries for
Venus-ATG4B(C74A) may contain contributions from both rapidly diffusing unbound protein and slowly
diffusing bound protein. If this is the case, we reasoned it may be possible to drive additional complex forma-
tion by transiently expressing additional LC3. Therefore, we next performed confocal FRAP measurements
of Venus-ATG4B(C74A) in cells co-expressing additional Cerulean-LC3 (Figure IV.6). As a control, we also
measured the diffusional mobility of Venus-LC3 in cells co-expressing additional Cerulean-ATG4B(C74A).
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The FRAP curves for Venus-ATG4B(C74A) and Venus-LC3 in cells co-expressing either Cerulean-LC3
or Cerulean-ATG4B(C74A) respectively were, again, effectively fit by a pure diffusion model in both the cy-
toplasm and nucleus (data not shown). Under these conditions, essentially 100 % of the molecules were mo-
bile on the timescale of our experiments (Table 1). The mean D for Venus-LC3 co-expressed with Cerulean-
ATG4B(C74A) was identical within error to that obtained for Venus-LC3 expressed alone (Figure IV.6).
This suggests excess Cerulean-ATG4B(C74A) binding to Venus-LC3 does not significantly influence the
size or dynamics of the putative macromolecular complex containing Venus-LC3. In contrast, the mean D
for Venus-ATG4B(C74A) in the cytoplasm of cells co-expressing Cerulean-LC3 was significantly slower at
17±2 µm2/s compared to cells expressing Venus-ATG4B(C74A) on its own, and is identical to that of LC3
itself (95 % CI, N = 20).
Using the Stokes-Einstein relation (D∝MW−1/3 , with Venus as a standard for MW )[148], we determined
the apparent molecular weight of Venus-LC3 diffusing in cells co-expressing Cerulean-ATG4B(C74A) is
400±200 kDa in the cytoplasm, and 2500±800 kDa in the nucleus, which is statistically identical to Venus-
LC3 expressed on its own (95 % CI, N = 30). This is also identical to the apparent molecular weight of
400±100 kDa for Venus-ATG4B(C74A) diffusing in the cytoplasm of cells co-expressing Cerulean-LC3
(95 % CI, N = 20) (Table IV.2). These results indicate the levels of LC3 in the cytoplasm of cells is an
important determinant of the diffusional mobility of ATG4B(C74A) when LC3 concentrations are limiting,
and suggests not only are LC3 and ATG4B(C74A) likely directly interacting in live cells, but they are also
part of the same multi-protein complex. As discussed above, if we assume the complex has a rod shape
instead of spherical, the actual MW may be smaller than estimated here.
IV.2.4 LC3 and LC3 are within FRET proximity in the nucleus, but not the cytoplasm of living cells.
The results of the above experiments suggest both LC3 and ATG4B(C74A) are part of the same multi-
protein complex in cells. However, it is unclear whether these complexes contain multiple copies of LC3
or ATG4B(C74A). Furthermore, it was reported an LC3 homolog, GABARAP, forms homo-oligomers [107,
108]. Therefore, the formation of large homo-oligomers of Venus-LC3 could possibly explain LC3s slower
than expected diffusional mobility. To test for the presence of homo-oligomers, as well as to test if multi-
ple copies of LC3 may be present within the same high molecular weight complex, we performed acceptor
photobleaching FRET experiments on cells co-expressing Venus-LC3 and Cerulean-LC3. We detected no
significant difference between E for cells co-expressing Venus-LC3 and Cerulean-LC3 in the cytoplasm and
E for negative controls (p > 0.05, N = 18) (Figure IV.7). However, we observed a small, but significant
amount of energy transfer (6±2 %) in the nucleus of cells expressing Venus-LC3 and Cerulean-LC3 com-
pared to the negative control (2±1 %) (95 % CI, N = 18) (Figure IV.7). These results suggest LC3 either
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Figure IV.7: FRET occurs between donor and
acceptor-labeled LC3 in the nucleus but not the cy-
toplasm of living cells, whereas no FRET is detected
between donor and acceptor-labeled Atg4B(C74A) in
either the cytoplasm or nucleus. FRET efficiency be-
tween Cerulean-LC3 and Venus-LC3, or Cerulean-
Atg4B(C74A) and Venus-Atg4B(C74A) as measured
using acceptor photobleaching FRET. Data are shown
for measurements in both the cytoplasm and the nu-
cleus. FRET efficiencies between the negative control
Cerulean and Venus are shown for comparison. Error
bars represent 95 % CI with N ≥ 18 COS-7 cells from
at least two independent experiments.
homo-oligomerizes, or more than one LC3 is in close proximity within a multi-protein complex in the nu-
cleus, but not the cytoplasm of live cells.
IV.2.5 ATG4B(C74A) and ATG4B(C74A) are not in FRET proximity in both the cytoplasm and nu-
cleus of living cells.
We also considered the possibility that ATG4B(C74A) forms homo-oligomers or that multiple copies of
ATG4B(C74A) may be present within the same multi-protein complex. To test this, we performed acceptor
photobleaching FRET experiments on cells co-expressing Venus-ATG4B(C74A) and Cerulean-ATG4B(C74A).
The energy transfer efficiencies between Venus-ATG4B(C74A) and Cerulean-ATG4B(C74A) were identical
within error to values obtained for the negative controls (Figure IV.7). These results demonstrate that if mul-
tiple copies of ATG4B(C74A) are present in the same multi-protein complex, they are not close enough to
yield detectable FRET.
IV.3 Discussion
In the current study, we used FRET and FRAP to characterize the properties of a protein complex formed
by the interaction of LC3 with a catalytically inert mutant form of Atg4B, the protease responsible for both
lipidation and delipidation of LC3. Our findings reveal several novel properties of the complex formed
between ATG4B(C74A) and LC3, as well as each of these molecules individually.
As a starting point for our study, we confirmed co-expression of Cerulean-ATG4B(C74A) with Venus-
LC3 results in a detectable shift in the subcellular localization of LC3 as reported previously [121, 173]. In
particular, upon co-expression with ATG4B(C74A), LC3 is de-enriched from the nucleus and becomes se-
questered in the cytoplasm. This suggests the localization of ATG4B(C74A) is dominant over that of LC3.
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Why this is the case has not been established. However, a predictive sequence analysis for nuclear export sig-
nals indicates ATG4B(C74A) contains a putative consensus leucine rich (LxxLxL) NES at residues 225-230
[208]. Thus, it is possible ATG4B(C74A) is actively exported from the nucleus, leading to the accumulation
of both LC3 and ATG4B(C74A) in the cytoplasm. LC3 was also predicted to have an NES; however, this
NES does not appear to be functional under steady state conditions [121]. Therefore, a functional NES on
Atg4B may control the nucleocytoplasmic distribution of both Atg4B and LC3.
Our FRET measurements provide supporting evidence that LC3 and ATG4B(C74A) likely directly inter-
act in the cytoplasm of living cells. The observation that these two proteins are in FRET proximity is in good
agreement with previous biochemical evidence showing these two proteins form a stable complex [101, 173].
We also show here the interaction of LC3 and ATG4B(C74A) is not exclusively confined to the cytoplasm,
where the lipidation and de-lipidation of LC3, and autophagosome formation are known to occur. Instead,
they interact within the nucleus as well, indicating either LC3 or Atg4B, or both may have currently uniden-
tified functions in the nucleus, consistent with our previous findings showing soluble LC3 itself is enriched
in the nucleus relative to the cytoplasm [121].
In addition, we observed a significant increase in energy transfer efficiency when the acceptor LC3 is
labeled with the acceptor as opposed to when ATG4B(C74A) is labeled with the acceptor. In our experi-
ments, the manner in which Cerulean or Venus is attached to LC3 and Atg4B is identical. Assuming the
average relative orientation of transition dipole moments in a complex between LC3 and Atg4B is the same
regardless of which protein is labeled with Cerulean or Venus, the only variable in a comparison of FRET
experiments where the donor and acceptors are switched is the relative amount of donor to acceptor. Based
on the recent crystal structure for the interaction, it is plausible two molecules of acceptor labeled LC3 are
within close proximity of a single donor labeled ATG4B(C74A) providing significantly more opportunity
for energy transfer to occur [101, 178]. This suggests the ATG4B(C74A)-LC3 complex may not only occur
under crystallographic conditions, but also in the native environment of live cells, and may represent an im-
portant mechanism for regulating LC3 post-translational modification. However, slight structural differences
in the two different fluorescent protein labels could lead to differences in the average relative orientation of
transition dipole moments when bound in the complex [179]. For this reason, brightness analysis or time-
resolved fluorescence anisotropy could be used in the future to further validate a 2:1 stoichiometry for the
LC3-ATG4B(C74A) complex in live cells [202, 209].
In a previous study, we found the mobility of LC3 is much slower than expected for a free monomer
in the cytoplasm and nucleus consistent with that of a high molecular weight complex [121]. The actual
molecular weight of this complex is currently unknown, as the relationship between D and MW is dependent
on the geometry of the complex, and for anisotropic molecules D will be dominated by the longest dimension
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of the molecule. Since ATG4B(C74A) should bind to endogenous LC3, we speculated it may also become
incorporated into a slowly diffusing complex as the result of this interaction. Here, we tested this possibility
by performing quantitative FRAP experiments using a laser scanning confocal microscope. If the transport
process leading to recovery of fluorescence after photobleaching is simple diffusion, quantitative analysis of
a FRAP curve yields the diffusion coefficient of the diffusing species, which is related to the temperature
and viscosity of the medium, as well as the size and shape of the diffusing species. To obtain quantitative
estimates of the diffusion coefficients from FRAP data we utilized a recently developed analytical FRAP
model applicable to laser scanning confocal microscopes (Eq. IV.6) [158]. The model is a generalized form
of the classical Axelrod equation which assumed a stationary Gaussian laser profile, but takes into account
diffusion which occurs before acquisition of the first image in the time series, by determining the initial
conditions from the post-bleach image intensity profile (Figure IV.4B-C) [155].
Our FRAP measurements revealed the diffusion coefficient of ATG4B(C74A) expressed in live cells
was much slower than expected for a freely diffusing monomer according to the Stokes-Einstein relation.
Although it is difficult to distinguish a monomer from a dimer using this method, a monomer is readily dis-
cernible from a much larger or more anisotropic complex. Thus, our finding strongly suggests ATG4B(C74A)
does not exist as a monomer, but rather is incorporated into a larger complex in live cells. However, we noted
D for ATG4B(C74A) was slightly faster than D for LC3. We hypothesized the difference in D between these
proteins expressed individually could be due to limiting concentrations of endogenous LC3 resulting in a
larger fraction of ATG4B(C74A) unbound from the complex. To test this, we co-expressed LC3 in an attempt
to drive additional complex formation, and reduce the fraction of unbound ATG4B(C74A). Interestingly, the
D for Venus-ATG4B(C74A) in cells expressing additional LC3 became significantly slower to match that of
LC3 itself. These results complement our conclusions based on the FRET data, and further suggest LC3 and
Atg4B are likely directly interacting to form a complex in live cells.
As a control, we also expressed additional ATG4B(C74A) and looked for changes in D for Venus-LC3. In-
terestingly, D for Venus-LC3 was unchanged in cells co-expressing additional ATG4B(C74A). These results
suggest there was little LC3 unbound from the complex, and that expression and binding of ATG4B(C74A)
to LC3 does not interfere with the size or dynamics of the LC3 interacting complex normally slowing its
diffusion. FCS could be used in future experiments to further validate these findings based on its ability to
readily resolve multiple diffusing components.
Given the approximate rod shape of the complex between LC3 and Atg4BC74S as observed from a
recent crystal structure[101] we examined the possibility that LC3 and ATG4B(C74A) may be diffusing as
a rod shaped complex in live cells. We found our diffusion measurements for LC3 and ATG4B(C74A) were
consistent with their incorporation into a complex of this size and shape in the cytoplasm, but fluorescence
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anisotropy measurements could potentially be used to further validate this finding. Interestingly, we observed
LC3 diffuses much slower in the nucleus implying LC3 may constitutively associate with a larger or more
anisotropic complex with currently unknown composition in this compartment.
Our FRAP measurements from cells expressing LC3 alone, ATG4B(C74A) alone, as well as cells co-
expressing the two proteins all displayed mobile fractions ≥ 99% in the regions of the cells where we per-
formed our measurements. This suggests the majority of LC3 and ATG4B(C74A) does not stably associate
with cellular superstructures e.g. microtubules or DNA which are essentially immobile on the time scale of
our FRAP experiments. We deliberately avoided bright punctate (∼ 0.5 µm) structures, which presumably
represent autophagosome vesicles. The large vesicles are also effectively stationary on the time scale of our
FRAP experiments. If these structures were selected for FRAP experiments, the mobile fractions would likely
be less than 100 %.
Since we found both LC3 and ATG4B(C74A) appear to diffuse as part of the same complex, this raised
the possibility that the slower than expected diffusion may be the result of homo-oligomerization of LC3
or ATG4B(C74A), or that multiple copies of LC3 and ATG4B(C74A) may be contained within the same
multi-protein complex. To test this possibility we performed acceptor photobleaching FRET measurements
on cells co-expressing Venus and Cerulean tagged versions of LC3 and ATG4B(C74A). In the cytoplasm we
found no evidence for the presence of LC3 or ATG4B(C74A) homo-oligomers. The absence of detectable
FRET between LC3 and LC3, or between ATG4B(C74A) and ATG4B(C74A) implies if more than one copy
of LC3 or ATG4B(C74A) is present in the same slowly diffusing complex, these molecules are positioned at
distances greater than 10 nm from one another in the cytoplasm. However, due to the orientation requirements
for FRET the absence of energy transfer efficiency cannot rule out the possibility of homo-oligomerization,
or more than one LC3 in a complex. For example, if two LC3s are bound to Atg4B as seen in the crystal
structure it is possible their N-terminal fluorescent protein labels are positioned on opposite sides of Atg4B
(r >∼ 10nm) preventing a detectable amount of energy transfer from occurring.
Conversely, in the nucleus we observed a detectable level of energy transfer between Cerulean-LC3 and
Venus-LC3 compared to negative controls. Therefore, in the nucleus, LC3 may either homo-oligomerize, or
more than one LC3 molecule is present in close proximity within the same multi-protein complex. Further,
this suggests the organization of LC3 within complexes in the nucleus may differ from that in the cytoplasm,
bringing the proteins into sufficiently close proximity to give rise to FRET.
In summary, our data are consistent with a model in which ATG4B(C74A) and LC3 not only directly
interact, but also associate with a slowly diffusing complex in both the cytoplasm and nucleus of living cells.
This complex could either have a relatively high molecular weight or be elongated in shape. The identities
of the components of the putative large complexes in the nucleus are not yet known, but are likely to involve
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other components of the conjugation machinery in the autophagy pathway. In addition, the organization of
LC3 within complexes in the nucleus may be different from that in the cytoplasm, or alternatively LC3 may
homo-oligomerize in the nucleus. These data also strongly suggest LC3 and Atg4B may both have currently
undefined functions in the nucleus. Ultimately, these types of fundamental measurements of live cell protein
diffusion and complex formation described here can be used to extend biochemical studies to the single living
cell in order to better understand intracellular pathways such as autophagy.
IV.4 Materials and Methods
IV.4.1 Cell lines and constructs
COS-7 cells were obtained from ATCC (Manassas, VA) and cultured in DMEM supplemented with 10 % fe-
tal calf serum, 1 % PenStrep, and phenol red. EGFP-LC3 and mStrawberry-Atg4B(C74A) were the gift of T.
Yoshimori (Osaka University)[173]. Cerulean and Venus were the gift of D. Piston (Vanderbilt University)[204].
Cerulean and Venus tagged versions of LC3 and Atg4B(C74A) were constructed as follows: cDNA for
Cerulean and Venus were inserted into Clonetech pEGFP-C1 vectors by AgeI and BsrGI double restriction
digestion resulting in pCerulean-C1 and pVenus-C1 vectors. Next, we inserted LC3 and Atg4B(C74A) cDNA
into the pCerulean-C1 and pVenus-C1 multiple cloning sites by BglII and EcoRI double restriction digestion.
IV.4.2 Microscope and cell preparation for live cell imaging
All FRET and FRAP microscopy experiments were carried out on a Zeiss LSM 510 confocal microscope
(Carl Zeiss MicroImaging, Inc., Thornwood, NY) using an Argon/2 30 mW laser (458, 488, 514 nm), oil
immersion 40X 1.3 N.A. Zeiss Plan-Neofluar objective, and 1 Airy Unit pinhole.
COS-7 cells were plated on the day before transfection in either MatTek (Ashland, MA) 35 mm No.
1.5 glass bottom culture dishes, or Lab-Tek II 4-well No. 1.5 glass bottom chamber slides (Thermo Fisher
Scientific, Rochester, NY). On the following day the cells (50 %–80 % confluent monolayer) were transfected
with the described mammalian expression constructs using FuGENE 6 (Roche Applied Science, Indianapolis,
IN) transfection reagent according to the manufacturer’s recommended protocol.
On the day of the experiment (24 hours after transfection) cell culture medium was rinsed and replaced
with phenol red-free DMEM supplemented with 10 % fetal calf serum, 1 % PenStrep, and 25 mM HEPES.
The cells were allowed to come to equilibrium at 37 ◦C ∼ 5 min before transferring to the temperature con-
trolled microscope stage set to 37 ◦C.
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IV.4.3 Acceptor photobleaching FRET data acquisition
When FRET occurs the intensity of fluorescence emission from the donor is quenched and fluorescence emis-
sion from the acceptor is stimulated. The FRET efficiency can be determined by quantifying the relative in-
tensity of fluorescence emission from the donor in the presence and absence of the acceptor. A form of FRET
microscopy known as acceptor photobleaching directly measures these quantities on a single sample by irre-
versibly photobleaching the acceptor. If donor and acceptor are undergoing FRET this procedure results in an
increase in the intensity of fluorescence emission from the donor called dequenching [191, 203, 210]. Of the
various methods available to experimentally measure FRET in single cells using fluorescence microscopy, the
acceptor photobleaching method is a straightforward approach that avoids many of the technical difficulties
involved in measuring FRET accurately. A limitation of acceptor photobleaching is that it only provides a
single time point steady-state measurement of FRET [203].
To perform acceptor photobleaching FRET experiments the microscope was configured for time lapse
imaging, and several images were collected: first, a 12 bit 512 X 512 (146 nm/pixel) image of the donor at
3X digital zoom using 0.375 mW 458 nm excitation followed by acquisition of a second image of the acceptor
using 0.075 mW 514 nm excitation (pre-bleach images). Next, we bleached the acceptor from the entire cell
using 30 iterations of 15 mW 514 nm excitation. Finally, we collected another set of images using the same
settings as described for the pre-bleach images (post-bleach images). With these settings, ∼ 3 seconds were
required to acquire a single image of the donor and acceptor, and ∼ 47 seconds were required to bleach the
acceptor. To separate the excitation and emission wavelengths we used an HFT 458/514 dichroic, followed
by an NFT 515 dichroic. In addition, a 470-500 band pass filter was positioned before the donor channel
detector, and a LP 530 filter was positioned before the acceptor channel detector.
IV.4.4 Acceptor photobleaching FRET data analysis
We defined freehand ROIs outlining the cytoplasm and nucleus of each cell using ImageJ (NIH), as well as
a background ROI in a similar manner for unlabeled cells. Next, we measured the mean intensity inside the
ROIs for the pre-bleach images in the donor (IDpre) and acceptor channels (IApre) followed by the mean inten-
sities inside the same ROIs for the post-bleach images in the donor (IDpost ) and acceptor (IA post) channels.
The background fluorescence levels were estimated by examining the mean intensity in the background ROI
from the post-bleach images in the donor channel (Ibkgd). In control experiments we found the background
intensity from unlabeled cells was very low, and was statistically identical to the background measured in
the media adjacent to the cell under the conditions of our experiments. In addition, we verified the back-
ground intensity in the donor channel was identical before and after a mock acceptor bleaching experiment,
indicating no bleaching of other fluorophores in the media was occurring. Although under the conditions of
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our experiments the background fluorescence was identical in media and unlabeled cells, for situations where
cells express lower levels of fluorescent proteins or have higher autofluorescence, the intensity measured
within unlabeled cells would be a more appropriate measure of the background. The percent FRET efficiency
E was calculated for each cell,
E =
[(
IDpost − Ibkgd
)− (IDpre− Ibkgd)
IDpost − Ibkgd
]
100 (IV.3)
we collected data from multiple cells over several different experiments and report the mean E ±95 % confi-
dence interval for the total number of cells. To ensure significant bleaching of the acceptor we verified,
(
IApost − Ibkgd
IApre− Ibkgd
)
100 < 5% (IV.4)
IV.4.5 Confocal FRAP data acquisition
The microscope was configured for time-lapse imaging of a 12-bit 512 X 90 pixel (110 nm/pixel) imaging
ROI at 4X digital zoom. We defined a circular bleaching ROI (9 pixel radius, 0.99 µm) centered at pixel
(x = 256, y = 45) within the imaging ROI. Imaging was performed using 0.15 mW 514 nm excitation, and
bleaching was performed by scanning 10 iterations of 30 mW 514 nm excitation throughout the bleaching
ROI. We utilized bi-directional rastering, and maximized the scan speed of our microscope. Under these
conditions, 45.1 msec were required to acquire a single image, and 150.1 msec were required to bleach the
circular ROI and acquire the next image. We collected 20 pre-bleach images followed by 280 post-bleach
images to monitor recovery after the bleach.
IV.4.6 Quantitative FRAP data analysis
In this study we analyzed the diffusion of fast moving proteins such as soluble Venus which have been a
challenge to quantitatively measure in cells by confocal FRAP [121, 148, 157, 158]. Under our experimental
conditions a significant amount of diffusion occurred during the time it took to perform the bleach step
(0.1501 sec). In order to quantitatively analyze the FRAP curve to obtain D, the initial conditions to solve the
diffusion equation in the derivation of the FRAP model must be empirically determined from the intensity
profile of the image collected immediately after photobleaching (post-bleach profile)[155],
I(x; t = 0) = I0 exp
[
−K exp−
(
2x2
r2e
)]
(IV.5)
where I0 = 1 for a normalized post-bleach profile, K is a bleaching parameter, x is the radial displacement
from the center of the bleaching ROI, and re is the effective radius. K and re reflect the diffusion that occurs
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in the time it takes to bleach and acquire the post-bleach image.
In a previous study, we collected line profiles from the post-bleach image and averaged them for multiple
cells to obtain the mean re [121]. This was necessary because line profiles are inherently noisy. Here, we
determined re on a cell-by-cell basis by increasing the signal to noise of the experimentally determined post-
bleach profiles as follows. First, we normalized the image acquired immediately after bleaching a circular
bleach ROI (post-bleach image) to the mean of 10 images acquired immediately prior to the post-bleach
image (pre-bleach images). Next, we calculated the radial displacement for each pixel in the image from the
center of the circular bleach ROI (x = 28.16 µm, y = 4.95 µm). The symmetry of a circular bleach ROI allows
us to reduce the dimensions of the post-bleach profile by plotting the intensity of a pixel in the normalized
post-bleach image vs. its radial displacement from the center of the circular bleaching ROI, I(x; t = 0).
To calculate D, we utilized a series representation of a closed-form analytical FRAP equation describing
free diffusion of unbleached molecules into a circular bleach ROI which is applicable to data obtained on a
laser scanning confocal microscope[158],
I(t) = I0
(
m=200
∑
m=0
−Kmr2e
m![r2e +m(8Dt+ r2n)]
)
M f +(1−M f )I(0) (IV.6)
where I0 = 1 for a normalized FRAP curve, t is time, D is the diffusion coefficient, and M f is the mobile
fraction. This equation is a modified form of the Axelrod equation[140] where a Gaussian laser profile, and
an approximation for the diffusion of molecules that occurred before acquisition of the post-bleach image is
taken into account by incorporation of K and re parameters from the post-bleach profile [158]. To obtain a
good match between K from the post-bleach profile, and K from the FRAP data we numerically evaluated K
using Eq. IV.6 at t = 0.
To obtain an experimental FRAP curve we measured the mean intensity inside the circular bleaching ROI
(rn = 0.99µm) at the location defined during data acquisition for each image in the time-lapse data set I(t).
Next, we normalized I(t) by the mean of I(t) for ten pre-bleach images.
Under our experimental conditions, there was a small amount of unintentional photobleaching that oc-
curred throughout FRAP data acquisition. We verified this decay could be approximated by a first order
exponential rate equation,
I(t) = exp(−kdecayt) (IV.7)
where kdecay is the first order rate constant for the decay. To correct the experimental curves we acquired
time-lapse data significantly longer than required for complete recovery after photobleaching, and used I(t)
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at these later time points to estimate kdecay [157]. The corrected FRAP curve is then,
Icorr(t) =
I(t)
Idecay(t)
(IV.8)
By fitting the corrected data to equation IV.6 we obtain the parameters D and M f . However, because a
significant fraction of fluorophores are irreversibly lost as the result of the photobleaching event, M f is
underestimated by this approach. To determine the true fraction of immobile fluorophores on the time scale
of our FRAP experiments, we calculated the difference between I(t) and the mean intensity inside an adjacent
circular ROI, Iad jacent(t), at time points after the recovery was complete [206].
IV.4.7 Other data analysis
Image analysis was performed using ImageJ (NIH), and non-linear least squares analysis was performed
using custom routines written in MATLAB (MathWorks; Natick, MA). All scatter plots and bar graphs were
created using MATLAB and Adobe Illustrator (Adobe Systems Incorporated; San Jose, CA).
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CHAPTER V
Fluorescence-based assays to probe for LC3 interacting proteins in living cells
Multiple proteins interact with LC3 to assist with its roles in cargo selection and autophagosome assembly.
Most LC3 interacting proteins have been identified using biochemical approaches. In Chapter IV we de-
scribed how FRET and FRAP can be used to gain insights into the nature of LC3 associated complexes in
living cells. In this chapter, we describe how an additional fluorescence microscopy assay based on quantify-
ing LC3’s nucleocytoplasmic (N/C) ratio, together with FRET and FRAP, can be used to detect the interaction
of specific proteins with LC3 in living cells. To validate these methods, we monitored the interaction of LC3B
and p62/sequestosome1 (SQSTM1), a well-known LC3 interacting protein involved in selective autophagy.
We verified the specificity of these techniques by demonstrating that interactions of SQSTM1 with LC3B
were inhibited by F52A and L53A mutations of LC3Bs hydrophobic protein binding interface as reported
by all three methods. Importantly, these assays take advantage of widely available technologies and offer
a complementary approach to existing methods to detect protein interactions with LC3. They can also be
readily adapted to characterize other protein complexes in the autophagy pathway, as illustrated here through
the analysis of soluble SQSTM1 homo-oligomers.
V.1 Introduction
Autophagy is a major degradation pathway whereby cytoplasmic contents are sequestered for degradation
via the lysosome [5]. A conserved pathway in eukaryotes, autophagy is vitally important for normal health,
development, and the prevention of disease [211]. Upregulation of autophagy leads to the formation of a dou-
ble membrane vesicular intermediate known as an autophagosome that is responsible for engulfing regions of
cytoplasm. The outer membrane of the autophagosome subsequently fuses with the lysosome thereby degrad-
ing its inner membrane and contents [5]. Autophagy can occur either with or without substrate specificity,
termed selective or macroautophagy, respectively. In selective autophagy, a ligand - usually ubiquitin - is
conjugated to specific substrates such as protein aggregates. Next, receptors and adaptors bind to the ubiqui-
tinated substrate, and target it to autophagosome associated ATG8 proteins [32, 38, 69]. The autophagosome
is subsequently trafficked to the lysosome for degradation and recycling of its contents.
Members of the ATG8 protein family are central to the autophagy pathway and are best known for
their role in autophagosome formation [80]. Human ATG8 proteins consist of three subfamilies, MAP1LC3
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(LC3), GABARAP, and GATE-16. The LC3 subfamily encompasses four genes, MAP1LC3A, MAP1LC3B,
MAP1LC3B2, and MAP1LC3C [79]. Among these genes the most widely studied is Microtubule Associated
Protein 1 Light Chain 3B (hereafter referred to as LC3B). The known functions of LC3 include contributions
to autophagosome membrane expansion and fusion, and selective recruitment of cargo to the autophagosome
[38]. LC3 is known to exist in at least two forms, a soluble form known as LC3-I, as well as lipid modified
LC3-II [90, 91]. LC3-II consists of phosphatidylethanolamine covalently attached to a glycine residue on the
C-terminus of LC3. The process of LC3 lipid modification is carried out through a series of enzymatic re-
actions resembling ubiquitination, and since LC3 itself is structurally similar to ubiquitin it has been dubbed
an ubiquitin-like protein [79]. Soluble LC3 is found in the nucleoplasm as well as in the cytoplasm, and
undergoes slow exchange between the two compartments by an unknown mechanism [121].
Consistent with their central role in the autophagy pathway, LC3 and other ATG8 family members interact
with a large network of over 65 different proteins with extensive overlap among ATG8 family members [9].
Many of these interactions are mediated by a consensus LC3 interacting region (LIR) in the interacting pro-
teins [212]. SQSTM1/p62 (sequestosome1) is one of the best characterized examples of an LC3-interacting
protein [67, 213]. A homo-oligomer, SQSTM1 functions as a cargo receptor and together with ubiquitin
and LC3 plays an important role in selective autophagy [32, 214]. The interactions of SQSTM1 and LC3
have been studied extensively using a combination of co-immunoprecipitation, pull down assays, structural
analysis, mass spectrometry, and colocalization approaches [9, 67, 68, 100, 129, 130, 215]. The results of
these studies have revealed that SQSTM1 interacts with LC3 via its LIR domain [68, 100, 129]. Interactions
of SQSTM1 with LC3 are mediated by LC3s N-terminal domain as well as residues F52, L53, and R70
[9, 129, 214]. The interaction of SQSTM1 with LC3 does not depend on lipidation of LC3, as a G120A mu-
tant of LC3 coimmunoprecipitates with it [100]. However, SQSTM1 binding to LC3 alone is not sufficient
to target SQSTM1 for degradation by autophagy [129].
In parallel to biochemical approaches to study protein-protein interactions, in recent years a number of
fluorescence-based approaches have emerged that enable the detection of protein complex formation in the
context of living cells [188, 216–219]. One good example is Fo¨rster resonance energy transfer, or FRET
[136, 178, 220, 221]. FRET is a photophysical process that occurs between a donor and acceptor fluorophore
when they are brought into sufficiently close distances, typically < 10nm to each other. Because of its
distinct distance dependence, FRET can be used to monitor the interactions of appropriately fluorescently
labeled proteins. The distance over which FRET occurs between a specific donor and acceptor is defined
with respect the to the Fo¨rster distance R0. R0 is a function of the average relative dipole-dipole orientation,
the refractive index, and the photophysical properties of the donor and acceptor fluorophores. FRET occurs
between a number of fluorescent protein pairs typically used to study protein localization in live cells, includ-
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ing Cerulean and Venus [136]. In FRET studies, Cerulean serves as the donor and Venus functions as the
acceptor. For this FRET pair, R0 is 5.4 nm [137].
The efficiency of energy transfer E between the donor and acceptor is a function of R0 and r, the distance
between the donor and acceptor. The functional relationship between E, r, and R0 is given by
E =
1
1+(r/R0)6
(V.1)
Thus, when r = 5.4 nm, E will be 50 % for the Cerulean and Venus pair, and when r > 10nm, E will drop
to ∼ 0 %. Importantly, FRET can be directly measured using fluorescence microscopy using a number of
methods, including sensitized acceptor fluorescence, acceptor photobleaching, fluorescence lifetime imaging,
and anisotropy [203, 222–228]. Despite the power of FRET to detect protein-protein interactions, this method
and related approaches have not yet gained widespread use in the autophagy field and to our knowledge have
only been applied in a handful of studies [124, 153, 164, 165].
A second class of biophysical approaches that can be used to study protein-protein interactions relies on
measurements of the diffusion of fluorescently labeled proteins. These include Fluorescence Recovery after
Photobleaching (FRAP), photoactivation/photoconversion, fluorescence correlation spectroscopy (FCS), and
single particle tracking [132, 218, 229–231]. Of these methods, FRAP is the most easily implemented, as
it can be readily performed using confocal microscopes [148, 155, 158, 164, 165, 171, 175, 197, 232–234].
These approaches take advantage of the fact that molecules undergo constant motion in the form of Brownian
diffusion. Diffusion is typically characterized in terms of a diffusion coefficient D, which provides a measure
of the mean squared displacement of a diffusing particle per unit time. Importantly, for soluble proteins, the
diffusion coefficient is related to the size of the diffusing species according to the Stokes-Einstein relation:
D =
kBT
6piηr
(V.2)
Here, the diffusion constant D is directly related to the absolute temperature T , and inversely related to
the viscosity η and the hydrodynamic radius of the diffusing species r. kB is Boltzmann’s constant. Thus,
measurements of D can be used provide an estimate of the size of soluble, freely diffusion proteins. Transient
binding of proteins to immobile structures such as DNA will slow their diffusion [148, 206, 235]. When
freely diffusing soluble proteins interact to form a complex, D can also decrease. Conversely, D for a multi-
component complex will increase upon breakdown of the complex. In these cases, the magnitude of the
change in D will depend on the differences in the hydrodynamic radius of the protein in the unbound state
and that of the bound complex according to equation V.2 [165].
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Using diffusion-based measurements, we previously showed that soluble LC3B diffuses slower than ex-
pected for a monomer [121]. We subsequently determined the slower than expected diffusion was the result
of LC3 constitutively associating with complexes with an effective molecular weight of about 500 kDa in
the cytoplasm of living cells and in cytoplasmic extracts by FCS [164]. Furthermore, we found that the size
of these complexes is modulated by disruption of residues known to be important for LC3 to bind to other
proteins [164]. However, the full potential of FRAP and related approaches to monitor the interactions of
specific proteins with LC3 in the cellular environment has yet to be tested.
In the current study, we demonstrate how a combination of FRET, FRAP, and LC3 localization measure-
ments can be used to monitor the specific interactions of proteins with LC3 in living cells. To validate these
approaches, we studied the interaction of Cerulean-SQSTM1 with Venus-LC3B. We show that all three as-
says are capable of detecting interactions of overexpressed SQSTM1 and LC3, and verify the specificity of
these interactions using LC3 mutants with decreased ability to bind LC3. Finally, we illustrate the broader
applicability of these approaches to study protein complexes in the autophagy pathway by characterizing the
properties of soluble SQSTM1-associated homo-oligomers.
V.2 Results
V.2.1 Proteins examined in this study
As a model system, we studied the interaction of fluorescent protein-tagged versions of SQSTM1 and LC3
in HeLa cells. To test for the specificity of binding, we utilized several mutant forms of LC3. These included
a G120A mutant, which is unable to be properly lipidated [106]; R70A, a mutant that exhibits decreased
binding to a subset of LC3-interacting proteins [9]; and F52A and L53A, another mutant that undergoes
decreased binding to a subset of LC3-interacting proteins [9]. Previous studies have indicated that the LC3
mutants G120A and R70A mutants are capable of binding to SQSTM1, while the F52A and L53A shows
greatly reduced binding [9, 69, 100, 129].
When transiently expressed in HeLa cells, both wild type and the mutant forms of Venus-LC3 were
found in soluble forms in the cytoplasm and nucleus (Figure V.1A). Venus-LC3 was also found in perinuclear
puncta. Fewer puncta were observed for the R70A mutant and G120A mutant, and very few puncta were
seen for F52A and L53A (Figure V.1C). In comparison, transiently expressed Venus-SQSTM1 was primarily
found in a soluble form in the cytoplasm. This is consistent with previous studies in HeLa cells reporting
that under basal conditions less than 5 % of the cells have SQSTM1 inclusions [68], and its steady-state
cytoplasmic localization is maintained by active nuclear export [236].
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Figure V.1: The nucleo-cytoplasmic ratio of soluble LC3 is decreased in the presence of overexpressed
SQSTM1. Representative confocal images of the localization of Venus-LC3, Venus-LC3(G120A), Venus-
LC3(F52A and L53A), Venus-LC3(R70A), and Venus-SQSTM1 when transiently co-expressed with (A)
Cerulean or (B) Cerulean-SQSTM1 in HeLa cells. Scale bars, 10 µm. An automated analysis routine was
used to quantify (C) the numbers of puncta/cell and (D) the N/C ratio of the puncta independent Venus signals
in cells coexpressing the indicated Venus-tagged constructs in combination with either Cerulean (gray boxes)
or Cerulean-SQSTM1 (white boxes.) (E) N/C ratio of the puncta independent Cerulean signals from cells
coexpressing the indicated Cerulean-tagged constructs in combination with either Venus or Venus-SQSTM1.
In C-E, bars are the mean ± 95 % confidence interval; N=20 cells from 2 independent experiments.
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V.2.2 The nucleocytoplasmic ratio of autophagosome independent LC3 is decreased in the presence
of overexpressed SQSTM1
Previous studies have noted that the soluble LC3 is shifted out of the nucleus when co-expressed with ATG4B
[165, 173]. This suggests the putative nuclear export signal on ATG4B dominates the nucleocytoplasmic
distribution of LC3 when the two proteins form a complex. We thus sought to determine whether this could
be used as a general method to quantify interactions of proteins with LC3.
To test this, we co-expressed Venus-LC3 or its mutants with Cerulean-SQSTM1. As a control, cells were
instead co-transfected with Cerulean. Co-expression of SQSTM1 and Venus-LC3 proteins led to a dramatic
shift in soluble Venus-LC3 out of the nucleus into the cytoplasm (Figure V.1). We used an automated image
analysis routine to quantify this effect across multiple cells in terms of a nucleo-cytoplasmic ratio (N/C ratio
in Figure V.1D). The Venus LC3 G120A mutant showed a similar decrease in N/C ratio, as did the R70A
mutant. Co-expression of SQSTM1 with a Venus-LC3(F52A L53A) mutant also led to a significant decrease
in the N/C ratio (p≤ 0.003; t-test). However, the magnitude of this decrease was much smaller than that seen
for either wild type LC3 or the other mutants. These findings are consistent with previous reports that the
F52A L53A mutant has a significantly decreased ability to bind to SQSTM1.
Because a significant fraction of LC3 is typically found in the nucleus, we wondered whether this nuclear
pool of LC3 might be able to recruit SQSTM1. To address this question we measured the N/C ratio for
SQSTM1 in these experiments. The N/C ratio of Cerulean-SQSTM1 remained essentially unchanged under
all conditions examined (Figure V.1E). These findings suggest that under steady state conditions, the active
nuclear export signal present in SQSTM1 will dominate the localization of LC3 when co-expression induces
their interaction, similar to the effect of binding of ATG4B(C74A) to LC3.
V.2.3 FRET reports on the close physical proximity of SQSTM1 and LC3
Direct protein-protein interactions bring proteins within close physical proximity of one another and thus
can be monitored using FRET [136, 178, 220, 228]. To measure FRET between Cerulean and Venus-tagged
versions of LC3 and SQSTM1, we used acceptor photobleaching, a well-characterized method to quantify en-
ergy transfer by fluorescence microscopy [153, 165, 186, 203, 210, 237, 238]. This approach takes advantage
of the fact that when energy transfer occurs, the fluorescence of the donor is quenched. Thus, fluorescence of
the donor is higher in the absence of the acceptor than in its presence. This change in donor intensity can be
measured experimentally on a single sample by photobleaching the acceptor.
An example of an acceptor photobleaching FRET experiment is shown in Figure V.2. In this approach,
cells are cotransfected with donor and acceptor-labeled proteins. Images are collected of the donor and
acceptor-labeled proteins before bleaching the acceptor. The acceptor fluorophore is then photobleached
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Figure V.2: Principles of acceptor photobleaching FRET experiment and positive and negative controls. HeLa
cells were transfected with either positive FRET controls (C5V, C17V, C32V) or a negative FRET control
(soluble Cerulean and Venus) and imaged using an acceptor photobleaching assay. (A) Representative donor
and acceptor images before and after acceptor photobleaching from a FRET experiment on C5V. Scale bars,
10 µm. (B) Representative energy transfer efficiency image calculated from the images in (A). (C) Quantita-
tion of the mean cytosolic FRET signals across multiple cells. N=20 cells from 2 indpendent experiments.
Bars are the mean ± 95 % confidence intervals.
to near background levels by repetitively imaging it using high laser excitation intensity. Another set of
images of the donor and acceptor labeled proteins are collected, using identical settings as the first pair of
images (Figure V.2). The energy transfer efficiency E can then be calculated using the background-corrected
fluorescence intensity of the donor fluorescence before Dpre and after photobleaching the acceptor Dpost
according to the following equation:
E =
Dpost −Dpre
Dpost
(V.3)
This calculation can be performed either using mean fluorescence values obtained from regions of interest
on the donor pre- and post-bleach images, or alternatively, energy transfer efficiency images can be calcu-
lated to yield spatially resolved FRET maps within the cell (Figure V.2B). In what follows, we report FRET
efficiencies that are averaged over the whole cell unless otherwise noted.
To optimize conditions for our FRET experiments we first carried out control experiments. As a negative
control, we co-expressed mCerulean and mVenus. Because these two proteins are monomeric they should
not specifically interact, and at moderate concentrations, FRET between them should be minimal. Thus,
FRET measurements between Cerulean and Venus can be used to define how much E is detected in the
absence of specific FRET, and also to determine the level of noise inherent in the measurements. Acceptor
photobleaching measurements of mCerulean and mVenus-coexpressing samples yielded E of 8±1 % under
the conditions of our experiments (Figure V.2C). As a positive control, we expressed constructs that exhibit
intra-molecular FRET. These constructs consists of Cerulean and Venus separated by variable length linkers
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of amino acids [205]. E of 43±1 % was measured for C5V, 38±1 % for C17V, and 31±2 % for C32V was
measured in HeLa cells (Figure V.2C).
Since SQSTM1 is known to homo-oligomerize [239, 240] we next asked if measurable FRET occurred
between mCerulean-SQSTM1 and mVenus-SQSTM1 (Figure V.3F). FRET of 13±1 % was observed under
these conditions, verifying that the method is capable of detecting homo-oligomers as expected. In contrast,
when SQSTM1 was co-expressed with mCerulean, FRET levels were comparable to background measure-
ments between Cerulean and Venus (Figure V.3F).
Next, we measured FRET between SQSTM1 and LC3 (Figure V.3). Co-expression of either wild type
Venus-LC3 or Venus-LC3(G120A) with Cerulean-SQSTM1 gave rise to substantial FRET, E 13±1 % and
14±1 % respectively (Figure V.3C). A similar level of FRET was also detected between Cerulean-SQSTM1
and Venus-LC3(R70A), indicative of their close interaction (12±1 %. However, E measured between SQSTM1
and the Venus-LC3(F52A and L53A) mutant was near background levels at 7±1 %. Similar results were ob-
tained between mCerulean-tagged LC3 constructs and mVenus-SQSTM (Figure V.3D). These results confirm
that as expected, SQSTM1 and LC3 are within close proximity of one another. It also verifies that this in-
teraction does not require LC3’s lipid modification with PE or residue R70, but does depend importantly on
residues F52 and L53.
V.2.4 LC3’s rate of diffusion changes when co-expressed with SQSTM1
We next asked whether binding of SQSTM1 to LC3 leads to a change in the size of LC3-associated protein
complexes. Because SQSTM1 is a homo-oligomer and binds to polyubiquitinated proteins, it would be
predicted to form a complex with LC3 that has a much larger hydrodynamic radius than that of unbound
LC3. To address this question we took advantage of a quantitative confocal FRAP-based assay directed at
the puncta independent pool of the proteins. In this assay we use a small circular 1 µm radius bleach region
placed in a relatively homogeneous region of the cytoplasm as to avoid any bright puncta (Figure V.4A).
The exact size of the SQSTM1 complexes with which LC3 associates is not clear, as SQSTM1 is capable
of interacting with a number of proteins as well as ubiquitinated substrates. However, by size exclusion
chromatography, endogenous SQSTM1 runs as a heterogeneous series of complexes in the range of 0.4 MDa–
5 MDa [241] suggesting they should be slowly diffusing. Thus, as a starting point for these experiments, we
performed FRAP measurements of soluble Venus-SQSTM1 in the cytoplasm. As an internal control, we
measured D for cytoplasmic Venus. In these experiments, Venus should diffuse as an inert protein with an
expected MW of ∼ 27 kDa. We obtained a D of 35±3 µm2/s for Venus, a result consistent with previous
measurements [164]. M f was near 100 % for Venus, as expected based on its ability to freely diffuse (Table
V.1).
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Figure V.3: FRET reports on the close physical proximity of SQSTM1 and LC3. (A) Representative donor
and acceptor images from a FRET experiments on cells coexpressing Cerulean-SQSTM1 and Venus-LC3.
Scale bars, 10 µm. (B) Representative energy transfer efficiency image from the images in (A). (C) FRET
analysis was performed on cells coexpressing the indicated Venus-tagged constructs with either Cerulean
or Cerulean-SQSTM1 and automatically analyzed across multiple cells. (D) FRET analysis was performed
on cells coexpressing the indicated Cerulean-tagged constructs coexpressed with either Venus or Venus-
SQSTM1. In panels C and D, bars show the mean ± 95 % confidence intervals; N > 20 cells from at least 2
independent experiments.
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Figure V.4: LC3’s rate of diffusion changes when co-expressed with SQSTM1. (A) A quantitative FRAP
assay was carried out on cells coexpressing various Venus- and Cerulean-tagged constructs using a rectan-
gular imaging ROI centered on the cytoplasm, and small circular bleach region (rn=1 µm) placed in a region
devoid of puncta. Scale bar is 10 µm (B) Examples of the averaged recoveries of Venus-LC3 coexpressed
with Cerulean (circles) or with Cerulean-SQSTM1 (squares). The solid lines are fits to a single compo-
nent diffusion model. (C) D values for Venus, Venus-LC3, Venus-LC3(G120A), Venus-LC3(F52A L53A),
Venus-LC3(R70A), or Venus-SQSTM1 either coexpressed with Cerulean or Cerulean-SQSTM1. (D) D val-
ues for Venus-SQSTM1 coexpressed with Cerulean, Cerulean-LC3, Cerulean-LC3(F52A L53A), Cerulean-
LC3(R70A), or Cerulean-SQSTM1. In C and D, bars show the mean ± 95 % confidence intervals; N > 20
cells from at least 2 independent experiments.
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Next, we performed FRAP measurements for SQSTM1. The recovery for Venus-SQSTM1 was substan-
tially slower than Venus with D = 6±1µm2/s (p≤ 0.003). We found that SQSTM1 was also 100 % mobile
(Table V.1). Puncta-indpendent SQSTM1’s diffusion is far slower than what we previously measured for
Venus-LC3 [164]. Assuming a spherical geometry, this would correspond to a complex with an apparent size
of ∼ 6 MDa (Table V.1).
We next measured the diffusional mobility of Venus-LC3 and Venus-LC3 mutants in the presence of
Cerulean in order to document inherent differences in the sizes of LC3-associated protein complexes. The re-
sults of these experiments revealed differences in the diffusional mobility of the different mutants, consistent
with those recently reported [164]. Assuming spherical complexes, LC3 and G120A were both ∼ 500 kDa,
while R70A was much smaller at ∼ 130 kDa, and F52A and L53A was larger at ∼ 1000 kDa (Table V.1).
Given the large size of Venus-SQSTM1-containing complexes detected by the FRAP measurements, we
hypothesized that the interaction of overexpressed Cerulean-SQSTM1 with Venus-LC3 would lead to the
formation of a larger complex that diffused more slowly than LC3 itself. We further hypothesized that such
changes should only be observed for LC3 mutants capable of binding to SQSTM1. FRAP measurements in
cells coexpressing the two proteins confirmed this is indeed the case (Figure V.4. D for wild type Venus-LC3,
G120A, and R70A were all significantly decreased in the presence of overexpressed Cerulean-SQSTM1
compared to cells co-expressing Cerulean (Figure V.4C p ≤ 0.003). This is in good agreement with the
results of the N/C measurements and FRET measurements, which also reported similar interactions between
SQSTM1 and either wild type LC3, G120A, or R70A. On the other hand, the diffusional mobility of the
F52A and L53A mutant was unchanged in the presence of overexpressed SQSTM1 (Figure V.4C p > 0.003).
This also is consistent with findings from the N/C ratio and FRET assays. Assuming spherical geometries,
we estimated the size of each of the Venus-LC3/Cerulean-SQSTM1-associated complexes using the Stokes-
Einstein relation, as summarized in Table V.1.
In principle, the effective size of the SQSTM1 complexes may also change upon co-expression of SQSTM1
and LC3. To test this, we performed experiments in which we measured the diffusional mobility of Venus-
SQSTM1 in the presence of overexpressed Cerulean-LC3 constructs (Figure V.4D). Surprisingly, no change
in the diffusional mobility of Venus-SQSTM1 was observed upon co-expression with any of the Cerulean-
LC3 constructs (p > 0.003). However, the diffusion of SQSTM1 suggests it is already associated with very
large complexes (∼ 6 MDa) when expressed individually, and therefore the binding of LC3 to the SQSTM1-
associated complexes may result in too small of a change in the hydrodynamic radius of SQSTM1 to be
detected using this approach.
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V.3 Discussion
Given the important role of LC3 in the autophagy pathway, it is critical to develop new approaches to un-
derstand how the complexes between LC3 and LC3-interacting proteins are regulated. In the current study,
we describe several complementary approaches to monitor the interaction of fluorescent protein chimeras of
SQSTM1 and LC3 in living cells using fluorescence microscopy. We also demonstrate the broader appli-
cability of these methods by showing they can detect the association of LC3 with slowly diffusing puncta
independent SQSTM1 homo-oligomers.
The first assay quantifies changes in the nucleocytoplasmic distribution of Venus-LC3 in the presence of a
putative interacting protein. This assay takes advantage of the fact that transiently overexpressed LC3 is found
in both the cytoplasm and nucleoplasm. LC3 lacks both a functional NES or NLS and normally undergoes
slow transport between the nucleus and cytoplasm by a mechanism that does not involve active nuclear
export [121]. However, many LC3 interacting proteins have intrinsic NES and NLS signals that regulate their
nucleo-cytoplasmic distribution. SQSTM1 has both NLS and NES signals, but its NES signal dominates
its steady-state localization, causing it to be enriched in the cytoplasm and depleted from the nucleus [236].
Overexpression of SQSTM1 relative to endogenous LC3 binding proteins drives complex formation between
LC3 and SQSTM1. Under these conditions, the localization of LC3 appears to be dominated by SQSTM1’s
CRM1-mediated NES. As a result, co-expression of Cerulean-SQSTM1 with Venus-LC3 leads to a dramatic
shift in the subcellular distribution of Venus-LC3 out of the nucleus. Binding of LC3 to SQSTM1 thus
provides LC3 with the new functionality of active nuclear export, and leads to a greater relative concentration
of LC3 in the cytoplasm. This type of functionality may be quite common, as it has also been observed
in the context of the nuclear protein DOR recruiting LC3 to cytoplasmic autophagosomes in response to
autophagy activation [123, 124]. Remarkably, we found that this assay was highly sensitive to the presence
of overexpressed SQSTM1, as well as mutations in LC3 that disrupt SQSTM1 binding (Figure V.5). This is
important because this assay is extremely straightforward, and also has the potential to be easily converted to
a high throughput format.
Our second assay utilized FRET to detect the close proximity between fluorescent proteins appended to
LC3 and SQSTM1. Because FRET only occurs within distances of < 10nm, it is well suited to test for
protein-protein interactions [136, 178, 220, 221]. Our FRET measurements revealed significant FRET oc-
curred between Venus-LC3 and Cerulean-SQSTM1, indicating the two proteins are closely apposed. We
also measured a high level of FRET between Venus-SQSTM1 and Cerulean-SQSTM1 consistent with the ex-
pected presence of homo-oligomers of SQSTM1. We focused primarily on using FRET as a semi-quantitative
readout for the presence of specific protein-protein interactions. From a more quantitative perspective, the
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Figure V.5: A comparison of the N/C ratio, FRET, and FRAP assays for detecting LC3 interactions. (A)
The percent change in E versus N/C ratio between cells expressing the Venus-LC3 constructs and Cerulean
or Cerulean-SQSTM1. (B) The percent change in D versus N/C ratio between cells expressing the Venus-
LC3 constructs and Cerulean or Cerulean-SQSTM1. The error bars are the propagated errors on the 95 %
confidence intervals.
absolute magnitude of FRET is a function of the distance and orientation between the donor and acceptor flu-
orophore as well as the fraction of donors bound by acceptors. Using more sophisticated analysis that takes
donor:acceptor ratios as well as protein expression levels into account it is in principle possible to obtain
information about the stoichiometries of protein complexes using this approach [242–244]. It is also possible
to directly couple FRET and diffusion measurements to assess the dynamics of protein interactions [190].
FRET microscopy has several advantages as a method to monitor specific protein-protein interactions. It
can be used to generate spatially resolved maps of where FRET occurs intracellularly, and thus can obtain
separate measurements for puncta, nucleus, and cytoplasm, or individual organelles. For example, it was
recently used to demonstrate FRET between SQSTM1 and LC3 in puncta [153]. In our experiments, the vast
majority of LC3 and SQSTM1 were present in a diffuse puncta independent form, and we did not observe
substantial differences in FRET between different subcellular compartments. FRET can also be performed
over time and has the potential of utilizing a wide range of fluorescent proteins as donors and acceptors
[136]. However, FRET measurements have some potential pitfalls that should be considered carefully. One
limitation of FRET is that a negative result does not exclude possible direct or indirect interactions, because
the fluorophores may not have a favorable orientation, or may be greater than 10 nm apart in the same complex
[178]. Thus, FRET signals can vary depending on the position of the fluorescent probes on the interacting
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proteins being tested. For example, recent studies showed that fluorescent proteins tagged at the N-terminus of
SQSTM1 yield detectable FRET, whereas little FRET was observed between N-terminally and C-terminally
tagged SQSTM1 constructs [153]. In addition, membranes are very crowded environments where FRET is
often significant due to the random close proximity of molecules integrally or peripherally associated with
membranes [245–247]. However, for soluble proteins, typically measurements of FRET efficiency are very
low unless specific interactions are present [248].
FRET can be measured in a number of different ways, each with their own particular advantages and
disadvantages [136, 249, 250]. In the current study we use the acceptor photobleaching FRET measure-
ment approach [153, 165, 186, 203, 210, 237, 238]. This particular approach to FRET measurements is very
straightforward and easily quantified. The disadvantage of acceptor photobleaching is that it requires photo-
bleaching of the acceptor, and is typically not suitable for timelapse FRET imaging. Also, photoswitching of
the acceptor to a donor-like state has been observed for some acceptor fluorophores which can give rise to a
false positive FRET signal [251]. However, when acceptor photobleaching is coupled with the use of photo-
switchable proteins, FRET can be performed over time. Use of photoswitchable proteins can also help over-
come problems of low signal-to-noise when the FRET efficiency is small, for example when there is only a
small fraction of interacting proteins [252]. Alternative strategies for FRET measurements include sensitized
emission, spectral unmixing [191, 253], lifetime imaging [228] and polarization [191, 203, 222–228, 253].
Homo-FRET measurements using fluorescence anisotropy are also useful for studying homo-oligomers or
clustering of like proteins [176, 184, 224, 254].
As a third approach, we used FRAP to test for changes in the hydrodynamic radius of LC3 as inferred
from changes in the diffusion coefficient D for LC3 upon binding SQSTM1. As a starting point for these
studies, we measured D for each protein expressed individually. In agreement with our previous studies, we
found that the diffusional mobility of Venus-LC3 is consistent with that of a∼ 500 kDa complex [164]. Here,
we found that when expressed on its own, Venus-SQSTM1 is associated with a much larger complex, with
a predicted MW of ∼ 6 MDa. Upon coexpression of Cerulean-SQSTM1 and Venus-LC3, D for Venus-LC3
decreased. Nevertheless, the diffusion of Venus-LC3 was still faster than that of Venus-SQSTM1 alone. This
suggests that not all of LC3 is bound to SQSTM1. If 100 % of the proteins were bound to each other we
would expect their diffusion to become identical. This could mean that endogenous proteins compete for
binding to Venus-LC3 and Cerulean-SQSTM1. Alternatively, the affinity of SQSTM1 for LC3 may be such
that they will not be 100 % complexed under the conditions of our measurements, or LC3 may bind to a subset
of SQSTM1-containing complexes with specialized composition and size. Interestingly, when we performed
the converse experiment, we did not observe a slowing in the diffusion of Venus-SQSTM1 to match that of
LC3’s mobility. We speculate that the size of the SQSTM1 complex is so large that the addition of LC3 does
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not cause a detectable increase in size. This result also implies that binding of LC3 to SQSTM1’s LIR does
not outcompete SQSTM1 binding to the components that cause SQSTM1’s very slow diffusion. This is in
agreement with the notion that SQSTM1’s domain architecture may help to segregate functions such as PKC
binding, LC3 binding, ubiquitin binding and homo-oligomerization [255].
FRAP has several advantages over currently available methods to measure protein diffusion. First, it
can be readily performed using most confocal microscopes. Second, FRAP data can be analyzed quanti-
tatively to yield diffusion coefficients. For example, we have developed several approaches to carry out
these measurements [158, 171, 175] and have developed freely available software for this purpose http:
//www.fraptoolbox.com). Third, FRAP has the advantage of being able to quantify very slowly moving
molecules all the way down to those that are completely immobile. Because FRAP reports on changes in D
that occur as the result of protein complex formation, this assay will be the most sensitive under conditions
where the diffusional mobility of the smaller protein is measured (in this case, that of LC3). Importantly,
FRAP provides information on the apparent size of the complex containing the diffusing proteins without
requiring knowledge of what the other molecules in the complex are. This also means that changes in D may
reflect remodeling of complexes that occur in response to binding, and not simply the additional mass due
to the binding of the interacting protein. The rate of diffusion is also sensitive to the shape of the diffusing
species. Thus, FRAP needs to be interpreted in the context of other assays. FRAP can also be used to study
reaction-diffusion events [148, 149, 256]. FRAP typically does not have adequate resolution to distinguish
multiple components, and thus provides a population average measure. Distinguishing bound and unbound
fractions can potentially be accomplished using more sophisticated methods such as fluorescence correlation
and cross-correlation spectroscopy [199, 229, 257].
Using the combination of assays described here, we recapitulated several key findings regarding the inter-
actions of LC3 and SQSTM1 obtained previously using biochemical approaches. Our FRET measurements
are in good agreement with previous studies showing that LC3 and SQSTM1 directly interact [68, 129],
including recent FRET measurements between LC3 and SQSTM1 in puncta [153]. Our experiments also
confirmed that the binding of LC3 to SQSTM1 depends on hydrophobic surface residues F52 and L53
[129], but does not depend on residue R70 [9]. In addition, our results indicate that disrupting LC3’s lipid
modification does not inhibit its interaction with SQSTM1. This is consistent with reports demonstrating
LC3-I can be recruited to SQSTM1 inclusions, and that LC3(G120A) retains affinity for SQSTM1 by co-
immunoprecipitation [100]. Indeed, under the conditions of our experiments, the majority of both LC3 and
SQSTM1 were present with a localization that was puncta independent and diffusely distributed. Thus, the
interactions between LC3 and SQSTM1 that we detected primarily occur independently of autophagosome
binding and also do not correspond to insoluble protein aggregates.
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Importantly, the combination of approaches we describe here can also be readily extended to study other
protein complexes in the autophagy pathway. As illustrated here, our current findings have already begun
to shed new light into the properties of SQSTM1-containing complexes. For example, SQSTM1 is thought
to form homo-oligomers [67, 239–241], and our FRET measurements suggest that this is the case in living
cells. Although we cannot infer the number of SQSTM1 monomers in each oligomer directly from FRET
measurements alone, more specialized techniques such as FPFA or brightness analysis could be used to
address this question in future studies [164, 176]. Our FRAP results also reveal that SQSTM1’s diffusion co-
efficient is extremely slow for a soluble protein. This is consistent with the known association of the protein
with high molecular weight complexes as detected by size exclusion chromatography of purified recombinant
SQSTM1 homo-oligomers [240] or as measured in cell lysates [241]. The size of the complexes implied by
our FRAP measurements is remarkably large. Assuming the SQSTM1-associated complexes are spherical,
they are predicted to have a ∼ 10 nm radius. This could correspond to very large complexes consisting of
homo-oligomers of SQSTM1 bound to selective autophagy substrates. SQSTM1 is also known to associate
with mTORC1 complexes [258]. This slowly diffusing SQSTM1 complexes inferred from our findings could
potentially also be assiciated with large macromolecular structures such as the ribosome or proteasomes.
For example, ribosomes have a large radius of about 15 nm [259]. The interaction of SQSTM1-containing
complexes with ribosomes could potentially be related to ribophagy [260], or cotranslational quality control
[261–263]. Alternatively, the slowly diffusing SQSTM1 complex could potentially be associated with pro-
teasomes, structures measuring approximately 7 nm in radius on their longest dimension [264]. This is an
attractive possibility given that in addition to its role in selective autophagy, SQSTM1 is involved in shuttling
ubiquitinated cargo to the proteasome for degradation and has been shown to directly bind to the proteasome
in the process [265]. Using the assays outlined here, it should be possible to distinguish between these and
other models in future studies.
V.4 Materials and Methods
V.4.1 Cells and constructs
Venus-LC3 and Venus-LC3 mutants were as previously described [164]. Venus-SQSTM1 and Cerulean-
SQSTM1 were constructed by BglII and EcoRI double restriction digestion of mVenus-C1, mCerulean-C1,
and DsRed-SQSTM1 vectors (http://www.addgene.org/28024/). A series of positive FRET controls consist-
ing of Cerulean and Venus separated by linkers of different lengths (C5V, C17V, C32V) was obtained from
Dr. Steven Vogel [205].
HeLa cells (American Type Culture Collection; CCL-2) were maintained in Dulbeccos Modified Eagle
Medium (DMEM) containing 10 % fetal bovine serum (Life Technologies; 10437028), 1 % PenStrep, and
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phenol red at 37 ◦C, 5 % CO2. For live cell imaging experiments, on the day prior to transfection, HeLa
cells were plated in MatTek 35 mm No. 1.5 glass bottom culture dishes (Ashland; P35G-1.5-10-C). On
the following day the cells (50 %–80 % confluent monolayer) were transfected with described mammalian
expression constructs using FuGENE6 transfection reagent according to the manufacturers recommended
protocol (Promega Corp.; E2691). Cells were imaged in phenol red free DMEM.
V.4.2 Confocal Microscopy
Microscopy was performed using a Zeiss LSM 510 laser scanning confocal microscope using a 40X 1.3 NA
objective as previously described [164]. Cells were maintained at 37 ◦C using an objective heater and stage
heater.
V.4.3 Quantification of nucleo-cytoplasmic ratio
Quantification of the nucleocytoplasmic ratio was performed using a custom MATLAB algorithm. Our MAT-
LAB scripts for quantifying N/C ratios are open source and are freely available at https://github.com/kraftlj/
LocalizeLC3. Just prior to imaging the cells were labeled with a far red DRAQ5 (Cell Signaling Technology,
Inc; #4084) nuclear label. Confocal images were acquired for the CFP, YFP, and far red channels. Masks for
the cell and nucleus were generated using a manually defined threshold intensity in either the YFP or the far
red channel respectively. Masks for the puncta were generated by first subtracting the uneven diffuse cellular
signal using a tophat filter. The cytoplasm mask was created by subtracting the nuclear and puncta masks
from the cell mask. The nucleus mask was created by subtracting the puncta mask from the nuclear mask.
V.4.4 Acceptor Photobleaching FRET
Acceptor photobleaching FRET measurements were performed using a custom MATLAB algorithm which
is essentially as previously described previously [44]. Our MATLAB scripts for quantifying FRET are open
source and are available at https://github.com/kraftlj/abFRET. In brief, confocal images of the acceptor and
donor before bleaching (Apre and Dpre respectively) as well as after photobleaching the acceptor (Apost and
Dpost respectively) were acquired. Masks were defined for the cell and the background using a manually
defined threshold intensity in the Acceptor channel. Masks were defined for the puncta by first subtracting
the uneven diffuse cellular signal using a median filtering approach. Averaged energy transfer efficiency for
the background subtracted cell (devoid of puncta) or punta was calculated according to equation V.3. Lateral
movement of the donor images before and after photobleaching were corrected by crosscorrelation. The
FRET efficiency images were calculated by first binning the images 5X to increase the signal/noise.
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V.4.5 FRAP
FRAP measurements were performed as recently described [164]. In brief, a smaller rectangular imaging
ROI was used for increased temporal resolution, and a small circular 1 µm radius bleach ROI was used for
bleaching. FRAP data were analyzed using FRAP-Toolbox - a freely available software for the analysis of
FRAP data available online at http://www.fraptoolbox.com. In particular, the diffusion model fit all of the
FRAP curves in this study well.
V.4.6 Statistics
Values reported throughout the text are the mean ± 95 % confidence intervals. Statiscal comparisons were
made we using a Bonferonni corrected t-test. Where multiple comparisons were made, we corrected the
p-value threshold such that the overall type-I error rate for all pairs of comparisons was 0.05. For example if
15 pairs of comparisons were made among 6 different groups the p-value threshold was set to 0.003.
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CHAPTER VI
The nucleocytoplasmic distribution and nuclear dynamics of LC3 are regulated by LC3’s
hydrophobic binding interface but not its ability to undergo lipidation
Although the formation of autophagosomes occurs in the cytoplasm, it is increasingly evident that several
key proteins in the autophagy pathway shuttle in and out of the nucleus. LC3, a protein that participates in
autophagosome formation and cargo selection in the cytoplasm, is also enriched in the nucleus in a slowly
diffusing form. However, the mechanisms that retain LC3 in the nucleus and control its nuclear dynamics
remain poorly understood. In this chapter, we investigate the contributions of interactions mediated by LC3’s
hydrophobic protein interaction surface and the ability of LC3 to undergo lipidation to the nuclear dynamics
of LC3. The results presented in the chapter clarify the roles for LC3’s hydrophobic protein interaction
surface as well its lipid modification in controlling the ability of LC3 to enter and exit the nucleus and
suggest that soluble LC3 is associated with high molecular weight complexes in both the cytoplasm and
nucleus, but that this may not be entirely responsible for its localization in the nucleus. We also show that
LC3’s localization in the nucleus is physiologically relevant.
VI.1 Introduction
Autophagy is a major catabolic lysosomal degradation pathway in cells. A distinctive intermediate in the
autophagy pathway is the formation of a double membrane vesicle called the autophagosome, and is respon-
sible for sequestering cytoplasmic materials. The formation of autophagosomes occurs in the cytoplasm, but
it is increasingly evident that several key proteins in the autophagy pathway may have important functions
in the nucleus [266]. More work needs to be done to investigate the functions of autophagy proteins in the
nucleus.
Surprisingly, LC3, a protein that participates in autophagosome formation and cargo selection, was re-
ported to be in the nucleus [120, 121]. Given that LC3 is primarily thought to function in the cytoplasm
where autophagosomes form, this discovery raises the possibility that nuclear LC3 may have currently un-
known functions in the autophagy pathway. A small number of studies have begun to examine LC3’s potential
functions in the nucleus. It was shown that LC3 interacts with the nuclear tumor suprresor TP53INP1 and
influences cell death by autophagy [122]. The interaction of LC3 with a TP53INP1 family member called
DOR, also a nuclear protein, functions in the dual regulation of autophagy and thyroid hormone receptor
transcription [123–125]. Recent studies suggest nuclear LC3 may also regulate signaling via interactions
with ERK signaling cascade components [126].
114
In previous studies GFP-LC3 was shown to be enriched in the nucleus by fluorescence microscopy [121].
However, it is unclear if the localization of LC3 in the nucleus is physiological, or if it may be due to an
artifact of transient overexpression or due to the GFP tag itself [173]. Although, prediction software showed
that LC3 may have an active nuclear export signal, it appears that LC3 does not utilize CRM1 mediated
active nuclear export to cross the nuclear envelope. Furthermore, transport of LC3 between the cytoplasm
and nucleus was significantly slowed compared to GFP, suggesting that LC3 was either being specifically
retained in the nucleus or was part of a complex that is too large to cross the nuclear envelope by passive
diffusion [121]. Previous diffusion based studies showed that, in the cytoplasm, a single soluble LC3 is
associated with a 500 kDa complex [164]. In addition, nuclear LC3 diffuses much more slowly than expected
for a monomer suggesting that it may also be bound to a large complex or may be reversibly binding to
DNA [121]. Furthermore, the diffusional mobility of the cytoplasmic pool of soluble LC3 is altered upon
disruption of the hydrophobic protein binding interface of LC3, but not its lipidation [164]. The composition
and function of these LC3-associated complexes is not entirely clear, but may be related to regulation of
autophagy. However, it is currently unknown if LC3 associates with similar or different complexes in the
nucleus, or if the association of LC3 with these putative complexes regulate the nucleo-cytoplasmic trafficking
of the protein.
Here, we investigate the contributions of interactions mediated by LC3’s hydrophobic protein interaction
surface and its lipid modification site to LC3’s intranuclear mobility, and its nucleocytoplasmic mobility. Our
results identify an important role for protein-protein interactions in controlling the ability of LC3 to enter and
exit the nucleus and suggest that although soluble LC3 exists in similar complexes in both the cytoplasm and
nucleus, this may not be the complete mechanism responsible for maintaining its nuclear localization.
VI.2 Results and Discussion
VI.2.1 Endogenous LC3 is in the nucleus
The nuclear localization of LC3 was recently questioned, as it was speculated that nuclear GFP-LC3 may
be an artifact of transient overexpression or the GFP label itself [173]. One study showed evidence for
endogenous LC3 in the nuclear fraction [120], but this study lacked proper controls for the various fractions
which leaves the question open for debate. In order to confirm that the localization of LC3 in the nucleus is
physiological, we set out to determine if endogenous LC3 is in the nucleus of HeLa cells using subcellular
fractionation to isolate nuclear and cytoplasmic fractions.
Nucleocytoplasmic fractionation experiments showed that like GFP-LC3, endogenous LC3 is in fact lo-
calized in the nucleus (Figure VI.1). This finding suggests that the localization of LC3 in the nucleus is phys-
iological relevant, and may have important implications for autophagy regulation or possibly an autophagy
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Figure VI.1: Both endogenous LC3 and Venus-LC3
are localized in the nuclear compartment. HeLa cells
expressing either Venus or Venus-LC3 were subjected
to subcellular fractionation. Nuclear (N) and cytoplas-
mic (C) fractions were blotted using antibodies against
beta tubulin as a control for a cytoplasmic protein, hi-
stone H3 as a control for a nuclear protein, GFP for
detection of both Venus and Venus-LC3, or LC3 for
detection of endogenous LC3.
independent function of the protein.
The nature of LC3’s localization in the nucleus remains a mystery. It was previously shown that it under-
goes slow nucleocytoplasmic shuttling, but it is not under the control of CRM1 mediated active nuclear export
[121]. In previous studies however, it was shown that LC3 interacts with the coregulator of thyroid hormone
receptor, DOR, and with perturbations to the autophagy pathway the proteins can shuttle to the cytoplasm
and stimulate autophagosome formation [125]. In addition it appears that starvation with Hank’s balanced
salt solution may also modulate the N/C ratio of LC3 [121]. Thus, we next sought to test whether the nuclear
localization of LC3 is regulated by perturbations to the autophagy pathway directly by using either known
activators or inhibitors. We addressed this by testing if the N/C ratio of LC3 changes after treatments with
either rapamycin or chloroquine. We found that for both of these treatments there were no significant changes
in LC3’s N/C ratio after the 2 hour treatment (p > 0.03) (Figure VI.2). This suggests that the proteins N/C
ratio may not be modulated by direct perturbation to the autophagy pathway.
Previous experiments by Drake et al. [121] showed that the N/C distribution and slow nucleocytoplasmic
shuttling of LC3 may be regulated by binding to a large complex. The experiments described in chapter
III showed that LC3 in fact associates with a large complex, and that the LC3(R70A) mutant’s ability to
associate with the complex is disrupted. We next sought to extend our FRAP measurements of the mutants
to the nuclear compartment to examine if these mutations play a role in regulating LC3’s association with
complexes there.
We performed FRAP measurements in the nucleus of HeLa cells under basal conditions, and after treat-
ment with either chloroquine or rapamycin (Figure VI.3). The effective sizes of the constructs in the nucleus
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Figure VI.2: Activation or inhibition of autophagy with rapamycin or chloroquine does not change LC3’s
nucleocytoplasmic distribution. (A) An automated image analysis routine was used to quantify the nucleo-
cytoplasmic distribution by creating masks for cytoplasm (green) using the Cerulean channel, nucleus (blue)
using the DRAQ5 channel, and puncta (red) using the Venus channel for HeLa cells co-expressing Venus-LC3
and Cerulean under either (A) basal conditions, or (B) after incubation with 100 nM rapamycin or 100 µM
chloroquine for 2 h. The cells were labeled with DRAQ5 as a marker for the nucleus, and imaged live using
a confocal microscope. Scale bar is 10 µm. (C) Bar graph of the mean nucleocytoplasmic ratio. Error bars
are 95 % confidence intervals. N values are the number of cells – 80 for basal; 30 for rapamycin; and 31 for
chloroquine.
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Figure VI.3: Disruption of LC3’s hydrophobic protein interaction surface but not its lipid modification de-
creases LC3’s effective hydrodynamic radius in the nucleus. (A) An example of the quantitative FRAP
protocol that we carried out in the nucleus of live HeLa cells. The imaging ROI was reduced in size for
speed, and the bleaching ROI was a 1 µm radius circle placed in the center of the nuclear compartment. (B)
Average FRAP curves for Venus and Venus-LC3 from 10 cells, normalized between 0 and 1, were well fit by
a single component diffusion model (data for G120A, F52A L53A, R70A, and R68-70A were similarly well
fit by this model). The mean diffusion coefficients from FRAP experiments under (C) basal conditions, (D)
after incubation with 100 nM rapamycin for 2 h, or (E) after incubation with 100 µM chloroquine for 2 h are
displayed as bar graphs. The error bars are 95 % confidence intervals, and the N > 20 cells from at least two
independent experiments.
were all larger than what was observed in the cytoplasm in chapter III; however, their values in the cytoplasm
and nucleus and across treatments were strongly correlated (Figure VI.4). Notably, the increased diffusion
of R70A suggests this mutation also disrupts its association with complexes in the nucleus, but mutations
affecting LC3’s lipidation have no affect on its diffusion. Thus, the nuclear and cytoplasmic complexes may
be very similar in both compartments.
Previous studies demonstrated LC3 associates with RNA via its triple arginine motif (LC3 residues R68-
R70) [118, 119]. This triple arginine region is overlapping with the R70A mutant that we examined in our
own studies. This suggests that RNA is one possible component of the large LC3-associated complexes. In
these studies we extended our analysis of LC3’s diffusion to include a triple LC3 mutant LC3(R68-70A).
Interestingly, this mutant’s diffusion is similar to LC3(R70A) (Figure VI.3).
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With the knowledge that R70A likely disrupts LC3’s association from complexes in both cytoplasm and
nucleus, we now have a tool to test if LC3’s slow nucleocytoplasmic transport is regulated by its association
with large complexes. Transport of small proteins can occur via passive diffusion through nuclear pores, and
the rate at which a protein passes through the pores by this mechanism is very sensitive to its hydrodynamic
radius [170, 267–269]. We next examined if the nucleocytoplasmic transport rate of the LC3 mutants is
altered by FRAP.
In this experiment, the entire nucleus was selectively photobleached (Figure VI.5A). Our results revealed
that the nucleocytoplasmic transport kinetics of all of the mutants of LC3 are statistically within error of the
wild-type protein (Figure VI.5B). Venus on the other hand recovered much faster, and its rate of nucleocy-
toplasmic transport was consistent with previous reports for GFP [170]. This suggests that the mechanism
that regulates LC3’s localization in the nucleus was not disrupted by mutations to LC3’s hydrophobic protein
interaction surface, or its lipid modification.
Our nuclear LC3 findings up to this point suggest that like cytoplasmic LC3, nuclear LC3 is also as-
sociated with large complexes, but that this may not be completely responsible for its nuclear localization.
We next began to consider possible functions of nuclear LC3 by turning to the literature on known LC3
interacting proteins. Interestingly, it was shown that the LC3 interacting protein SQSTM1 associates with
nuclear puncta colocalized with promyelocytic leukemia (PML) bodies after inhibition of CRM1 mediated
active nuclear export, and it was proposed that the protein may be involved in degradation of nuclear protein
aggregates [236]. Therefore, we hypothesize since LC3 interacts with SQSTM1, nuclear LC3 may also play
a role in degradation of nuclear protein aggregates by functioning together with SQSTM1 and ubiquitin. In
order to test this we next took a closer look at the subnuclear distribution of LC3.
Indeed, we found that LC3 localizes to nuclear puncta (Figure VI.6). These nuclear LC3 puncta colocalize
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Figure VI.5: Disruption of LC3’s hydrophobic protein
interaction surface and disruption of its lipid modifi-
cation does not change LC3’s rate of nucleocytoplas-
mic transport. (A) An example of the quantitative
FRAP protocol that we carried out to examine nucleo-
cytoplasmic transport. The entire nuclear region was
selectively photobleached using a user defined ROI,
and the whole cell fluorescence intensity was used
for normalization. Scale bar is 10 µm. (B) Average
FRAP curves, from cells expressing Venus, Venus-
LC3, Venus-LC3(G120A), Venus-LC3(F52A L53A),
Venus-LC3(R70A), or Venus-LC3(R68-70A) were all
well fit by a two phase exponential model. The fast
component was consistent with intracompartmental
diffusion, while the slow component was due to nucle-
ocytoplasmic transport. Here we have transformed the
data such that the slow exponential nucleocytoplasmic
transport between constructs can be more easily com-
pared. The solid gray lines are the 95 % confidence
intervals for the fit to Venus, and the solid black lines
are the 95 % confidence intervals for the fit to Venus-
LC3.
with both SQSTM1 and ubiquitin puncta (Figure VI.6). These results point to a possible novel nuclear
function for LC3 in nuclear quality control processes along with SQSTM1 and ubiquitin.
To our surprise, we also found that LC3 partitions into the nucleolar compartment (Figure VI.7A). We
went on to test if the nucleolar localization of LC3 was sensitive to autophagy perturbations, but we found no
noticeable differences after treatment with rapamycin or chloroquine, similar to the N/C ratio (Figure VI.7B).
LC3 does not have any known NLS or NES sequences. Given the large apparent size of the LC3-
associated complexes it is surprising that LC3 is not excluded from both the nucleus and nucleolar compart-
ments. It is thought that generally only small soluble proteins with radii less than 5 nm are able to passively
diffuse in and out of the nucleus [267, 269]. However, the nuclear localization of some proteins is maintained
not by means of binding to a chaperone for transport across the nucleus envelope, but by retention via affinity
for nuclear components. In addition, the nucleolus does not have a membrane boundary, but is instead a
dense meshwork of nucleic acid and protein. It is believed that proteins that localize in the nucleolus have
an affinity for nucleolar components, and are thereby detained there, as opposed to chaperoned [270]. In
addition, it is thought that proteins with a general affinity for RNA will partition into the nucleolus due to
interactions with the large amount of ribosomal RNA in this compartment [271]. We hypothesized that LC3’s
nucleolar localization may depend on its triple arginine RNA binding motif.
120
Cy5-Anti-SQSTM1 Merge
C
A1 B1 C1
Venus-LC3
A B B C
A1 B1 C1
D E F
Cy5-Anti-Ubiquitin MergeVenus-LC3
D1 E1 F1
D1 E1 F1
Figure VI.6: Venus-LC3 colocalizes with SQSTM1 and ubiquitin in nuclear puncta. Confocal z-stacks col-
lected from fixed cells expressing Venus-LC3. Maximum intensity projections along with XZ- and YZ-
sections of the fluorescence signal from Venus-LC3 (A,A1,D,D1); antibodies against SQSTM1 (B,B1); and
antibodies against ubiquitin (E,E1). Merged pseudo colored images are shown in C,C1,F,F1. Arrowheads
mark nuclear puncta.
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Figure VI.7: Nuclear LC3 partitions into the nucleolar compartment. (A) Confocal images of the nucleus of
HeLa cells co-expressing Cerulean and Venus-LC3. Cerulean was used a control for protein that is excluded
from the nucleolus. LC3 labeled puncta are visible in the nuclear compartment. (B) Autophagy was activated
or inhibited by treatment with 100 nM Rapamycin or 100 µM chloroquine for 2 h, and the nucleolar ratio for
Venus-LC3 was quantified by averaging across multiple nucleoli. Error bars are 95 % confidence intervals.
N is the number of cells – 120 for basal; 36 for Rapamycin; and 45 for chloroquine.
Interestingly, mutations to the arginine residues R68-70 on LC3 completely abolish its nucleolar local-
ization (Figure VI.8). This finding suggests LC3’s ability to bind to RNA may regulate its localization to the
nucleolus. Furthermore, the nature of nucleolar targeting sequences is not entirely clear, but some of these
sequences appear to partially overlap with NLSs. Interestingly, we also saw a modest decrease in LC3’s N/C
ratio for the mutants with mutations to the triple arginine motif, but not mutations affecting its lipidation
(data not shown). These results suggest that LC3’s triple arginine motif may be a novel nucleolar detention
sequence, and that LC3’s general affinity for RNA may be responsible for its nuclear localization.
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Figure VI.8: Mutations to
LC3’s triple arginine motif
disrupt its ability to partition
into the nucleolus. Example
confocal images of the nucleolar
compartment of HeLa cells
co-expressing Cerulean as a
control and Venus-LC3, Venus-
LC3(G120A), Venus-LC3(F52A
L53A), Venus-LC3(R70A),
Venus-LC3(R68-70A), or
Venus. The nucleolar ratios
were quantified by averaging
across all of the nucleoli in each
cell, and across mulitple cells.
Error bars are 95 % confidence
intervals. N is the number of
cells – 120 for LC3; 65 for
G120A; 66 for F52A L53A and
Venus; 62 for R70A; and 37 for
R68-70A.
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CHAPTER VII
Summary and Future Directions
The findings in this dissertation open up several new avenues for future research. This chapter outlines the
ideas for these future directions, and a subset of the relevant preliminary findings are presented. Finally, the
chapter ends with a brief summary of the major findings presented in this dissertation, and a discussion of
their importance to the scientific community is given.
VII.1 Future Directions
VII.1.1 What is composition and function of the large LC3-associated complex?
LC3 is known to interact with a large network of proteins. Many of the LC3 interacting proteins are believed
to form complexes. In our studies we showed that a single soluble LC3 interacts with a large ∼ 500 kDa
complex. The composition and function of these LC3-associated complexes remains unknown. We speculate
that these complexes may be involved in the regulation of autophagy, as our results showed that autophagy
perturbations modulate their size. For example, these complexes may correspond to a novel LC3-associated
complex that functions as a scaffold in the assembly of the ULK complex. LC3 was already shown to play a
role in the assembly of the ULK complex [44, 45]. Alternatively, the LC3-associated complex may function
in targeting the Vps34 complex to the site of autophagosome formation, and thereby promote autophagosome
maturation. Yet another possibility is that this complex may play an important role in coupling autophago-
somes to the microtubule network when autophagy is upregulated. LC3 was recently shown to interact with
FYCO1, which together with Rab7, functions in plus-end directed movement of autophagosomes along mi-
crotubules [59].
Our experiments revealed that the LC3 mutation, R70A, disrupts its association with the complex. This
mutation was shown to disrupt interactions with at least 18 different proteins [9], and thus some of these
proteins may be in a constitutive complex with LC3. The LC3(R70A) mutant is an important tool that can
be leveraged in future studies directed at determining both the composition and function of the large LC3-
associated complex. In previous studies it was shown that knockdown of all three LC3 subfamily members
(LC3A, LC3B, and LC3C) disrupts autophagosome formation [80]. In the future, it would very interesting to
construct a stable cell line expressing the siRNAs against endogenous LC3A, LC3B, and LC3C. Expressing
either exogenous LC3B or LC3B(R70A) from Rattus norvegicus (siRNA resistant) would allow us to test if
LC3’s interaction with the ∼ 500 kDa complex is required for autophagosome formation. This type of tool
would also allow us to examine the composition of the complexes using a comparative proteomics approach
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by analyzing the components that co-immunoprecipitate (Co-IP) with LC3 from the LC3 expressing cell line
compared to what co-IPs with LC3 from the LC3(R70A) cell line.
Our findings in chapter V raise some interesting possibilities for studying the nature of LC3-associated
complexes formed in other contexts, for example, in the presence of over-expressed SQSTM1. Namely, our
studies showed that when over-expressed with SQSTM1, LC3 associates with a substantially larger complex.
In addition, since SQSTM1 homo-oligomerizes presumably there will be multiple LC3 proteins in this com-
plex. Little is known about the mechanisms of selective targeting of autophagy cargoes [32], and it would
be interesting to understand how the size, stoichiometry, and organization of the LC3-associated complexes
change in response to changes in the levels of SQSTM1, as well as how these properties change in response
to physiological modulators of selective autophagy such as metabolic stress.
VII.1.2 Does LC3 homo-oligomerize on autophagosomal membranes?
LC3 functions include contributing to membrane expansion and fusion events during the formation of the
autophagosome [79]. LC3 was found to associate with autophagosome independent aggregates when tran-
siently overexpressed [105, 130]. It was proposed that LC3 may non-specifically form aggregates [79, 105].
Furthermore, LC3’s N-terminus promotes membrane tethering and hemifusion in in vitro liposome assays
[93]. The energy for these fusion events was proposed to be contributed by the self-association of LC3’s
on opposing membranes via their N-termini [93]. Another LC3 family member, GABARAP, was shown
to homo-oligomerize [107]. However, our studies revealed that autophagosome independent LC3 does not
homo-oligomerize or aggregate, suggesting if homo-oligomerization of LC3 contributes to fusion events,
they must be limited to the autophagosome membrane.
In the future it would be interesting to carry out detailed studies of the self-association properties of
LC3 on autophagosomes by FRET and FPFA in living cells. In our studies we relied on a semiquantitative
approach for the analysis of FRET microscopy data in cells, and our FPFA data for LC3 was collected
in cell extracts where LC3 in autophagosomes was likely excluded [164, 165]. However, more advanced
methods of analysis that takes donor:acceptor ratios as well as protein expression levels into account have
the potential to reveal information about the stoichiometries of protein complexes by FRET microscopy in
cells [242–244]. These methods may be able to shed additional light on the self-association properties of
LC3 on autophagosome membranes in cells. In addition, FPFA experiments are capable of making spatially
resolved measurements in cells using slight modifications of the experimental setup [176], or alternatively a
slightly different extraction procedure could provide an enriched fraction of autophagosomes [39] for FPFA
measurements in vitro.
Furthermore, there is some evidence to support the notion that members of the other ATG8 subfamilies
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GABARAP and GATE-16 may have unique functions. For example, it was shown that although both LC3 and
GATE-16 are essential for autophagosome formation, the LC3 subfamily contributes to membrane elongation,
while the GATE-16 subfamily functions at a later stage of autophagosome maturation [80]. This points to
a general need for our future efforts to be expanded to include analyses of GABARAP and GATE-16, as
our unique assays may provide valuable information for determining what exactly the role of each ATG8
subfamily is in autophagy.
VII.1.3 High throughput characterization of LC3 interacting proteins in living cells
In chapters II and V we described several software tools to automate fluorescence based microscopy assays
of LC3’s N/C ratio, FRET with LC3 interacting proteins, and FRAP. These assays can be easily reformatted
for high throughput analyses. A recently described program called Micropilot allows for automated acqui-
sition of complex fluorescence microscopy imaging protocols using a standard LSM 510 microscope [152].
Thus acquisition of not only confocal images, but also FRAP and FRET data can now be automated. But
the problem of how to collect very large, quantitative datasets goes hand-in-hand with the perhaps more
challenging problem of data analysis. Automated data analysis is where the software programs that were pre-
sented in this dissertation will be especially useful. We developed a software program called FRAP-Toolbox
that allows one to automatically analyze FRAP data sets using recently available quantitative FRAP models
(http://www.fraptoolbox.com). We developed an algorithm called AbFRET that allows one the opportunity to
automate the analysis of acceptor photobleaching FRET microscopy data (http://github.com/kraftlj/abFRET).
We also developed an algorithm called LocalizeLC3 that makes it possible to automatically analyze im-
ages of GFP-LC3 in terms of the numbers of cytoplasmic and nuclear puncta, their intensity, and their
size; it reports a statistic for the amount of scatter in the locations of puncta; and also reports the N/C ratio
(http://github.com/kraftlj/LocalizeLC3). In the future these automated data analysis tools can be integrated
with a high throughput system of data collection to enable fully automated high throughput screening for
LC3 interacting proteins and complexes in vivo.
High throughput fluorescence-based assays for characterizing LC3 interacting proteins in living cells
would open up the possibility to not only discover LC3 interacting proteins, but to also discover proteins
that regulate LC3’s association with complexes, as well as proteins that regulate its subcellular localization.
Importantly, these studies could be subject to physiological perturbations to examine changes in the emergent
properties of LC3. As a start, we used the LocalizeLC3 algorithm to analyze a recently published high-
content-screen (HCS) of GFP-LC3 in response to autophagy perturbations rapamycin, and Hank’s balanced
salt solution, as well as a panel of siRNAs against LC3 interacting proteins provided to us by Dr. Christian
Behrends [9]. This HCS consisted of analyzing over 1×105 confocal images. A preview of a subset of
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Figure VII.1: A preview of the results from the analysis of a high content screen of siRNAs against LC3
interacting proteins. The LocalizeLC3 automated image analysis routine was adapted to analyze the high
content screen published by Behrends et al. [9]. A preview of the results are shown for the quantification of
the numbers of cytoplasmic puncta (A), the nucleocytoplasic distribution (B), and the scatter in the location
of the puncta (C) under basal conditions. The cells are U2OS cells stably expressing EGFP-LC3 incubated in
complete DMEM media. The siRNAs for various LC3 interacting proteins were transiently transfected before
fixation and imaging on an Opera high content screening confocal microscope. Each gene was targeted with
at least 4 different siRNAs. The boxes are color coded according to the mean value of the particular statistic.
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the results for: a) the number of cytoplasmic puncta, b) the N/C ratio, and c) the puncta scatter are shown in
Figure VII.1. This study can be followed up in the future with experiments in living cells to verify some of the
interesting findings of the HCS analyses. In addition, it would be interesting to determine if siRNA against
particular genes that modulate either the N/C ratio, the number of puncta, or the puncta scatter statistics
also disrupt LC3’s association with the 500 kDa complexes. This would allow one to gain insights into the
function and composition of the LC3-associated high molecular weight complexes.
VII.1.4 Size, stoichiometry, and organization of other autophagy related complexes
Up to this point we have focused almost exclusively on investigating the properties of LC3-associated com-
plexes. This is justified by the fact that LC3 plays such a central role in the autophagy pathway. However,
there are a number of other very interesting autophagy related complexes which deserve attention. Some
of these other complexes include SQSTM1-associated selective autophagy complexes, the LC3 UBL con-
jugation complexes, and the signaling complexes ULK and Vps34. In the future, it would be interesting to
investigate these other autophagy related complexes using FRAP, and FPFA in terms of their size, stoichiom-
etry, and organization as we did for LC3 in chapter III. In collaboration with Dr. Steve Vogel’s group at the
NIH we have already collected some very interesting preliminary data on SQSTM1 where we found this pro-
tein diffuses as a homo-oligomer with multiple diffusion times. These experiments are expected to provide
important details about the nature of SQSTM1-related selective autophagy complexes.
We also obtained FRAP data for several protein components in the ULK complexes and UBL conjugation
complexes (Figure VII.2). As of now, these results are still a bit premature to interpret with great detail. For
example, reports in the literature suggested that in yeast, newly synthesized ATG12 is immediately conjugated
to ATG5. The formation of the ATG12-ATG5 covalent conjugate is constitutive, and there is virtually no free
ATG12 [200]. If 100 % of ATG12 is conjugated to ATG5, their diffusion should be closer to identical.
Instead, the FRAP results suggest that the apparent molecular weight of ATG12 is approximately 100 kDa
- consistent with an ATG12-ATG5 conjugate, but the apparent molecular weight of ATG5 is much larger at
about 500 kDa. Is all of ATG5 conjugated to ATG12, or is some ATG5 functioning elsewhere? It would be
informative to examine ATG12 and ATG5 by western blot in order to determine how much of the conjugate
is formed in HeLa cells. Notably, diffusion of ATG14 is very slow. ATG14 is thought to function as a
component of the Vps34 complex and contributes to the regulation of autophagosome formation [40]. The
diffusion coefficient of ATG14 is so slow in fact that it suggests it is most likely associated with membranes.
This is very reasonable given the known function of Vps34 – it is a PI3K which is essential for generating
PI3P at the phagophore membrane [40].
Our in vivo diffusion results are also important for understanding the effects of the intracellular envi-
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Figure VII.2: FRAP analyses of other autophagy related complexes. FRAP experiments were performed
using a 1 µm radius circle placed in puncta independent regions of the cytoplasm of live HeLa cells. The dif-
fusion coefficients from experiments across multiple cells are shown for protein compents of the autophagy
UBL complexes (ATG5, ATG16, ATG12, ATG3), and a protein component of the Vps34 complex (ATG14).
Horizontal lines represent the median. We are grateful for Mike Davidson’s assistance preparing the fluores-
cently labeled ATG5, ATG16, ATG14, ATG3, and ATG12.
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Figure VII.3: Effect of ionic strength on
the effective size of soluble LC3 associated
complexes in vitro. We prepared cytoplas-
mic extracts with varying ionic strengths by
either dilution or addition of NaCl to the
buffer. Shown in the plot are the experimen-
tal data points (open circles), along with a
fit to a dose-response relationship (dashed
line). The IC50 was about 60 mM, with
a hill slope of about 3.7. The minimum
molecular weight was constrained to the
theoretical size of a Venus-LC3 monomer
(45 kDa), and the theoretical maximum
molecular weight at 0 mM ionic strength
was about 590 kDa.
ronment on diffusion. There has been some controversy about the effects of the intracellular environment
on the nature of molecular diffusion [272–275]. Our FRAP results show that the diffusion of proteins with
radii in the range of 2 nm–6 nm are identical both in vivo and in vitro in solution. These results suggest that
molecules of this size may not be heavily influenced by the crowded environment of the cell. The diffusion
results that we obtained for the other autophagy related complexes extend the range of sizes of complexes
that we have measured. They also extend the range of overall charge and hydrophobicity properties that we
have examined. In the future, performing parallel studies on the in vitro diffusion of these complexes may
contribute to our understanding of the effects of the intracellular environment on the diffusion of molecules.
For these types of in vitro diffusion studies, it might also be interesting to examine how crowding agents
[275], or reconstituted cytosol [276] affect the apparent size of autophagy related complexes in vitro.
As a final word of caution, we have come across at least one potential pitfall of performing diffusion
experiments in vitro. In addition to the obvious point that labile complexes fall apart in a dilute solution, our
studies also revealed that LC3-associated complexes were very sensitive to the concentration of salts in cell
extracts (Figure VII.3). Therefore, a comparison of the results obtained in vivo with those obtained in vitro is
helpful in screening for the optimal conditions of experiments.
Using the optimized salt conditions for LC3-associated complexes, we compared the results of our diffu-
sion based estimate of molecular weight using the Stokes-Einstein relation to the classical method of sizing
complexes by size exclusion chromatography. We subjected cytoplasmic extracts from HeLa cells expressing
Venus or Venus-LC3 to size exclusion chromatography using a Superose 6 column. The FPLC fractions cor-
responding to sizes of 5 MDa all the way down to 5 kDa were collected and subjected to western blotting with
antibodies against LC3, GFP, and various LC3 interacting proteins (Figure VII.4). To our satisfaction, we
were able to obtain results which were consistent with our findings by diffusion. These results confirm that
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Figure VII.4: Size exclusion chromatography of autophagy related protein complexes. Cytoplasmic extracts
from cells expressing Venus or Venus-LC3 were prepared and seperated according to their size and shape by
FPLC gel filtration on a Superose 6, 10/300 GL 25 mL size exclusion column. The gel filtration fractions
were subjected to SDS-PAGE, and western blotted using antibodies against GFP for detection of Venus and
Venus-LC3; LC3 for detection of both Venus-LC3 and endogenous LC3; MAP1B; ATG16; SQSTM1; and
beta tubulin.
with Venus as a control for a monomer, using the Stokes-Einstein relationship to estimate the hydrodynamic
radius of a protein is a very reasonable first approximation.
VII.1.5 Does LC3 have a novel nuclear function?
Previous work highlighted LC3’s surprising nuclear localization [121], but currently LC3’s role in the nucleus
and the nature of its localization there is unknown. In chapter VI we investigated the regulation of LC3’s
nuclear localization and nuclear dynamics in some detail using mutants of LC3 that had defects in their
hydrophobic protein interaction surfaces, or their lipid modification. Our results suggested that soluble LC3
is associated with high molecular weight complexes in both the cytoplasm and nucleus, but that this may not
be entirely responsible for its localization in the nucleus. We also show that LC3’s localization in the nucleus
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is physiologically relevant.
There were some surprising and unexpected findings highlighted in the studies in chapter VI, such as, the
findings that show LC3 associates with subnuclear structures. The LC3 associated nuclear puncta colocalized
with the selective autophagy receptor SQSTM1 and ubiquitin. It was previously shown that after inhibition of
CRM1 mediated active nuclear export, SQSTM1 colocalizes in nuclear puncta with promyelocytic leukemia
(PML) bodies. It was proposed that SQSTM1 may be involved in degradation of nuclear protein aggregates
[236]. Based on this evidence we hypothesize nuclear LC3 may also play a role in degradation of nuclear
protein aggregates by functioning together with SQSTM1 and ubiquitin. However, we note that under basal
conditions the bulk of Venus-LC3 is not associated with puncta.
We speculate that stress upregulates the formation of nuclear protein aggregates, which prompts ubiqui-
tination and SQSTM1 association. Finally, LC3 would participate in the process by binding to SQSTM1 and
targeting the complex for degradation by autophagy. Thus this model implies an entirely new mechanism for
quality control of nuclear aggregates that are too large for the proteasome to degrade. In the cytoplasm, there
are chaperones, proteasomes, as well as lysosomes to prevent misfolded proteins from accumulating, but in
the nucleus there are only chaperones and proteasomes. If protein aggregates become too large for degrada-
tion by the proteasome they can still be degraded by the autophagy pathway [32]. However, currently, there
are no known mechanisms to degrade very large aggregates that form in the nucleus via autophagy. An alter-
native hypothesis involves the known connections between LC3 and SQSTM1 and proteasomal degradation
[70, 265]. LC3 may function together with SQSTM1 to target ubiquitinated nuclear aggregates for degrada-
tion via nuclear proteasomes. Thus these autophagy proteins may be involved in proteasomal degradation in
the nucleus, and the nuclear puncta may correspond to the proteasome mediated degradation centers [277].
We found that LC3 also localizes to the nucleolus, and that this localization depends on LC3’s triple argi-
nine RNA binding motif. The nucleolar localization of LC3 may also be a very important clue as to what the
function of nuclear LC3 may be. The nucleolus is a processing facility where ribosomal subunits are assem-
bled, and there is evidence that ribosomal proteins are rapidly turned over in a proteasome dependent manner
[278]. However, the nucleolus is devoid of proteasomes [279]. It is tempting to speculate that perhaps LC3
is somehow involved in regulating the assembly of ribosomal subunits via a mechanism that includes nuclear
LC3 cycling in and out of the nucleolus to mediate ribosomal protein turnover via the proteasome. There
is also evidence that the ATG8 homologue of LC3 in yeast functions in ribosome decay through selective
autophagy [77].
In the future it would be interesting to examine LC3’s RNA binding ability, and to test if the R70A mutant
disrupts binding to RNA. This could be done using gel shift assays, or alternatively diffusion based methods
could be used to test RNA binding by examining differences in the rate of diffusion after treating with RNase
132
to digest all of the polymerized RNA. These results point to a novel nuclear function for LC3 in nuclear quality
control processes. In the future it would be interesting to follow this up in at least two ways: a) to examine
if nuclear puncta are disrupted in cells expressing the LC3 mutants in order to determine the structural nature
of LC3’s association with them; and b) to use the previously discussed stable LC3 knockdown cell line to test
if these puncta require LC3 for their formation.
Does LC3 have a novel nucleolar detention sequence? A promising future direction would include ligating
this region of LC3’s sequence to the N-terminus of GFP to examine if it is a bonafide nucleolar detention
sequence. In the future it will be important to test the potential models for LC3’s nuclear function that were
raised here. Experiments could be directed at tracking down what LC3 interacts with in the nucleus using a
co-IP mass spectrometry approach similar to what was done in Behrends et al. [9]. We constructed a mutant of
Venus-LC3 with a nuclear export signal attached to its N-terminus such that a relative comparison of nuclear
and cytoplasmic LC3 interacting proteins could be examined using mass spectrometry. The stable LC3
knockdown cell line described above would be useful for these experiments. By identifying novel nuclear
LC3 interacting proteins one may be able to gather some additional clues about the function of nuclear LC3.
VII.2 Summary
The cell is far from equilibrium, and its molecules undergo dynamic self-assembly to form ordered structures
on a scale from nanometers to tens of microns [1]. Some proteins function as isolated monomeric enzymes
continuously processing substrates into products, while many others function as very large, labile multicom-
ponent complexes. Function (and dysfunction), patterns, and behaviors of a cell ultimately emerge from the
collective behaviors of its molecules and assemblies. Emergent properties arise when numerous interacting
components produce collective patterns or behaviors that are not attainable by the individual components
themselves [2]. The autophagy pathway is an example of a metabolic process that displays stunning com-
plexity, and that has exceptional relevance to human health and disease. Autophagy is a major catabolic
pathway whereby cytoplasmic components including proteins, bacteria, and organelles are sequestered and
degraded via the lysosome. LC3 is a central protein component in the autophagy pathway with functions
in autophagosome membrane expansion, fusion, and autophagy substrate selectivity. LC3 interacts with a
large number of proteins, but little is known about their physiological regulation, and whether LC3 interacts
with these proteins in a binary fashion or if the proteins dynamically self-assemble to form multicomponent
complexes.
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VII.2.1 Novel findings related to autophagy protein LC3
In order to test if LC3 associates with complexes, we carried out quantitative in vivo diffusion measurements
in chapter III in order to estimate its hydrodynamic radius. We found that the diffusion of LC3 was unaffected
by either mutational disruption of its lipid modification or microtubule depolymerization. Brightness and
homo-FRET analysis indicated LC3 does not homo-oligomerize. However, mutation of specific residues on
LC3 required for binding other proteins and mRNA altered the effective hydrodynamic radius of the protein
as well as its stoichiometry. We conclude that when not bound to autophagosomes, LC3 associates with a
novel multi-component complex with an effective size of 500 kDa in the cytoplasm. These findings provided
new insights into the nature of soluble LC3. We know that the effective size of the LC3-associated complexes
increases in response to perturbations to the autophagy pathway, but the composition and function of these
complexes remains to be determined.
In chapter IV we used FRET microscopy and FRAP to investigate the interactions of LC3 with ATG4B(C74A),
a catalytically inactive mutant of the cysteine protease involved in lipidation and de-lipidation of LC3, as a
model system to probe protein complex formation in the autophagy pathway. We found evidence that these
proteins interact in live cells to form a complex which is consistent with the structure proposed by Satoo et al.
[101]. The 2:1 complex formed between LC3 and ATG4B suggests a mechanism for regulation of LC3’s
lipid modification.
The site of autophagosome formation is in the cytoplasm, but surprisingly, LC3 is located in the nucleus
as well, suggesting it may have a novel nuclear function. In chapter VI we investigated the mechanisms that
retain LC3 in the nucleus and control its nuclear dynamics. We studied the contributions to these processes
resulting from interactions mediated by LC3’s hydrophobic protein interaction surface as well as its ability
to undergo lipidation. These studies suggest that LC3 associated with large complexes in the nucleus as well,
but that binding to these complexes may not be solely responsible for its nuclear localization. Importantly,
our results raised several intriguing models for what LC3 might be doing in the nucleus and opened up several
avenues for promising future research on the subject.
VII.2.2 New fluorescence microscopy based tools for studying biopolymers in vivo
Traditional studies rely on in vitro approaches to isolate the molecule before performing an analysis of struc-
ture and function, but these approaches are limited, because the function of a protein is highly dependent on
its cellular context. Fortunately, new developments in fluorescence microscopy of GFP tagged proteins are
making it possible to overcome these limitations. However, these approaches are currently not being widely
used to their full potential for reasons that include a lack of easy-to-use analytical tools. In this dissertation,
the fluorescence-based microscopy tools that were developed open up new possibilities to study the properties
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of biopolymers in the physiological context of a living cell.
Diffusion is fundamental to life. The diffusion of molecules over time is what is largely responsible for
the transfer of material and information from one place to another at the scale of a cell. For the purposes
of measuring diffusion in cells, FRAP is a widely available experimental method. FRAP has the potential
to quantitatively measure diffusion coefficients [158]; however, the widespread use of this technology is
currently limited by the requirement of experience in programming and mathematics for performing image
analysis and non-linear curve fitting routines. In chapter II we presented a freely available software tool
called FRAP-Toolbox for the automated analysis of FRAP data. The FRAP-Toolbox software tool promises
to make quantitative FRAP more broadly available to the scientific community.
Finally, in chapter V we developed two additional fluorescence microscopy-based assays to probe for
LC3 interacting proteins in living cells. To date, most LC3 interacting proteins have been identified using
biochemical approaches. We describe three fluorescence microscopy-based assays that can be used to detect
the interaction of specific proteins with LC3 in living cells. The first approach is astonishingly simple, as it
consists of simple measurements of LC3’s N/C ratio in the presence and absence of overexpressed SQSTM1.
The analysis of these data was automated using a freely available software utility called LocalizeLC3. The
second assay uses FRET microscopy to detect the close physical proximity of Cerulean- and Venus-tagged
versions of LC3 with its interacting proteins. We also automated this approach by developing a freely avail-
able software utility called abFRET. Finally, we show that FRAP can measure decreases in the diffusional
mobility of Venus-LC3 in the presence of overexpressed LC3 interacting proteins. We verified the specificity
of these techniques by demonstrating that interactions of SQSTM1 with LC3B were inhibited by F52A and
L53A mutations of LC3B’s hydrophobic protein binding interface as reported by all three methods. Impor-
tantly, these assays take advantage of widely available technologies and offer a complementary approach to
existing methods to detect protein interactions with LC3. They can also be readily adapted to characterize
other protein complexes in the autophagy pathway.
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